EP2994758B1 - Biomarkers for age-related macular degeneration (amd) - Google Patents
Biomarkers for age-related macular degeneration (amd) Download PDFInfo
- Publication number
- EP2994758B1 EP2994758B1 EP14731098.1A EP14731098A EP2994758B1 EP 2994758 B1 EP2994758 B1 EP 2994758B1 EP 14731098 A EP14731098 A EP 14731098A EP 2994758 B1 EP2994758 B1 EP 2994758B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- vegf
- vegfr
- amd
- subject
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000002780 macular degeneration Diseases 0.000 title claims description 211
- 206010064930 age-related macular degeneration Diseases 0.000 title claims description 202
- 239000000090 biomarker Substances 0.000 title claims description 66
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims description 363
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims description 361
- 238000000034 method Methods 0.000 claims description 121
- 238000011282 treatment Methods 0.000 claims description 111
- 238000005259 measurement Methods 0.000 claims description 81
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 70
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 65
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims description 63
- 239000012472 biological sample Substances 0.000 claims description 62
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 47
- 241000282414 Homo sapiens Species 0.000 claims description 43
- 238000002560 therapeutic procedure Methods 0.000 claims description 34
- 108020004999 messenger RNA Proteins 0.000 claims description 28
- 208000035719 Maculopathy Diseases 0.000 claims description 24
- 239000000523 sample Substances 0.000 claims description 22
- 210000004369 blood Anatomy 0.000 claims description 20
- 239000008280 blood Substances 0.000 claims description 20
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 19
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims description 18
- 230000037361 pathway Effects 0.000 claims description 17
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 16
- 239000003550 marker Substances 0.000 claims description 15
- 210000002381 plasma Anatomy 0.000 claims description 14
- 210000002966 serum Anatomy 0.000 claims description 8
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 6
- 230000002250 progressing effect Effects 0.000 claims description 6
- 230000000391 smoking effect Effects 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 5
- 101000742596 Homo sapiens Vascular endothelial growth factor C Proteins 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 235000005911 diet Nutrition 0.000 claims description 2
- 230000037213 diet Effects 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 170
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 158
- 239000003112 inhibitor Substances 0.000 description 101
- 239000012634 fragment Substances 0.000 description 70
- 108090000765 processed proteins & peptides Proteins 0.000 description 48
- 229940091171 VEGFR-2 tyrosine kinase inhibitor Drugs 0.000 description 47
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 44
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 44
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 42
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 42
- 230000027455 binding Effects 0.000 description 42
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 40
- 102000004196 processed proteins & peptides Human genes 0.000 description 40
- 238000011161 development Methods 0.000 description 39
- 229920001184 polypeptide Polymers 0.000 description 36
- 108090000623 proteins and genes Proteins 0.000 description 33
- 230000008901 benefit Effects 0.000 description 30
- 201000010099 disease Diseases 0.000 description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 29
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 29
- 102000005962 receptors Human genes 0.000 description 27
- 108020003175 receptors Proteins 0.000 description 27
- 239000003795 chemical substances by application Substances 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 238000004891 communication Methods 0.000 description 25
- 239000000203 mixture Substances 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 23
- 206010029113 Neovascularisation Diseases 0.000 description 22
- 239000003446 ligand Substances 0.000 description 22
- 239000002609 medium Substances 0.000 description 21
- 230000001717 pathogenic effect Effects 0.000 description 20
- 108091008606 PDGF receptors Proteins 0.000 description 18
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 230000000638 stimulation Effects 0.000 description 18
- 239000003814 drug Substances 0.000 description 17
- 238000003556 assay Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 210000004379 membrane Anatomy 0.000 description 15
- 239000012528 membrane Substances 0.000 description 15
- 238000003860 storage Methods 0.000 description 14
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 239000007943 implant Substances 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 208000027418 Wounds and injury Diseases 0.000 description 12
- 230000006378 damage Effects 0.000 description 12
- 208000014674 injury Diseases 0.000 description 12
- 230000001404 mediated effect Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 230000033115 angiogenesis Effects 0.000 description 11
- 230000000692 anti-sense effect Effects 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 108020004459 Small interfering RNA Proteins 0.000 description 10
- 230000002452 interceptive effect Effects 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 239000004055 small Interfering RNA Substances 0.000 description 10
- 238000002626 targeted therapy Methods 0.000 description 10
- 108091008605 VEGF receptors Proteins 0.000 description 9
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 9
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 230000003902 lesion Effects 0.000 description 9
- 230000000649 photocoagulation Effects 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 108010081667 aflibercept Proteins 0.000 description 8
- -1 for example Substances 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 108091023037 Aptamer Proteins 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 7
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 7
- 230000004438 eyesight Effects 0.000 description 7
- 229940051306 eylea Drugs 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 7
- 230000009885 systemic effect Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 6
- 239000000074 antisense oligonucleotide Substances 0.000 description 6
- 238000012230 antisense oligonucleotides Methods 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000013534 fluorescein angiography Methods 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 108091070501 miRNA Proteins 0.000 description 6
- 239000002679 microRNA Substances 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 238000012340 reverse transcriptase PCR Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 239000004037 angiogenesis inhibitor Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 108010017992 platelet-derived growth factor C Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000002207 retinal effect Effects 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 5
- 230000004393 visual impairment Effects 0.000 description 5
- XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 4
- 108010081589 Becaplermin Proteins 0.000 description 4
- 206010061818 Disease progression Diseases 0.000 description 4
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 description 4
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 4
- 238000002583 angiography Methods 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 208000030533 eye disease Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- FSASIHFSFGAIJM-UHFFFAOYSA-N 3-methyladenine Chemical compound CN1C=NC(N)=C2N=CN=C12 FSASIHFSFGAIJM-UHFFFAOYSA-N 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- 108010074051 C-Reactive Protein Proteins 0.000 description 3
- 102100032752 C-reactive protein Human genes 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 208000008069 Geographic Atrophy Diseases 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 3
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 3
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 3
- 229940127432 VEGFR3 Inhibitors Drugs 0.000 description 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000011122 anti-angiogenic therapy Methods 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 229960005167 everolimus Drugs 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 3
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000000779 smoke Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 238000011285 therapeutic regimen Methods 0.000 description 3
- 230000008646 thermal stress Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 3
- 229960000241 vandetanib Drugs 0.000 description 3
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- CDFKCKUONRRKJD-UHFFFAOYSA-N 1-(3-chlorophenoxy)-3-[2-[[3-(3-chlorophenoxy)-2-hydroxypropyl]amino]ethylamino]propan-2-ol;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.C=1C=CC(Cl)=CC=1OCC(O)CNCCNCC(O)COC1=CC=CC(Cl)=C1 CDFKCKUONRRKJD-UHFFFAOYSA-N 0.000 description 2
- OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102100029470 Apolipoprotein E Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 102100035432 Complement factor H Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 102100040681 Platelet-derived growth factor C Human genes 0.000 description 2
- 102100040682 Platelet-derived growth factor D Human genes 0.000 description 2
- 101710170209 Platelet-derived growth factor D Proteins 0.000 description 2
- 206010063381 Polypoidal choroidal vasculopathy Diseases 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 238000013381 RNA quantification Methods 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 2
- 102000005406 Tissue Inhibitor of Metalloproteinase-3 Human genes 0.000 description 2
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102100040959 Tyrosine-protein kinase FRK Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000008236 biological pathway Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 208000011325 dry age related macular degeneration Diseases 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000005081 epithelial layer Anatomy 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 235000012680 lutein Nutrition 0.000 description 2
- 229960005375 lutein Drugs 0.000 description 2
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 2
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 2
- 239000001656 lutein Substances 0.000 description 2
- 229940124302 mTOR inhibitor Drugs 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- 239000006014 omega-3 oil Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 229960003876 ranibizumab Drugs 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 208000029257 vision disease Diseases 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- VPBYZLCHOKSGRX-UHFFFAOYSA-N 1-[2-chloro-4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-propylurea Chemical compound C1=C(Cl)C(NC(=O)NCCC)=CC=C1OC1=NC=NC2=CC(OC)=C(OC)C=C12 VPBYZLCHOKSGRX-UHFFFAOYSA-N 0.000 description 1
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- PTBDIHRZYDMNKB-UHFFFAOYSA-N 2,2-Bis(hydroxymethyl)propionic acid Chemical compound OCC(C)(CO)C(O)=O PTBDIHRZYDMNKB-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- ZPBYVFQJHWLTFB-UHFFFAOYSA-N 3-methyl-7H-purin-6-imine Chemical compound CN1C=NC(=N)C2=C1NC=N2 ZPBYVFQJHWLTFB-UHFFFAOYSA-N 0.000 description 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 1
- 102000043966 ABC-type transporter activity proteins Human genes 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 102100038568 Age-related maculopathy susceptibility protein 2 Human genes 0.000 description 1
- YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 229940123672 Cadherin antagonist Drugs 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 101800005309 Carboxy-terminal peptide Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 235000021538 Chard Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 1
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 1
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 description 1
- 108010074466 Chromosomal Puffs Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010022510 Collagen Type X Proteins 0.000 description 1
- 102000030746 Collagen Type X Human genes 0.000 description 1
- 102100036217 Collagen alpha-1(X) chain Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108090000955 Complement C2 Proteins 0.000 description 1
- 102000004381 Complement C2 Human genes 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 108010053085 Complement Factor H Proteins 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 102100034622 Complement factor B Human genes 0.000 description 1
- 102100031867 DNA excision repair protein ERCC-6 Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000018672 Dilatation Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 101150009958 FLT4 gene Proteins 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000019267 Hepatic lipases Human genes 0.000 description 1
- 108050006747 Hepatic lipases Proteins 0.000 description 1
- 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 description 1
- 101000808726 Homo sapiens Age-related maculopathy susceptibility protein 2 Proteins 0.000 description 1
- 101000851684 Homo sapiens Chimeric ERCC6-PGBD3 protein Proteins 0.000 description 1
- 101000875027 Homo sapiens Collagen alpha-1(X) chain Proteins 0.000 description 1
- 101000920783 Homo sapiens DNA excision repair protein ERCC-6 Proteins 0.000 description 1
- 101000941289 Homo sapiens Hepatic triacylglycerol lipase Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 1
- 101001041393 Homo sapiens Serine protease HTRA1 Proteins 0.000 description 1
- 101000742599 Homo sapiens Vascular endothelial growth factor D Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 229940123038 Integrin antagonist Drugs 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- JSHDAORXSNJOBA-UHFFFAOYSA-N Isopropyl hexanoate Chemical compound CCCCCC(=O)OC(C)C JSHDAORXSNJOBA-UHFFFAOYSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000018501 Lymphatic disease Diseases 0.000 description 1
- 102100026849 Lymphatic vessel endothelial hyaluronic acid receptor 1 Human genes 0.000 description 1
- 101710178181 Lymphatic vessel endothelial hyaluronic acid receptor 1 Proteins 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 206010063341 Metamorphopsia Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 101600105505 Mus musculus Vascular endothelial growth factor C (isoform 1) Proteins 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical class CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102000002111 Neuropilin Human genes 0.000 description 1
- 108050009450 Neuropilin Proteins 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 229940116355 PI3 kinase inhibitor Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010005642 Properdin Proteins 0.000 description 1
- 102100038567 Properdin Human genes 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 101000739162 Rattus norvegicus Secretoglobin family 2A member 2 Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 208000032436 Retinal depigmentation Diseases 0.000 description 1
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 235000013290 Sagittaria latifolia Nutrition 0.000 description 1
- 206010039729 Scotoma Diseases 0.000 description 1
- 229940123578 Selectin antagonist Drugs 0.000 description 1
- 102100021119 Serine protease HTRA1 Human genes 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102000012753 TIE-2 Receptor Human genes 0.000 description 1
- 108010090091 TIE-2 Receptor Proteins 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 102400000731 Tumstatin Human genes 0.000 description 1
- 101710089880 Tyrosine-protein kinase FRK Proteins 0.000 description 1
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 229960001232 anecortave Drugs 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001775 bruch membrane Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 229960002412 cediranib Drugs 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 210000003799 chromosomal puff Anatomy 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 235000015246 common arrowhead Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- LNGNZSMIUVQZOX-UHFFFAOYSA-L disodium;dioxido(sulfanylidene)-$l^{4}-sulfane Chemical compound [Na+].[Na+].[O-]S([O-])=S LNGNZSMIUVQZOX-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 208000035548 disruptive behavior disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- TZMQHOJDDMFGQX-UHFFFAOYSA-N hexane-1,1,1-triol Chemical compound CCCCCC(O)(O)O TZMQHOJDDMFGQX-UHFFFAOYSA-N 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003425 hypopigmentation Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- UHEBDUAFKQHUBV-UHFFFAOYSA-N jspy-st000261 Chemical compound C1=CC=C2C3=C(C(=O)NC4)C4=C(C=4C(=CC=C(C=4)COC(C)C)N4CCCOC(=O)CN(C)C)C4=C3CC2=C1 UHEBDUAFKQHUBV-UHFFFAOYSA-N 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000000492 lymphangiogenic effect Effects 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
- 229950010895 midostaurin Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229950008516 olaratumab Drugs 0.000 description 1
- 229940096984 ophthalmic cream Drugs 0.000 description 1
- 229940100655 ophthalmic gel Drugs 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 210000003733 optic disk Anatomy 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 229960003407 pegaptanib Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000005043 peripheral vision Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical class O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 229940099538 rapamune Drugs 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000000964 retinal cone photoreceptor cell Anatomy 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 210000001957 retinal vein Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 239000002412 selectin antagonist Substances 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- UXXQOJXBIDBUAC-UHFFFAOYSA-N tandutinib Chemical compound COC1=CC2=C(N3CCN(CC3)C(=O)NC=3C=CC(OC(C)C)=CC=3)N=CN=C2C=C1OCCCN1CCCCC1 UXXQOJXBIDBUAC-UHFFFAOYSA-N 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229940094060 tykerb Drugs 0.000 description 1
- 108010012374 type IV collagen alpha3 chain Proteins 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- LLDWLPRYLVPDTG-UHFFFAOYSA-N vatalanib succinate Chemical compound OC(=O)CCC(O)=O.C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 LLDWLPRYLVPDTG-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
- 150000003735 xanthophylls Chemical class 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1
- 229950009819 zotarolimus Drugs 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/164—Retinal disorders, e.g. retinopathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7014—(Neo)vascularisation - Angiogenesis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Definitions
- This invention relates to methods of using biomarkers as diagnostic and prognostic tools for age-related macular degeneration (AMD).
- AMD age-related macular degeneration
- Age-related macular degeneration is a sudden worsening and distortion of central vision that progresses rapidly, typically with a course of only weeks or months. AMD is characterized by abnormalities in the macular area.
- the central area (or fovea) of the macula contains the highest density of cone photoreceptors in the retina and mediates high-acuity vision.
- the disease typically has a preclinical, asymptomatic phase, in which extracellular waste material accumulates in the space between the basement membrane (Bruch's membrane) and the epithelial layer, forming yellow-white spots known as drusen.
- Advanced forms of AMD includes both dry and wet (or "neovascular”) AMD.
- the dry form of AMD is far more common, but the wet form occurs simultaneously with the dry form in about 15 % of cases.
- Dry AMD is characterized by progressive apoptosis of cells in the epithelial layer, in the overlying photoreceptor cells and in the underlying cells in the choroidal capillary layer.
- Wet AMD is characterized by choroidal neovascularization with vascular leakage into subretinal spaces.
- AMD impairs central vision that is required for reading, driving, face recognition and fine visual tasks.
- Neurosensory detachment, retinal hemorrhages and retinal scarring gradually result in decreased visual function of photoreceptors in the central vision, eventually resulting in legal blindness, with preservation of peripheral vision.
- AMD is the most common cause of blindness among the elderly.
- Subjects with a family history of AMD and those who smoke have a higher risk than non-smokers and those with no family history. Nevertheless, subjects who have favorable risk profiles also develop the disease.
- Current therapeutic efforts and clinical trials are primarily aimed at halting the growth of the neovascular membrane in wet AMD, e.g., using angiogenesis (VEGF-A) inhibitors, laser photocoagulation and/or photodynamic therapy.
- VEGF-A angiogenesis
- Antioxidants can retard the progression of the disease.
- WO 2004/009773 describes methods and compositions for activating or inhibiting VEGF-D and/or VEGF-C.
- WO 2004/009773 mentions that diabetic retinopathy and ocular neovascularisation may be treated by inhibition of plasmin activation of VEGF-C.
- WO 2004/009733 does not mention VEGF-C as a biomarker for any disease.
- Goydos et al. (2003, Clinical Cancer Research, Vol. 9, pages 5962-5967 ) describe the measurement of VEGF-C mRNA levels in melanomas presenting different stages of progression in an attempt to determine whether expression of VEGF-C correlates with stage of progression in patients with melanoma.
- Goydos et al. conclude that high levels of VEGF-C may be important in regional lymphatic disease in melanoma and that VEGF-C and LYVE-1 levels may identify tumors with a high risk of nodal metastases.
- RT-PCR real-time quantitative PCR
- Zhao et al. (2006, British J. Ophthalmology, 90(8), pages 1052-1059 ) report that VEGF-A regulates the expression of VEGF-C in human retinal pigment epithelial (RPE) cells and propose that a synergistic action of VEGF-C with VEGF-A may play a role in the aetiology of choroidal neovascularisation.
- RPE retinal pigment epithelial
- Lavey et al. 2011, Optical Interactions with Tissue and Cells XXII, Proc. of SPIE, Vol. 7897, No. 1, pages 1-7 ) report that levels of VEGF-C and mRNA both increase in human retinal pigment epithelial cell cultures (hTERT-RPE1) following thermal stress produced by uniform heating in a water bath and that this supports previous research suggesting VEGF-C is a thermal stress protein.
- Lavey et al. conclude that VEGF-C expression within hTERT-RPE1 cells and within the extracellular matrix, and VEGF-C mRNA may serve as viable biomarkers of thermal stress in retinal cells, once a standard level of expression is established.
- WO2000/064946 discloses antibodies that specifically inhibit VEGF binding to VEGF2 receptors.
- CCR3 may be a viable biomarker for early diagnosis of neovascular age-related macular degeneration.
- WO 2001/006262 describes a method for determining a predisposition to developing macular degeneration, including age-related macular degeneration through detection of one or more markers for arterial wall disruptive disorder.
- WO 2005/084188 describes methods of using levels of markers of systemic inflammation, such as CRP, IL-6, TNF-alpha receptor II, ICAM and VCAM, to predict a subject's risk of development or progression of age-related macular degeneration.
- markers of systemic inflammation such as CRP, IL-6, TNF-alpha receptor II, ICAM and VCAM
- US 2010/0150920 describes a testing an ocular fluid for a biomarker for an ocular disease, including wet age-related macular degeneration , in which the biomarker is selected from CC9 D330, VEGFRY1175, VEGFRY996, PEDF, TNF-alpha, VEGF-A, VEGFRY951 and IL-1B.
- VEGF-C vascular endothelial growth factor C
- the level of VEGF-C gene or protein expression can be used as a biomarker for assessing the risk of developing and/or progression of AMD and/or to determine the likelihood that specific subjects will benefit from certain treatments or therapies for AMD.
- VEGF-C can be broadly considered to be a "predictive biomarker". These methods can be used, for example, to predict risk of development or progression of age-related maculopathy.
- VEGF-C can be broadly considered to be a "selective biomarker", i.e. it is being used to identify subjects likely to benefit from certain treatments, treatment regimes or therapies (i.e. targeted therapy) or in a particular clinical trial for an AMD therapy.
- subjects are identified who will benefit from treatment with an anti-angiogenic agent.
- subjects are identified who will benefit from treatment with a VEGFR-2 inhibitor molecule and/or a VEGFR-3 inhibitor molecule (e.g. an inhibitor of VEGF-A, VEGF-C, VEGF-D, VEGFR-2 or VEGFR-3).
- VEGF-C can be broadly considered to be a "responsive biomarker” or a “tracking biomarker” in which, for example, it is being used to monitor or track the response to a certain treatment, treatment regime or therapy.
- the biological sample comprises a tissue biopsy and the VEGF-C is measured in the tissue.
- the biological sample includes blood or lymphatic tissue and the VEGF-C is measured in the vessel tissue.
- the biological sample includes fluid from or around the area of the AMD (e.g. fluid from or around the eye) and the VEGF-C is measured in the fluid.
- the biological sample comprises blood, and the VEGF-C is measured in the blood, or in plasma or serum from the blood.
- VEGF-C acts as a systemic biomarker.
- the biological sample comprises blood, and the VEGF-C is measured in the blood, or in plasma or serum from the blood.
- the biological sample comprises blood, and the VEGF-C is measured in plasma from the blood.
- the VEGF-C measurement may be used as a "predictive" biomarker for the prediction of development and/or progression of AMD, as a “selective” biomarker for the selection of subjects for clinical trials or the selection of subjects likely to benefit from certain treatments for AMD, or as a "responsive" or “tracking” biomarker for monitoring of AMD disease progression in a subject and/or monitoring the efficacy of a particular treatment, treatment regime or therapy in a subject being treated for AMD.
- VEGF-C measurements in otherwise healthy subjects, regardless of whether they have ever smoked, may also be predictive of development and progression of AMD.
- the likelihood that a specific subject will benefit to a greater or a lesser extent from the use of certain therapeutic agents for reducing the risk of development or progression of AMD can be determined by evaluating levels of VEGF-C in the subject, and comparing the levels to a reference or control for the marker.
- Described herein are new methods for characterizing a mammalian subject's risk of development or progression of AMD comprising measuring the level of VEGF-C expression in a biological sample from a mammalian subject to obtain a VEGF-C measurement and comparing the subject's VEGF-C measurement with a reference or control level, the subject's risk of development or progression of AMD being characterized based upon the VEGF-C measurement in comparison to the reference or control.
- the level of the subject's VEGF-C is higher than the reference or control (e.g. increased relative to a control or other reference (including a previous level obtained from the same subject)), and indicates that the subject:
- the level of the subject's VEGF-C is lower than the reference or control (e.g. reduced relative to a control or other reference (including a previous level obtained from the same subject)), and indicates that the subject:
- progression of AMD refers to an increase in severity of the disease, e.g., an objective worsening in one or more parameters or symptoms associated with the disease, e.g., a progression from Category 1 or 2 to Category 3 or 4, or a progression from Category 1, 2, or 3 to Category 4.
- the subject is re-evaluated, e.g., the level of the VEGF-C as a biomarker is obtained again after or during administration of a treatment (e.g., after administration of one or more doses of an inhibitor of the VEGFR-2 and/or VEGFR-3 pathway, and in particular the VEGFR-3 pathway), and the level is compared to a reference or control, e.g., the level previously obtained, to evaluate the efficacy of the treatment.
- the level of VEGF-C is reduced as compared to a previously-obtained level, and it indicates that the subject's risk or development or progression of AMD is reduced.
- methods that use a subject's VEGF-C level together with one or more risk factors or other biomarkers for AMD, e.g., as described herein, to characterize a subject's risk profile of development and/or progression of AMD.
- the methods include obtaining a level of VEGF-C as biomarker in the subject which level is compared to a reference or control to establish a first risk value. At least one risk factor or other biomarker for AMD is also evaluated. The presence or level of the risk factor or other biomarker in the subject is compared to a second reference to establish a second risk value.
- the subject's risk profile for development or progression of AMD is characterized based upon the combination of the first risk value and the second risk value, wherein the combination of the first risk value and second risk value establishes a combined risk value, which is typically different from the first and second risk values.
- the combined risk value is greater than either of the first and second risk values, e.g., the first and second risk values are additive.
- the combined risk value is calculated with a multiplicative model.
- logistic regression is used to calculate a combine risk value.
- methods for evaluating the likelihood that a subject will benefit from treatment with a VEGFR-2 inhibitor molecule and/or a VEGFR-3 inhibitor molecule, and in particular the VEGFR-3 pathway, to reduce the risk of development or progression of AMD.
- the methods include obtaining a level of VEGF-C (e.g. active angiogenesis VEGF-C level) in a subject. This level then is compared to a reference or control, wherein the level of the VEGF-C in the subject in comparison to the reference or control is indicative of the likelihood that the subject will benefit from treatment with the agent.
- the subject then can be characterized in terms of the net benefit likely to be obtained by treatment with the agent.
- a treatment or prevention for reducing risk of development of AMD or progression to advanced AMD is having an effect in a subject.
- the methods include obtaining a first level of VEGF-C in a subject; administering a selected treatment or prevention for AMD to the subject; obtaining a second level of VEGF-C in the subject; and comparing the first VEGF-C level to the second level of VEGF-C.
- a difference, or lack of difference, in the second level as compared to the first level indicates whether the treatment or prevention is effective or not effective. For example, if the second level is lower than the first level, then the treatment or prevention is likely to be effective.
- the methods can include re-testing the subject a plurality of times, e.g., to determine whether the treatment is effective over time.
- the subject can be tested one or more additional times to determine if their risk of developing AMD has changed or the subject has relapsed into AMD or AMD has started to progress after being in a stable condition.
- the subject is apparently healthy, e.g., has no or few overt clinical signs of AMD (e.g., is in the first AERDS category); has minimal or early AMD (e.g., is in the second AERDS category); has intermediate AMD (e.g., is in the third AERDS category); or has advanced AMD (e.g., is in the fourth AERDS).
- the subject is a non-smoker, e.g., has never smoked, or is a smoker, e.g., a current or past smoker.
- a non-smoker is a subject who, at the time of the evaluation, has never smoked, or has smoked less than a minimal number, e.g., 100 cigarettes in a lifetime, or less than a minimal duration, e.g., less than six months.
- Smokers include subjects who currently smoke, as well as subjects who have smoked at some time in the past but presently no longer smoke, or smoked more than a minimal number, e.g., 100 cigarettes in a lifetime, or more than a minimal duration, e.g., more than six months.
- the subject has no risk factors as described herein.
- the subject has one or more risk factors as described herein.
- characterizing a subject's risk of development or progression of AMD includes characterizing the subject's risk of developing advanced AMD. In some embodiments, characterizing the subject's risk of future development or progression of AMD includes characterizing the subject's risk of developing neovascular AMD.
- the reference can be a single value, multiple values, a single range or multiple ranges. In some embodiments, the reference is a median value. In some embodiments, the reference is a plurality of marker level ranges, e.g., ranges associated with low, medium, and high risk categories, and the comparing step comprises determining in which marker level range the subject's level falls.
- levels of multiple AMD biomarkers are obtained concurrently.
- the methods described herein can be adapted to determine which subjects are most likely to benefit from treatment with an agent for reducing the risk in the development or progression of AMD.
- the methods can also be used to select candidate subjects and/or populations for clinical trials and for treatment with candidate drugs, by identifying, for example, subjects most likely to benefit from a new treatment or from a known treatment with a high risk profile of adverse side effects.
- the methods described herein can provide information for evaluating the likely net benefit of certain treatments for candidate subjects.
- the measuring comprises measuring VEGF-C protein in the biological sample.
- Exemplary techniques for measuring amounts or concentrations of VEGF-C protein in a sample are immunological techniques that involve use of a polyclonal or monoclonal antibody that specifically binds VEGF-C, or use of a VEGF-C-binding fragment of such an antibody.
- the measuring comprises contacting the biological sample with a VEGF-C antibody (or with a polypeptide comprising an extracellular domain (ECD) fragment of VEGFR-3 that binds VEGF-C) or antigen-binding fragment thereof.
- ECD extracellular domain
- Quantification of the amount of bound antibody provides a measurement of VEGF-C protein expressed in the sample.
- Immunoassays such as radioimmunoassay, immunoradiometric assay (labeled antibody), or an enzyme-linked immunosorbent assay (ELISA) are contemplated.
- the measuring comprises measuring VEGF-C mRNA in the biological sample.
- Any available assay for measuring specific oligonucleotides is suitable.
- One technique for measuring VEGF-C mRNA comprises in situ hybridization to measure VEGF-C mRNA in the biological sample.
- Other techniques involve steps of isolating mRNA from the biological sample and measuring VEGF-C mRNA in the isolated mRNA, for example, by Northern hybridization procedures.
- quantitative reverse transcriptase polymerase chain reaction (PCR), real-time PCR, or other PCR techniques are employed to quantitatively amplify VEGF-C mRNA (relative to control samples) to provide a quantitative measurement of VEGF-C mRNA in the biological sample.
- the screening, diagnosing or selecting methods described herein may optionally comprise the step of prescribing for or administering to the subject identified as having elevated VEGF-C expression in the biological sample a composition comprising a VEGFR-2 inhibitor molecule and/or a VEGFR-3 inhibitor molecule (e.g. a VEGF-C antibody or a soluble VEGFR-3 protein trap).
- a VEGFR-2 inhibitor molecule e.g. a VEGFR-2 inhibitor molecule
- a VEGFR-3 inhibitor molecule e.g. a VEGF-C antibody or a soluble VEGFR-3 protein trap.
- a method of treatment comprising obtaining a biological sample from a mammalian subject, determining that the biological sample has elevated expression of VEGF-C, and prescribing for or administering to the subject a composition comprising a VEGFR-2 inhibitor molecule and/or a VEGFR-3 inhibitor molecule (e.g. a VEGF-C antibody or a soluble VEGFR-3 protein trap).
- a composition comprising a VEGFR-2 inhibitor molecule and/or a VEGFR-3 inhibitor molecule (e.g. a VEGF-C antibody or a soluble VEGFR-3 protein trap).
- the subject for whom the inhibitor composition is prescribed receives the composition following the prescribing.
- the determining step comprises ordering a laboratory test that measures VEGF-C in the biological sample and learning the measurement from a report from the laboratory. In other variations, the determining step comprises measuring VEGF-C mRNA or VEGF-C protein in the biological sample.
- compositions that comprises a VEGFR-2 inhibitor molecule and/or a VEGFR-3 inhibitor molecule for the treatment of AMD in a subject identified with AMD and identified with elevated VEGF-C expression (wherein the subject is identified as having elevated VEGF-C expression in the AMD by a method described herein).
- VEGFR-2 inhibitor molecules for use in the methods (or uses) described herein include, but are not limited to, (a) a VEGF-A antibody that inhibits ligand-mediated stimulation of VEGFR-2; (b) a VEGF-C antibody that inhibits ligand-mediated stimulation of VEGFR-2; (c) a VEGF-D antibody that inhibits ligand-mediated stimulation of VEGFR-2; (d) a soluble polypeptide that comprises an extracellular domain fragment of VEGFR-2 (i.e.
- a soluble VEGFR-2 trap that binds VEGF-A and/or VEGF-C and/or VEGF-D and inhibits VEGF-A and/or VEGF-C and/or VEGF-D, as the case may be, from stimulating VEGFR-2; (e) an antisense or interfering nucleic acid (e.g., antisense oligonucleotide; micro-RNA, short interfering RNA) that inhibits VEGF-A, VEGF-C and/or VEGF-D expression; (e) an antisense or interfering nucleic acid (e.g., antisense oligonucleotide; micro-RNA, short interfering RNA) that inhibits VEGFR-2 expression; (f) an antibody that binds VEGFR-2 and inhibits VEGF-A and/or VEGF-C and/or VEGF-D from binding to and stimulating VEGFR-2; (g) a small molecule that inhibits VEGFR
- VEGFR-3 inhibitor molecules for use in the methods (or uses) described herein include, but are not limited to, (a) a VEGF-C antibody that inhibits ligand-mediated stimulation of VEGFR-3; (b) a VEGF-D antibody that inhibits ligand-mediated stimulation of VEGFR-3; (c) a soluble polypeptide that comprises an extracellular domain fragment of VEGFR-3 (i.e.
- a soluble VEGFR-3 trap that binds VEGF-C and/or VEGF-D and inhibits VEGF-C and/or VEGF-D, as the case may be, from stimulating VEGFR-3; (d) an antisense or interfering nucleic acid (e.g., antisense oligonucleotide; micro-RNA, short interfering RNA) that inhibits VEGF-C and/or VEGF-D expression; (e) an antisense or interfering nucleic acid (e.g., antisense oligonucleotide; micro-RNA, short interfering RNA) that inhibits VEGFR-3 expression; (f) an antibody that binds VEGFR-3 and inhibits VEGF-C and/or VEGF-D from binding to and stimulating VEGFR-3; (g) a small molecule that inhibits VEGFR-3 expression or signaling; and (h) a molecule that inhibits proteolytic cleavage-activation of VE
- the methods optionally comprise administering to the subject in combination a VEGFR-2 inhibitor molecule and/or a VEGFR-3 inhibitor molecule and a standard or care therapeutic.
- the VEGFR-2 inhibitor molecule and/or a VEGFR-3 inhibitor molecule can be administered simultaneously with the other active agents, which may be in admixture with the VEGFR-2 inhibitor molecule and/or a VEGFR-3 inhibitor molecule, or may be in a separate composition.
- Each composition preferably includes a pharmaceutically acceptable diluent, adjuvant, or carrier. When the agents are separately administered, they may be administered in any order.
- kits including a package including one or more assays for an AMD biomarker as described herein and instructions for use in a method described herein, and optionally related materials such as marker level or range information for correlating the level of the marker as determined by the assay with a risk of development or progression of AMD.
- information can be in any useful form, e.g., charts, e.g., numeric or colour charts.
- the instructions include information for determining the subject's risk of development or progression of AMD, by correlating the level of the marker determined by the assay and one or more risk factors with a risk of development or progression of AMD.
- the kit includes assays for two, three, four or more AMD biomarkers.
- the kit can include a microarray or a microfluidic device that can be used to determine the levels of two, three, four, or more AMD biomarkers, e.g., substantially simultaneously.
- an agent which inhibits VEGF-C is administered to a subject who is known to have (i.e., has been determined to have, e.g., by a method described herein) an above-normal level of VEGF-C.
- the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule is administered in an amount effective to treat, prevent, and/or delay the development or progression of AMD.
- the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule is administered in an amount effective to reduce the subject's levels of VEGF-C to below a preselected value, e.g., a reference value that is associated with a lower risk category.
- the eye disorder is age-related macular degeneration (AMD).
- the polypeptide has an amino terminal residue selected from the group consisting of positions 1 to 47 of SEQ ID NO: 4, and a carboxy-terminal residue selected from the group consisting of positions 226 to 775 of SEQ ID NO: 4, wherein VEGFR-3 fragment binds at least one of VEGF-C and VEGF-D.
- the polypeptide comprises the first through third Ig-like domains of VEGFR-3, and the polypeptide lacks Ig-like domains IV-VII of the VEGFR-3 amino acid sequence.
- the polypeptide consists of, or consists essentially of, the first three Ig-like domains, fused to a heterologous peptide.
- the portion of the polypeptide corresponding to VEGFR-3 is selected from the group consisting of defined by positions 1-226, positions 1-229, and positions 1-329, positions 47-224, positions 47-225, positions 47-226, positions 47-227, positions 47-228, positions 47-229, positions 47-230, positions 47-231, positions 47-232, positions 47-236, positions 47-240, positions 47-245, positions 47-314, positions 47-210, and positions 47-247 of SEQ ID NO: 4.
- packages including a VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule, e.g., in a pharmaceutical composition, and instructions for administering the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule to a subject in order to treat, prevent, and/or delay the development or progression of AMD.
- the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule is in a therapeutic composition also including a pharmacologically acceptable carrier.
- the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule is in a form suitable for local delivery to the macular area.
- the system includes tools for performing at least one step, preferably two or more steps, and in some aspects all steps of a method of the invention, where the tools are operably linked to each other.
- tools include laboratory equipment or reagents for performing assays and computer systems for processing data, comparing data, and/or transforming one type of data (e.g., VEGF-C measurements) into another (e.g., a risk score).
- Operable linkage describes a linkage through which components can function with each other to perform their purpose, and may include, for example, linkage through a computer network and/or the internet.
- AMD age-related macular degeneration
- AMD includes both early, intermediate, and advanced AMD.
- Patients with early AMD are usually asymptomatic, and present clinically with yellowish drusen seen underneath the retinal pigment epithelium, with areas of mottled retinal pigment epithelium hyperpigmentation and hypopigmentation.
- Neovascular AMD is characterised by subretinal or intraretinal fluid and haemorrhage; occasionally, the choroidal neovascularisation complex can be seen clinically.
- Advanced AMD includes both dry AMD and wet AMD (wet AMD is also referred to as neovascular AMD). Subjects with advanced AMD are those who can be categorized in Category 4 according to the AREDS classification.
- AREDS Age-Related Eye Disease Study
- the 5-year risk of developing advanced AMD in at least one eye in control participants was 1.3% in eyes in Category 2, 18.3% in those in Category 3, and 43.9% in those in Category 4.
- Polypoidal choroidal vasculopathy is difficult to distinguish clinically from choroidal neovascularisation. Occasionally, orange, bulging dilatations might be visible under the retina. However, polypoidal choroidal vasculopathy more commonly presents with recurrent serous and haemorrhagic retinal pigment epithelium detachments. Retinal angiomatous proliferation is characterised clinically by signs of haemorrhage, oedema, and exudates within the retinal layers in addition to other typical signs of choroidal neovascularisation. In some cases, the anastomosis between the retinal and subretinal new vessels might be visible.
- a "subject" is a mammal, e.g., human, canine, feline, ovine, primate, equine, porcine, caprine, camelid, avian, bovine, and murine organisms.
- the subject is a human.
- Appendix healthy means that a subject does not have clinical signs of AMD, e.g., is in AERDS Category 1, and is essentially free of current need for treatment. In other words, such subjects, if examined by a medical professional, would be characterized as healthy and generally free of symptoms of acute disease.
- a "risk factor” means a risk factor that is known to be associated with an increased risk of development or progression of AMD.
- an absolute risk of developing a disease or trait defined as the chance of a person developing the specific disease or trait over a specified time-period.
- a woman's lifetime absolute risk of breast cancer is one in nine. That is to say, one woman in every nine will develop breast cancer at some point in their lives.
- Risk is typically measured by looking at very large numbers of people, rather than at a particular individual. Risk is often presented in terms of Absolute Risk (AR) and Relative Risk (RR). Relative Risk is used to compare risks associating with two variants or the risks of two different groups of people.
- a relative risk of 2 means that one group has twice the chance of developing a disease as the other group.
- the risk presented is usually the relative risk for a person, or a specific genotype of a person, compared to a matched population, such as a population with matched gender and ethnicity, with the understanding that ethnicity is usually as self-reported by a subject.
- VEGF-C is a major driver of AMD.
- elevated VEGF-C levels can, independently of or dependently on other risk factors and/or biomarkers, be predictive of developing AMD, of AMD progression and of suitability of certain subjects for targeted therapy or clinical trials.
- monitoring VEGF-C levels can also be predictive of efficacy of a treatment, treatment regime or therapy.
- the information about VEGF-C levels as a biomarker does not duplicate, and is likely to be independent of the information provided by other known or presumed risk factors. Even when numerous other known risk factors are controlled for, VEGF-C measurement as a biomarker improves prediction.
- using an AMD biomarker as an assay for AMD risk can provide a simpler method of evaluating a subject's risk that does not require information about a subject's personal medical history.
- VEGF-C levels are associated with development and/or progression of AMD.
- Anti-VEGF-C agents or agents which inhibit the biological pathway of VEGF-C i.e. inhibitors of the VEGFR-2 and/or VEGFR-3 pathways, may have a role in slowing the progression to advanced AMD, with VEGF-C levels providing a biomarker to provide a method of identifying people for whom these agents would be more or less effective.
- anti-VEGF-C agents or agents which inhibit the biological pathway of VEGF-C i.e. inhibitors of the VEGFR-2 and/or VEGFR-3 pathways, may have a role in preventing and/or treating AMD, with VEGF-C levels providing a biomarker to provide a method of identifying people for whom these agents would be more or less effective.
- angiogenesis is associated with the pathogenesis of AMD. It is believed that VEGF-A, a key molecule in driving angiogenesis, is associated with the pathogenesis of AMD. As a result, there are several anti-VEGF-A products approved for treatment of AMD. These include LucentisTM (an antibody fragment targeting VEGF-A) and EyleaTM (a soluble VEGFR-1/VEGFR-2 trap). Both LucentisTM and EyleaTM target and bind to VEGF-A (but not to VEGF-C). AvastinTM, the full length antibody version of LucentisTM is also used in off-label treatment of AMD. The findings described herein demonstrate that angiogenesis associated with AMD pathogenesis may not just involve VEGF-A. Elevated levels of VEGF-C, a molecule also associated with driving angiogenesis, also appears to be associated with AMD development and progression.
- LucentisTM an antibody fragment targeting VEGF-A
- EyleaTM a soluble VEGFR-1/VE
- the measuring of VEGF-C can occur at any one or more of the following time points: prior to an AMD diagnosis being made (e.g. in apparently healthy subjects), after a diagnosis of AMD has been made (e.g. in a screening or selection for potential targeted therapy), prior to initiation of a standard of care treatment, treatment regime or therapy for AMD, during treatment for AMD with a standard of care therapy or a targeted treatment, treatment regime or therapy, or after a course of treatment, treatment regime of therapy has been completed (e.g. to monitor for relapse).
- the measuring of VEGF-C occurs after a subject with AMD does not respond to anti-angiogenic therapies, including standard of care anti-angiogenic therapies.
- the measuring of VEGF-C occurs after a subject with AMD does not respond to, stops responding to or becomes less responsive to treatment with a standard of care anti-angiogenic agent such as, for example, LucentisTM, AvastinTM or EyleaTM.
- a standard of care anti-angiogenic agent such as LucentisTM, AvastinTM or EyleaTM.
- the subject may benefit from treatment with a VEGFR-3 inhibitor molecule that inhibits the action of VEGF-C such as, for example, a VEGF-C antibody, a VEGFR-3 antibody or a soluble VEGFR-3 trap.
- a VEGFR-3 inhibitor molecule that inhibits the action of VEGF-C such as, for example, a VEGF-C antibody, a VEGFR-3 antibody or a soluble VEGFR-3 trap.
- the subject may benefit from treatment with a standard of care anti-angiogenic agents or an agent that more specifically inhibits the action of VEGF-C such as, for example, a VEGF-C antibody, a VEGFR-3 antibody or a soluble VEGFR-3 trap.
- a combination of a standard of care anti-angiogenics for AMD e.g. LucentisTM, AvastinTM or EyleaTM
- a VEGFR-3 inhibitor molecule e.g. a VEGF-C antibody, a VEGFR-3 antibody or a soluble VEGFR-3 trap
- Such a combination anti-angiogenic therapy may provide significant benefits to the patient.
- VEGF-C (SEQ ID NOs: 1 and 2) is originally expressed as a larger precursor protein, prepro-VEGF-C, having extensive amino- and carboxy-terminal peptide sequences flanking a VHD, with the C-terminal peptide containing tandemly repeated cysteine residues in a motif typical of Balbiani ring 3 protein.
- the prepro-VEGF-C polypeptide is processed in multiple stages to produce a mature and most active VEGF-C polypeptide ( ⁇ N ⁇ C VEGF-C) of about 21-23 kD (as assessed by SDS-PAGE under reducing conditions).
- Such processing includes cleavage of a signal peptide (approximately residues 1-31 of SEQ ID NO: 2); cleavage of a carboxyl-terminal peptide (approximately residues 228-419 of SEQ ID NO: 2) to produce a partially-processed form of about 29 kD; and cleavage (apparently extracellularly) of an amino-terminal peptide (approximately residues 32-102 of SEQ ID NO: 2) to produce a fully-processed mature form of about 21-23 kD (approximately residues 103-227 of SEQ ID NO: 2).
- VEGF-C partially-processed forms of VEGF-C (e.g., the 29 kD form) are able to bind the Flt4 (VEGFR-3) receptor, whereas high affinity binding to VEGFR-2 occurs only with the fully processed forms of VEGF-C.
- amino acids 103-227 of SEQ ID NO: 2 are not all critical for maintaining VEGF-C functions.
- a polypeptide consisting of amino acids 112-215 (and lacking residues 103-111 and 216-227) of SEQ ID NO: 2 retains the ability to bind and stimulate VEGF-C receptors.
- the cysteine residue at position 156 has been shown to be important for VEGFR-2 binding ability. It appears that VEGF-C polypeptides naturally associate as non-disulfide linked dimers.
- a level of VEGF-C as a biomarker in a subject can be obtained by any art recognized methods. Typically, the level is obtained by measuring the level of VEGF-C in a sample including a body fluid, for example, blood, lymph, saliva, urine and the like. In a preferred embodiment, a level of VEGF-C is measured in a blood sample. In a preferred embodiment, a level of VEGF-C is measured in plasma.
- methods described herein are practiced through the detection of a VEGF-C protein.
- methods for detecting a VEGF-C protein can comprise contacting a biological sample with a compound that binds to and forms a complex with the polypeptide for a period sufficient to form the complex, and detecting the complex, so that if a complex is detected, a polypeptide disclosed herein is detected.
- the level of VEGF-C can be determined by immunoassays, e.g., enzyme-linked immunoassays (EIA) or enzyme-linked immunosorbent assays (ELISA); particle agglutination or flocculation tests (e.g., rapid latex agglutination); laser and rate nephelometry; turbidometry; or other known techniques for determining the presence and/or quantity of the marker.
- VEGF-C protein detection can be accomplished using antibodies specific for the protein in any of a number of formats commonly used by those of skill in the art for such detection.
- the compound is a polypeptide comprising an ECD fragment of VEGFR-3 that binds VEGF-C.
- the biological sample can be any tissue or fluid as described herein.
- the tissue of fluid is from the eye, including the back of the eye; in some variations, the tissue or fluid is systemic, such as blood or serum/plasma.
- the antibodies or fragments can be utilized in enzyme immunoassays, wherein the subject antibody or fragment, or second antibodies, are conjugated to an enzyme.
- a biological sample comprising a VEGF-C protein is combined with the subject antibodies, binding occurs between the antibodies and the VEGF-C protein.
- a biological sample containing cells expressing a mammalian VEGF-C protein, or biological fluid containing secreted VEGF-C is combined with the subject antibodies, and binding occurs between the antibodies and the VEGF-C protein present in the biological sample comprising an epitope recognized by the antibody.
- This bound protein can be separated from unbound reagents and the presence of the antibody-enzyme conjugate specifically bound to the VEGF-C protein can be determined, for example, by contacting the sample with a substrate of the enzyme which produces a color or other detectable change when acted on by the enzyme.
- the subject antibodies can be unlabeled, and a second, labeled antibody can be added which recognizes the subject antibody.
- suitable protein assay kits include those based on Luminex technology (i.e. which use the Luminex analysers) and microbead capture such as the BioPlexTM kits available from BioRad.
- the methods can include obtaining a level of VEGF-C in a subject by sending one or more samples of the subject biological sample (e.g. body fluid) to a laboratory, e.g., a commercial laboratory, for measurement of levels.
- the methods include measuring the level of the biomarker in a body fluid from a subject, and providing information regarding the level of the biomarker, e.g., to the subject or a caregiver, e.g., a clinical entity such as a physician, nurse, hospital, clinical practice, or third-party payor, e.g., an insurance company.
- Assaying VEGF-C by immunohistochemistry requires at least one anti-VEGF-C antibody.
- the anti-VEGF-C antibody can be used to detect the presence of VEGF-C protein in tissue samples obtained from the subject, including paraffin-embedded and frozen tumor sections. Typically, the tissue sections are initially treated in such a way as to retrieve the antigenic structure of proteins that were fixed in the initial process of collecting and preserving the tumor material. Slides are then blocked to prevent non-specific binding by the anti-VEGF-C detection antibody. The presence of VEGF-C protein is then detected by binding of the VEGF-C antibody to the VEGF-C protein.
- the detection antibody is linked to an enzyme, either directly or indirectly, e.g., through a secondary antibody that specifically recognizes the detection antibody.
- a secondary antibody that specifically recognizes the detection antibody.
- the tissue sections are washed and blocked with non-specific protein such as bovine serum albumin (BSA) between steps.
- BSA bovine serum albumin
- the slide is developed using an appropriate enzyme substrate to produce a visible signal, and the samples are then counterstained with hematoxylin.
- a method of detecting and/or quantitating expression of a mammalian VEGF-C protein or a portion of the VEGF-C protein by a cell in which a composition comprising a cell or fraction thereof (e.g., a soluble fraction) is contacted with an antibody or functional fragment thereof which binds to a mammalian VEGF-C protein or a portion of the VEGF-C protein under conditions appropriate for binding of the antibody or fragment thereto, and binding is monitored. Detection of the antibody, indicative of the formation of a complex between antibody and or a portion of the protein, indicates the presence of the protein.
- the method can be used to detect expression of VEGF-C in a biological sample of a mammalian subject (e.g., in a sample, such as a body fluid, such as blood, saliva or other suitable sample).
- a biological sample of a mammalian subject e.g., in a sample, such as a body fluid, such as blood, saliva or other suitable sample.
- the level of expression of VEGF-C in a biological sample of that subject can also be determined, for instance, by flow cytometry, and the level of expression (e.g., staining intensity) can be correlated with disease susceptibility, progression or risk.
- VEGF-C polynucleotides such as mRNA encoding a mammalian VEGF-C protein may be measured.
- methods for detecting VEGF-C mRNA can comprise contacting a biological sample with a compound that binds to and forms a complex with VEGF-C mRNA for a period sufficient to form the complex, and detecting the complex in a quantitative or semi-quantitative way.
- Such methods can also comprise amplification techniques involving contacting a biological sample with nucleic acid primers that anneal to VEGF-C mRNA or its complement, and amplifying annealed polynucleotides, so that if a polynucleotide is amplified, a VEGF-C polynucleotide is detected.
- polynucleotide sequences encoding a VEGF-C protein may be used in hybridization or PCR assays of fluids or tissues from biopsies to detect VEGF-C protein expression.
- Such methods may be qualitative or quantitative in nature and may include Southern or northern analysis, dot blot or other membrane-based technologies; PCR technologies; dip stick, pin, chip and ELISA technologies. All of these techniques are well known in the art and are the basis of many commercially available diagnostic kits.
- Real-time quantitative PCR can be conveniently accomplished using the commercially available ABI PRISM® 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions.
- PCR reagents can be obtained from PE-Applied Biosystems, Foster City, CA.
- Gene target quantities obtained by real time RT-PCR may be normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreenTTM (Molecular Probes, Inc. Eugene, OR).
- GAPDH expression is quantified by real time RT-PCR, by being run simultaneously with the target, multiplexing, or separately.
- RNA quantification reagent from Molecular Probes. Methods of RNA quantification by RiboGreenTM are taught in Jones et al. (1998). Controls are analyzed in parallel to verify the absence of DNA in the RNA preparation (-RT control) as well as the absence of primer dimers in control samples lacking template RNA. In addition, RT-PCR products may be analyzed by gel electrophoresis.
- a reverse transcriptase PCR (RT-PCR) amplification procedure may be performed in order to quantify the amount of mRNA amplified.
- Methods of reverse transcribing RNA into cDNA are well known and described in Sambrook et al. (1989).
- Alternative methods for reverse transcription utilize thermostable DNA polymerases. These methods are described in WO 90/07641, filed December 21, 1990 .
- Conditions for incubating a nucleic acid probe or antibody with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the nucleic acid probe or antibody used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or immunological assay formats can readily be adapted to employ the nucleic acid probes or antibodies disclosed herein. Examples of such assays can be found in Chard (1986); Bullock et al., (1982, 1983 and 1985); and Tijssen (1985). The tests disclosed herein include cells, protein extracts of cells, or biological fluids such as, blood, serum, and plasma.
- test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed.
- Methods for preparing protein extracts or membrane extracts of cells are well known in the art and can be readily be adapted in order to obtain a sample which is compatible with the system utilized.
- such assays may be useful in evaluating the efficacy of a particular therapeutic treatment regime in animal studies, in clinical trials, or in monitoring the treatment of an individual patient.
- the screening methods described herein may optionally comprise the step of prescribing for or administering to the subject identified as having elevated VEGF-C expression in the biological sample a composition comprising a molecule that inhibits the VEGFR-2 and/or VEGFR-3 pathway, preferably the VEGFR-3 pathway.
- precribing is meant providing an order or authorization for the therapy, which may be dispensed to the subject for self-administration and/or administered by a medical professional that is difference from the prescribing professional.
- the subject receives (is administered or self-administered) the therapy following the prescribing.
- the level of VEGF-C expression in a biological sample can be subjected to one or more of various comparisons. In general, it can be compared to: (a) VEGF-C mRNA or protein expression levels in a collection of comparable biological samples from subjects with AMD; (b) VEGF-C mRNA or protein expression levels in a collection of biological samples from healthy subjects; or (c) VEGF-C mRNA or protein expression levels in an arbitrary standard.
- VEGF-C measurements from multiple individuals are obtained, both healthy individuals and individuals with AMD, to establish a data set of VEGF-C mRNA or protein expression.
- a variety of standard statistical analyses can be performed to identify when a measurement of VEGF-C is elevated, e.g., in a statistically significant manner relative to a healthy control.
- the level of VEGF-C expression in a biological sample from a subject with AMD can be subjected to one or more of various comparisons.
- VEGF-C mRNA or protein expression level(s) in comparable biological samples from healthy subjects; or (b) VEGF-C mRNA or protein expression level in an arbitrary standard.
- a VEGF-C measurement of at least 1.0, 1.5, 2.0, 2.5 or at least 3.0 standard deviation(s) greater than a median VEGF-C measurement in corresponding healthy tissue is scored as elevated VEGF-C expression.
- a VEGF-C measurement that is statistically significantly greater than VEGF-C measurements in corresponding healthy tissue, with a p-value less than 0.1, or less than 0.05, or less than 0.01, or less than 0.005, or less than 0.001 is scored as elevated VEGF-C expression.
- the comparison can be refined by stratifying the data for additional variables, such as the age, sex, ethnicity, body mass, smoking habits or other factors that differentiate subjects.
- the screening methods described herein comprise comparing VEGF-C expression in the biological sample of an individual subject with a previous VEGF-C expression in the same subject, wherein elevated VEGF-C expression in the subsequent measurement identifies the subject as a subject for whom targeted AMD therapy will have efficacy.
- the methods described herein also include comparing the level of VEGF-C for the subject with a reference.
- the reference can take a variety of forms. It can be a single predetermined "cut-off" (threshold) value or concentration of VEGF-C, such as a median or mean, that has been determined from observations to represent an elevated measure of VEGF-C that (when equalled or exceeded) is predictive of the risk of development or progression of AMD in a subject or is predictive of the suitability of a subject for a clinical trial or is predictive of the suitability of a subject to be treated for AMD by use of particular treatments or therapies.
- the reference can depend upon the particular population selected. For example, an apparently healthy, non-smoker population (no detectable disease and no prior history of AMD) can have a different "normal" range of markers of VEGF-C than a smoking population, or a population the members of which have some stage of AMD. Accordingly, the reference selected may take into account the category in which a subject falls. Appropriate ranges and categories can be selected with no more than routine experimentation by those of ordinary skill in the art. In some embodiments, the reference is a predetermined value.
- Determination of a suitable cut-off is made using, e.g., statistical analysis of VEGF-C protein or mRNA concentration data collected from multiple healthy and/or AMD patients (including subjects in whom VEGF-C has been measured and for whom targeted therapy based on the VEGF-C biomarker measurement has been employed and monitored for efficacy).
- the cut-off concentration preferably is statistically determined to have optimal discriminating value for subjects who benefit from the targeted therapy (e.g., to have maximum sensitivity and specificity). It will be appreciated that statistical analysis of a dataset will permit clinicians to make informed decisions based on concentrations other than the optimal discriminating concentration (e.g., above or below the optimal discriminating concentration).
- the practitioner is capable of selecting a cut-off VEGF-C concentration having a desired level of sensitivity or specificity for predicting efficacy of targeted therapy. Considerations regarding the probability of success of targeted therapy based on VEGF-C measurement, versus the probability of success of alternative therapies based on any available clinical data, can guide the selection of an appropriate cut-off concentration of VEGF-C for making a treatment decision.
- the identifying, monitoring or selecting step of the screening or diagnostic methods described herein optionally comprises comparing the measurement of VEGF-C to a reference or control measurement of VEGF-C, and scoring the VEGF-C measurement from the sample as elevated, lowered (e.g. during targeted therapy) or normal based on statistical analysis or a ratio relative to the reference or control measurement.
- the reference or control measurement comprises at least one of the following; (a) a database containing multiple VEGF-C measurements from healthy subjects and/or AMD subjects in biological samples of the same type (e.g. blood, tissue etc.); or (b) a reference value calculated from multiple VEGF-C measurements from healthy subjects and/or subjects with AMD, optionally further including statistical distribution information for the multiple measurements, such as standard deviation.
- a VEGF-C measurement of at least 1.0 standard deviation greater than a median VEGF-C measurement in corresponding healthy subjects is scored as elevated VEGF-C expression.
- a VEGF-C measurement that is statistically significantly greater than VEGF-C measurements in corresponding healthy subjects, with a p-value less than 0.1, or less than 0.05, or less than 0.01, or less than 0.005, or less than 0.001 is scored as elevated VEGF-C expression.
- VEGFR-2 and/or VEGFR-3 is used to measure the amount of VEGF-C in a sample.
- the methods described herein comprises contacting the biological sample with VEGFR-2 and/or VEGFR-3 (or fragments thereof that bind to VEGF-C) and measuring the amount of bound VEGFR-2 and/or VEGFR-3.
- VEGFR-2 and VEGFR-3 are receptor tyrosine kinases that bind VEGF-C and the ligand-binding portions of the extracellular domain have been well characterized ( U.S. Patent No. 7,422,741 and International Patent Publication No. WO 2005/087808 ).
- VEGFR-2/VEGFR-3 is used as a capture moiety, then the sample can be pre-treated to remove VEGF-D or probed with a detection antibody that is specific for the VEGF-C.
- Elevated levels of VEGF-C in a sample indicate an increased risk of developing AMD or of AMD progression or an increased likelihood that the subject will benefit from a targeted therapy for AMD comprising use of a VEGFR-2 inhibitor molecule and/or a VEGFR-3 inhibitor molecule, for example, a VEGF-A antibody (e.g. AvastinTM; LucentisTM), a VEGF-C antibody, a soluble VEGFR-2 trap (e.g. EyleaTM), a soluble VEGFR-3 trap (e.g. VGX-300) or a VEGFR-3 antibody.
- a VEGFR-2 inhibitor molecule for example, a VEGF-A antibody (e.g. AvastinTM; LucentisTM), a VEGF-C antibody, a soluble VEGFR-2 trap (e.g. EyleaTM), a soluble VEGFR-3 trap (e.g. VGX-300) or a VEGFR-3 antibody.
- kits or assays that are specific for, and have appropriate sensitivity with respect to, biomarker references selected on the basis of the present invention.
- the kits or assays would differ from those presently commercially available, by including, for example, different cut-offs, and/or different sensitivities at particular cut-offs as well as instructions or other printed material for characterizing risk of developing AMD or progressing to advanced AMD, based upon the outcome of the assay.
- Risk factors for AMD include, for example, smoking, obesity, poor body mass index, fat intake, antioxidant vitamin and mineral intake, low dietary intake of vitamins A, C and E, and zinc, low dietary intake of lutein and omega-3 fatty acids, age, sex, family history of AMD, and physical exercise levels.
- biomarkers for AMD include genetic biomarkers, inflammatory biomarkers, nutrient biomarkers and other biomarkers.
- Examples of reported genetic biomarkers for AMD include CFH (complement factor H; chr 1), ABCA4 (ATP-binding cassette transporter; chr 1), COL8A1 (collagen type 8 alpha 1 subunit; chr 3), CF1 (complement factor 1; chr 4), VEGF-A (vascular endothelial growth factor A; chr 6), FRK / COL10A1 (fyn-related kinase/alpha chain of type X collagen; chr 6), CFB (complement factor B [properdin]; chr 6), C2 (complement component 2; chr 6), ARMS2/ HTRA1 (HtrA-serinepeptidasel; chr 10), LIPC (hepatic lipase; chr 15), CETP (cholesterylester transfer protein; chr 16),
- inflammatory biomarkers for AMD include markers of systemic inflammation such as, for example, CRP (C-reactive protein), cytokines, TNF-R2 (tissue necrosis factor alpha receptor-II and cellular adhesion molecules (CAMs). Cytokines include the human interleukins. In particular, IL-6 has been reported as a biomarker for AMD. Other reported inflammatory biomarkers of AMD include fibrinogen and VEGF-A.
- biomarkers for AMD include homocysteine levels, von Willebrand factors, and plasma leptin levels.
- VEGF-C measurement as a predictive, selective or responsive/tracking biomarker is dependent on combining the VEGF-C measurement (or a "risk” or “benefit” value associated with the VEGF-C measurement) as a factor in combination with one or more other risk factors for AMD and/or measured values of another biomarker for AMD. Prediction, selection or responsiveness/tracking based may be based on a multifactorial evaluation in which the VEGF-C measurement (or value associated with the measured level) is combined with at least one other biomarker or risk factor level or value.
- VEGF-C levels may be used in combination with other factors such as, for example, smoking, obesity, body mass index, fat intake, antioxidant vitamin and mineral intake, age, sex, family history of AMD, and physical exercise levels, inter alia.
- VEGF-C levels may be used in combination with another biomarker such as, for example, VEGF-A levels. Standard multivariate statistical analysis tools are used to optimize the predictive value of VEGF-C in combination with one or more of these additional biomarkers and/or risk factors.
- the method includes determining the level of VEGF-C in the subject; if the level of VEGF-C is high, then the subject is likely to benefit from the administration of a VEGFR-2 inhibitor molecule and/or a VEGFR-3 inhibitor molecule.
- the methods described herein can also be used to evaluate the efficacy of a treatment for reducing the risk of development or progression of AMD.
- the method can include determining the level of VEGF-C before, concurrently with, and/or after the administration of the treatment.
- the subject receives multiple treatments, e.g., a treatment is administered in multiple doses, e.g., one or more doses per day for one or more days, weeks, months, or years, and the level of VEGF-C is determined, e.g., before any treatment, and after one or more treatments.
- the treatment is the administration of a VEGF-A antibody, a VEGF-C antibody, a VEGFR-3 antibody, a soluble VEGFR-2 trap or a soluble VEGFR-3 trap or a combination of two or more, preferably no more than two, of these.
- the methods described herein are performed as part of a clinical trial of a treatment to reduce the risk of the development or progression of AMD. These methods have important implications for subject treatment and also for clinical development of new therapeutics. Physicians typically select therapeutic regimens for subject treatment based upon the expected net benefit to the subject. The net benefit is derived from the risk to benefit ratio. The present methods permit selection of subjects who are more likely to benefit by intervention, thereby aiding the physician in selecting a therapeutic regimen.
- the methods provide entry criteria and methods for selecting subjects for clinical trials, e.g., trials of AMD therapeutics, by selecting subjects having a given level of VEGF-C biomarker, having a level that is above or below a reference.
- Anti-angiogenic agents which can be used in methods of treatment or treatment steps described herein include, e.g., anecortave acetate (Alcon), which reduces production of matrix metalloproteinase, a key agent in the growth of neovascular membranes; or an agent that inhibits vascular endothelial growth factor A (VEGF-A).
- Alcon anecortave acetate
- VEGF-A vascular endothelial growth factor A
- a number of inhibitors of VEGF-A signalling are known in the art and can include, e.g., ZD6474 ( Tuccillo et al., Clin Cancer Res.
- COX-2 Tie2 receptor, angiopoietin, and neuropilin inhibitors; pigment epithelium-derived factor (PEDF), endostatin, and angiostatin (21-25); VEGF-A inhibitory aptamers, e.g., MacugenTM (pegaptanib, Pfizer); antibodies or fragments thereof, e.g., VEGF-A antibodies, e.g., bevacizumab (AvastinTM, Genentech), or fragments thereof, e.g., ranibizumab (LucentisTM, Genetech); soluble fms-like tyrosine kinase 1 (sFltl) polypeptides or polynucleotides ( Harris et al., Clin Cancer Res.
- PDF pigment epithelium-derived factor
- endostatin endostatin
- angiostatin 21-25
- VEGF-A inhibitory aptamers e.g., MacugenTM
- VEGF-A and its inhibitors see, e.g., Campochiaro, Ocular neovascularisation and excessive vascular permeability, Expert Opin Biol Ther. 2004 Sep;4(9): 1395-402 ; Ferrara, Vascular Endothelial Growth Factor: Basic Science and Clinical Progress, Endocr. Rev., August 1, 2004; 25(4):581-611 ; and Verheul and Pinedo, Vascular endothelial growth factor and its inhibitors, Drugs Today (Bare). 2003;39 Suppl C:81-93 .
- VEGFR-2 inhibitor molecule refers to any molecule that acts with specificity to reduce VEGF-C/VEGFR-2, VEGF-D/VEGFR-2 or VEGF-A/VEGFR-2 interactions, e.g., by blocking VEGF-C or VEGF-D binding to VEGFR-2, by blocking VEGF-A binding to VEGFR-2 or by reducing expression of VEGFR-2.
- the VEGFR-2 inhibitor inhibits VEGF-C and VEGF-D binding to VEGFR-2.
- the VEGFR-2 inhibitor inhibits binding of VEGF-A to VEGFR-2.
- the VEGFR-2 inhibitor can be a polypeptide comprising a soluble VEGFR-2 ECD fragment (amino acids 20-764 of human VEGFR-2, whose sequence is set forth in UniProtKB/Swiss-Prot accession no.
- a VEGFR-2 polypeptide fragment is fused to alkaline phosphatase (AP).
- the molecule that inhibits the VEGFR-2 pathways is, bevacizumab (AvastinTM, Genentech), or fragments thereof, e.g., ranibizumab (LucentisTM, Genentech) or Soluble VEGFR1/2 trap (VEGF-TrapTM (EyleaTM, Regeneron)).
- VEGFR-3 inhibitor molecule refers to any molecule that reduces the interaction of VEGF-C and/or VEGF-D with VEGFR-3 and includes, but is not limited to, an antibody that binds VEGF-C and inhibits VEGF-C stimulation of VEGFR-3; or a fragment of said antibody that retains the inhibitory activity; an antibody that binds VEGFR-3 and inhibits VEGF-C stimulation of VEGFR-3; or a fragment of said antibody that retains the inhibitory activity; a polypeptide that comprises a VEGFR-3 ECD fragment that binds VEGF-C and inhibits VEGF-C stimulation of VEGFR-3 ( WO 2005/098909 ); an antisense or interfering nucleic acid (e.g., antisense oligonucleotide; micro-RNA, short interfering RNA) that inhibits VEGF-C expression; an antisense or interfering nucleic acid that inhibits VEGFR-3 expression
- VEGF-C inhibitor molecule refers to any molecule that reduces the interaction of VEGF-C with VEGFR-2 and/or VEGFR-3 and includes, but is not limited to, an antibody that binds VEGF-C and inhibits VEGF-C stimulation of VEGFR-3; or a fragment of said antibody that retains the inhibitory activity; an antibody that binds VEGFR-3 and inhibits VEGF-C stimulation of VEGFR-3; or a fragment of said antibody that retains the inhibitory activity; an antibody that binds VEGFR-2 and inhibits VEGF-C stimulation of VEGFR-2; or a fragment of said antibody that retains the inhibitory activity; a polypeptide that comprises a VEGFR-2 or VEGFR-3 ECD fragment that binds VEGF-C and inhibits VEGF-C stimulation of VEGFR-2 or VEGFR-3 ( WO 2005/098909 ); an antisense or interfering nucleic acid (e.g., antisense
- VEGF-A inhibitor molecule refers to any molecule that reduces the interaction of VEGF-A with VEGFR-1 or VEGFR-2 (especially VEGFR-2), and includes, but is not limited to, an antibody that binds VEGF-A and inhibits VEGF-A stimulation of its receptors; an antibody that binds the receptor(s) and inhibits ligand-mediated stimulation of the receptor(s); antibody fragments; soluble extracellular domain fragments of the receptor(s) that bind VEGF-A, including domain swap fusions of receptors; and the like.
- a VEGFR-3 ECD receptor fragment comprises at least the first three Ig-like domains of the receptor.
- Soluble receptors capable of binding VEGF-C and VEGF-D, thereby inhibiting VEGF-C or VEGF-D activity or signaling via VEGFR-3 are also disclosed in WO2000/023565 , WO2000/021560 , WO2002/060950 and WO2005/087808 .
- Those soluble receptors, optionally modified with the ⁇ N2 sequon change described below and optionally other modifications described herein, are contemplated as aspects disclosed herein.
- Table 1 defines approximate boundaries of the Ig-like domains for human VEGFR-3. These boundaries are significant as the boundaries chosen can be used to form ligand binding molecules, and so can influence the binding properties of the resulting constructs. It will be appreciated that a construct containing two (or more adjacent Ig-like domains preferably will include most or all of the amino acids that naturally occur between the include domains.
- Table 1 Immunoglobulin-like domains for human VEGFR-3 VEGFR-3 SEQ ID NO: 3 positions VEGFR-3 SEQ ID NO: 4 positions D1 158-364 47-115 D2 479-649 154-210 D3 761-961 248-314 D4 1070-1228 351-403 D5 1340-1633 441-538 D6 1739-1990 574-657 D7 2102-2275 695-752
- the complete ECD extends to about position 775 of SEQ ID NO: 4.
- Soluble receptor constructs for use as a VEGFR-3 ECD fragment comprise at least one Ig-like domain of VEGFR-3 as described in Table 1, to as many as seven.
- the ligand binding molecule optionally will include sequence before the most N-terminally positioned Ig-like domain, optionally will include sequence beyond the most C-terminally Ig-like domain, and optionally will include sequence between the Ig-like domains as well. Variants, e.g., with one or more amino acid substitutions, additions, or deletions of an amino acid residue, are also contemplated.
- the ligand binding molecule comprises a fragment of human VEGFR-3 comprising at least the first three Ig-like domains of human VEGFR-3.
- the VEGFR-3 ECD fragment comprises Ig-like domains I-III of VEGFR-3 (referred to herein as "VGX-300") as described in Makinen et al., Nat. Med., 7:199-205 and International Publication Nos. WO2000/023565 , WO2000/021560 , WO2002/060950 and WO2005/087808 .
- the VEGFR-3 ECD fragment comprises a portion of a human VEGFR-3 ECD, wherein the portion binds to one or both of human VEGF-C and human VEGF-D, and comprises at least the first, second and third Ig-like domains of the VEGFR-3 ECD and preferably polypeptide lacks VEGFR-3 Ig-like domains 4-7 and preferably any transmembrane domain and preferably any intracellular domain.
- VEGFR-3 ECD fragments are contemplated in which the soluble receptor polypeptide comprises an amino acid sequence at least 90, 91, 92, 93, 94, or 95% identical to a VEGFR-3 fragment, wherein the VEGFR-3 fragment comprises an amino acid sequence consisting of a portion of SEQ ID NO: 4, wherein the carboxy-terminal residue of the fragment is selected from the group consisting of positions 211 to 247 of SEQ ID NO: 4, and wherein the fragment and the polypeptide bind VEGF-C or VEGF-D.
- the fragment has an amino terminal amino acid selected from the group consisting of positions of 1 to 47 of SEQ ID NO: 4.
- the VEGFR-3 fragment used to make the soluble receptor has an amino terminal residue selected from the group consisting of positions 1 to 47 of SEQ ID NO: 4, and a carboxy-terminal residue selected from the group consisting of positions 226 to 775 of SEQ ID NO: 4, wherein VEGFR-3 fragment binds at least one of VEGF-C and VEGF-D.
- Specific peptides include a fragment of VEGFR-3 defined by positions 1-226, positions 1-229, and positions 1-329, positions 47-224, positions 47-225, positions 47-226, positions 47-227, positions 47-228, positions 47-229, positions 47-230, positions 47-231, positions 47-232, positions 47-236, positions 47-240, positions 47-245, positions 47-314, positions 47-210, and positions 47-247 of SEQ ID NO: 4.
- the amino acid sequence of the ECD fragment of VEGFR-3 is modified from wildtype VEGFR-3 to eliminate the second putative N-linked glycosylation sequon of wildtype VEGFR-3, and wherein the polypeptide lacks VEGFR-3 Ig-like domains 4-7 and preferably any transmembrane domain and preferably any intracellular domain.
- the VEGFR-3 ECD fragment comprises a modified VEGFR-3 ECD fragment (referred to as VGX-301 ⁇ N2) as described in International Patent Application Nos.: PCT/AU2014/000161 and PCT/AU2014/000114 .
- the VEGFR-3 ECD fragment is a polypeptide that comprises a portion of a human VEGFR-3 ECD, wherein the portion binds to human VEGF-C and comprises at least the first, second and third Ig-like domains of the VEGFR-3 ECD.
- the amino acid sequence of the ECD fragment of VEGFR-3 is modified from wildtype VEGFR-3 to eliminate the second putative N-linked glycosylation sequon of wildtype VEGFR-3, and wherein the polypeptide lacks VEGFR-3 Ig-like domains 4-7 and preferably any transmembrane domain and preferably any intracellular domain.
- the VEGFR-3 ECD fragment comprises a polypeptide similar or identical in amino acid sequence to a human VEGFR-3 polypeptide (SEQ ID NO: 4) or fragment thereof, with the proviso that positions of the VEGFR-3 ECD fragment corresponding to positions 104-106 of the human VEGFR-3 polypeptide set forth in SEQ ID NO: 4 are not identical to N-X-S or N-X-T, wherein the VEGFR-3 ECD fragment binds human VEGF-C.
- the fragment minimally comprises enough of the VEGFR-3 sequence to bind the ligand, and may comprise the complete receptor. Extracellular domain fragments are preferred.
- Preferred polypeptides have an amino acid sequence at least 80% identical to a ligand binding fragment thereof.
- Fragments that are more similar e.g., 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100% are highly preferred. Fragments that are 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, and 75% are also contemplated.
- a genus of similar polypeptides can alternatively be defined by the ability of encoding polynucleotides to hybridize to the complement of a nucleotide sequence that corresponds to the cDNA sequence encoding the VEGFR-3 receptor.
- the VEGFR-3 ECD fragment comprises a polypeptide comprising a fragment of human VEGFR-3 (SEQ ID NO: 4) selected from the group consisting of positions 1-226 or 25-226 of SEQ ID NO: 4, positions 1-229 or 25-229 of SEQ ID NO: 4 and positions 1-329 or 25-229 of SEQ ID NO: 4, with the proviso that positions 104-106 of SEQ ID NO: 4 are not identical to N-X-S or N-X-T.
- SEQ ID NO: 4 human VEGFR-3
- the VEGFR-3 ECD fragment is a polypeptide comprising a fragment of human VEGFR-3 (SEQ ID NO: 4) selected from the group consisting of positions 47-224 of SEQ ID NO: 4, positions 47-225 of SEQ ID NO: 4, positions 47-226 of SEQ ID NO: 4, positions 47-227 of SEQ ID NO: 4, positions 47-228 of SEQ ID NO: 4, positions 47-229 of SEQ ID NO: 4, positions 47-230 of SEQ ID NO: 4, positions 47-231 of SEQ ID NO: 4, positions 47-232 of SEQ ID NO: 4, positions 47-236 of SEQ ID NO: 4, positions 47-240 of SEQ ID NO: 4, and positions 47-245 of SEQ ID NO: 4, with the proviso that positions 104-106 of the encoded ligand binding fragment of VEGFR-3 are not identical to N-X-S or N-X-T.
- the VEGFR-3 ECD fragment is a polypeptide comprising a fragment of human VEGFR-3 (SEQ ID NO: 4), selected from the group consisting of positions 47-314 of SEQ ID NO: 4, positions 47-210 of SEQ ID NO: 4, and positions 47-247 of SEQ ID NO: 4, with the proviso that positions 104-106 of SEQ ID NO: 4 are not identical to N-X-S or N-X-T.
- the VEGFR-3 ECD fragment is operably linked to an immunoglobulin or a portion of an immunoglobulin as the fusion partner.
- the VEGFR-3 ECD fragment is operably linked to all or a portion of an immunoglobulin, particularly a human immunoglobulin, even more particularly the Fc portion of a human immunoglobulin.
- fusion proteins can be prepared by transfecting cells with DNA encoding VEGFR-3 subunit:Fc fusion protein and expressing the dimers in the same cells.
- the ligand binding polypeptides are the same on each monomer subunit (i.e the dimer is a homodimer).
- the VEGFR-3 ECD fragment comprises an amino acid sequence that is similar or identical to the amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the VEGFR-3 ECD fragment comprises an amino acid sequence comprising amino acids 22-290 or 23-290 of SEQ ID NO: 5. In some embodiments, the ligand binding molecule comprises amino acids 22-537or 23-537 of SEQ ID NO: 5 or amino acids 1-537 of SEQ ID NO: 5.
- the molecule comprises short interfering RNA (siRNA) that inhibits VEGF-C expression.
- siRNA short interfering RNA
- RNA interference of the VEGF family of proteins and receptors is described in U.S. Patent application Publication Nos.: 2006/0217332 , 2006/0025370 , 2005/0233998 , 2005/0222066 and 2005/0171039 .
- Interfering RNA directed to VEGF or VEGFR family members is described in U.S. Patent Publication No. 2006/0217332 .
- the molecule comprises a zinc finger protein that inhibits VEGF-C expression.
- VEGFR-3 antibodies and their production are described in U.S. Patent Nos. 6,107,046 and 6,824,777 ; U.S. Patent Publication Nos. 2006/0269548 and 2006/0177901 ; and International Patent Application No. PCT/FI95/00337 ( WO 95/33772 ).
- VEGF-C antibodies are described, for example, in International Patent Application Nos. PCT/FI1996/000427 ( WO/1997/005250 ) and PCT/US1998/001973 ( WO/1998/033917 ); and U.S. Patent Publication Nos. 2004/0147726 , 2005/0232921 , 2005/0192429 , 2005/0059117 , 2005/0282228 , 2003/0176674 , and 2006/0121025 , 2006/0030000 , and U.S. Patent No. 6,403,088 .
- VEGFR antibodies and other inhibitor compounds are described, for example, in U.S. Patent Nos. 7,056,509 ; 7,052,693 ; 6,986,890 ; 6,897,294 ; 6,887,468 ; 6,878,720 ; 6,344,339 ; 5,955,311 ; 5,874,542 ; and 5,840,301 .
- VEGF-A mediated stimulation of VEGF receptors Any chemical substance that can be safely administered as a therapeutic and that can be used to modulate biochemical pathway targets identified herein, such as VEGF-A mediated stimulation of VEGF receptors, may be used as disclosed herein.
- Small molecules that inhibit the interaction between VEGF-C and/or VEGFR-3 with VEGFR-3 are specifically contemplated.
- VEGF-C/VEGF-D inhibitors are disclosed in U.S. Patent No. 7,045,133 .
- That patent describes, for example, monomeric monocyclic peptide inhibitors based on loop 1, 2 or 3 of VEGF-D.
- a preferred peptide interferes with at least the activity of VEGF-D and VEGF-C mediated by VEGF receptor-2 and VEGF receptor-3 (VEGFR-3).
- a particularly preferred peptide interferes with the activity of VEGF-D, VEGF-C and VEGF mediated by VEGFR-2 and the activity of VEGF-D and VEGF-C mediated by VEGFR-3.
- the patent also describes a dimeric bicyclic peptide inhibitor which comprises two monomeric monocyclic peptides, each individually based on loop 1, 2 or 3 of VEGF-D, linked together. Such dimeric bicyclic peptides may comprise two monomeric monocyclic peptides which are the same or different. (See, for example, Table 1-3 of the '133 patent.)
- the VEGF receptors are receptor tyrosine kinases and intracellular signaling is initiated through receptor phosphorylation. Accordingly, one preferred class of molecules for practice as disclosed herein is tyrosine kinase inhibitors, including those described in and Morin, Oncogene, 19(56):6574-83, 2000 . VEGFR-3 inhibitors are disclosed in U.S. Patent Publication No. 2002-0164667 .
- the methods described herein optionally further comprise administering a tyrosine kinase inhibitor that inhibits VEGFR-2 and/or VEGFR-3 activity.
- Exemplary tyrosine kinase inhibitors for use in the methods described herein include, but are not limited to, AEE788 (TKI, VEGFR-2, EGFR: Novartis); ZD6474 (TKI, VEGFR-1, -2,-3, EGFR: Zactima: AstraZeneca); AZD2171 (TKI, VEGFR-1, -2: AstraZeneca); SU 11248 (TKI, VEGFR-1, -2, PDGFR: Sunitinib: Pfizer); AG13925 (TKI, VEGFR-1, -2: Pfizer); AG013736 (TKI, VEGFR-1, -2: Pfizer); CEP-7055 (TKI, VEGFR-1, -2,-3: Cephalon); CP-547,632 (TKI, VEGFR-1, -2: Pfizer); GW7S6024 (TKL VEGFR-1, -2, -3: GlaxoSmithKline); GW
- TKI ErbB-2, EGFR, and GD-2016: Tykerb: GlaxoSmithKline.
- MLN518 TKI, Flt3, PDGFR, c-KIT (T53518: Millennium Pharmaceuticals); lestaurinib (TKI, FLT3, CEP-701, Cephalon); ZD 1839 (TKI, EGFR: gefitinib, Iressa: AstraZcneca); OSI-774 (TKI, EGFR: Erlotininb: Tarceva: OSI Pharmaceuticals); lapatinib (TKI, ErbB-2, EGFR, and GD-2016: Tykerb: GlaxoSmithKline).
- the methods described herein further comprise administering a tyrosine kinase inhibitor that inhibits angiogenesis to the subject.
- a tyrosine kinase inhibitor that inhibits angiogenesis.
- Exemplary anti-angiogenic tyrosine kinases and their targets are provided below in Table 2.
- the methods described herein further comprise administering an inhibitor of the PI3/AKT/mTOR pathway.
- the inhibitor is a PI3 kinase inhibitor selected from the group consisting of wortmannin (Calbiochem), 3-methyladenine (3-MA, Sigma), LY294002 (Calbiochem) and chloroquine.
- the inhibitor is a mTOR (mammalian target of rapamycin) inhibitor.
- mTOR inhibitors include, but are not limited to, the following: Brand Name or Product # Generic Name Patent (U.S. Unless Specified) or Reference Rapamune® rapamycin (sirolimus) 3,929,992; 5,288,711; 5,516,781 RAD001 (Certican®) everolimus; 40-O-(2-hydroxyethyl)-rapamycin EP663916 ; U.S. Pat. Appl.
- Rapamycin derivatives may also include without limitation "rapalogs," e.g., as disclosed in WO 98/02441 and WO01/14387 ; deuterated rapamycin analogs, e.g., as disclosed in U.S. Pat. 6,503,921 . Derivatives of other mTOR inhibitors are also contemplated.
- VEGFR-2 inhibitors or VEGFR-3 inhibitors described herein include, but are not limited to, the compounds provided below in Table 1.
- VEGFR-2 inhibitors or VEGFR-3 inhibitors described herein include PDGF inhibitors.
- a PDGF Inhibitor Product inhibitor product may be administered in combination with one or more of the agents described herein for inhibiting binding between the VEGF family of proteins and VEGF receptors.
- the inhibitor products are co-administered in a single composition.
- the inhibitor products administered as separate compositions.
- Exemplary PDGF inhibitors are also described in Table 1 above.
- Exemplary PDGF inhibitors include antibodies that bind to a PDGF protein (e.g., PDGF-A, -B, -C, and/or -D and/or homodimers or heterodimers thereof); antibodies that bind to a PDGF receptor (e.g., PDGF- ⁇ and/or PDGF- ⁇ and/or heterodimers or homodimers thereof); and PDGF ligand traps comprised of a soluble, ligand-binding extracellular domain fragment of either or both receptors, optionally fused to a heterologous protein such as an immunoglobulin constant domain.
- a PDGF protein e.g., PDGF-A, -B, -C, and/or -D and/or homodimers or heterodimers thereof
- antibodies that bind to a PDGF receptor e.g., PDGF- ⁇ and/or PDGF- ⁇
- PDGF refers to a platelet-derived growth factor that regulates cell growth or division.
- PDGF includes the various subtypes of PDGF including PDGF-B, PDGF-A, PDGF-C, PDGF-D, variant forms thereof and dimerized forms thereof, including PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD.
- Platelet derived growth factors includes homo- or heterodimers of A-chain (PDGF-A) and B-chain (PDGF-B) that exert their action via binding to and dimerization of two related receptor tyrosine kinase platelet-derived growth factor cell surface receptors (i.e., PDGFRs), PDGFR- ⁇ and PDGFR- ⁇ .
- PDGFRs receptor tyrosine kinase platelet-derived growth factor cell surface receptors
- PDGFR- ⁇ two related receptor tyrosine kinase platelet-derived growth factor cell surface receptors
- PDGF-C and PDGF-D two additional protease-activated ligands for the PDGFR complexes, have been identified ( Li et al., (2000) Nat. Cell. Biol. 2: 302-9 ; Bergsten et al., (2001) Nat. Cell. Biol.
- PDGFR- ⁇ / ⁇ binds PDGF-AA, PDGF-BB, PDGF-AB, and PDGF-CC
- PDGFR- ⁇ / ⁇ binds PDGF-BB and PDGF-DD
- PDGFR- ⁇ / ⁇ binds PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD
- PDGF also refers to those members of the class of growth factors that induce DNA synthesis and mitogenesis through the binding and activation of a PDGFR on a responsive cell type.
- PDGFs can effect, for example: directed cell migration (chemotaxis) and cell activation; phospholipase activation; increased phosphatidylinositol turnover and prostaglandin metabolism; stimulation of both collagen and collagenase synthesis by responsive cells; alteration of cellular metabolic activities, including matrix synthesis, cytokine production, and lipoprotein uptake; induction, indirectly, of a proliferative response in cells lacking PDGF receptors; and potent vasoconstrictor activity.
- the term “PDGF” can be used to refer to a "PDGF” polypeptide, a "PDGF” encoding gene or nucleic acid, or a dimerized form thereof.
- PDGF inhibitor product refers to an agent that reduces, or inhibits, either partially or fully, the activity or production of a PDGF.
- a PDGF inhibitor product can directly or indirectly reduce or inhibit the activity or production of a specific PDGF such as PDGF-B.
- PDGF inhibitor products include agents that act on a PDGF ligand or its cognate receptor so as to reduce or inhibit a PDGF-associated receptor signal.
- PDGF inhibitor products include antisense molecules, ribozymes or RNAi that target a PDGF nucleic acid; PDGF aptamers, PDGF antibodies to PDGF itself or its receptor, or soluble PDGF receptor decoys that prevent binding of a PDGF to its cognate receptor; antisense molecules, ribozymes or RNAi that target a cognate PDGF receptor (PDGFR) nucleic acid; PDGFR aptamers or PDGFR antibodies that bind to a cognate PDGFR receptor; and PDGFR tyrosine kinase inhibitors.
- PDGFR PDGF receptor
- the PDGF inhibitor product is selected from: a compound of Formula A, B, C, D or E as described and defined is US 2012/0100136 , p1B3 antibody, CDP860, IMC-3G3, 162.62 antibody, 163.31 antibody, 169.14 antibody, 169.31 antibody, ⁇ R1 antibody, 2A1E2 antibody, M4TS.11 antibody, M4TS.22 antibody, Hyb 120.1.2.1.2 antibody, Hyb 121.6.1.1.1 antibody, Hyb 127.5.7.3.1 antibody, Hyb 127.8.2.2.2 antibody, Hyb 1.6.1 antibody, Hyb 1.11.1 antibody, Hyb 1.17.1 antibody, Hyb 1.18.1 antibody, Hyb 1.19.1 antibody, Hyb 1.23.1 antibody, Hyb 1.24 antibody, Hyb 1.25 antibody, Hyb 1.29 antibody, Hyb 1.33 antibody, Hyb 1.38 antibody, Hyb 1.39 antibody, Hyb 1.40 antibody, Hyb 1.45 antibody, Hyb 1.46 antibody, Hyb 1.48 antibody, Hyb 1.49 antibody,
- one or more inhibitors of VEGF-A/VEGF-C//VEGF-D/VEGFR-2/VEGFR-3 described herein are administered in combination with a PDGFR-beta antibody (such as that being developed by Regeneron Inc. for ocular indications) or an anti-PDGF aptamer (such as E10030 being developed by Ophthotech Inc. for ocular indications).
- a PDGFR-beta antibody such as that being developed by Regeneron Inc. for ocular indications
- an anti-PDGF aptamer such as E10030 being developed by Ophthotech Inc. for ocular indications.
- the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule is administered in conjunction with another modality for treating, preventing or delaying the development of AMD.
- a number of such treatments are known in the art, e.g., photodynamic therapy or laser photocoagulation to treat wet AMD, diet and exercise regiments, and or vitamin supplements, e.g., as described in AREDS Research Group, Arch Ophthalmol 2001 :119, 1417-1436 ; Seddon et al, JAMA, 1994; 272: 1413-1420 , and U.S. Pat. No. 6,660,297 .
- the methods include administering to the subject an anti-angiogenesis agent as described above.
- a system that is capable of carrying out a part or all of a method of the invention, or carrying out a variation of a method of the invention as described herein in greater detail.
- Exemplary systems include, as one or more components, computing systems, environments, and/or configurations that may be suitable for use with the methods and include, but are not limited to, personal computers, server computers, hand-held or laptop devices, multiprocessor systems, microprocessor-based systems, set top boxes, programmable consumer electronics, network PCs, minicomputers, mainframe computers, distributed computing environments that include any of the above systems or devices, and the like.
- a system disclosed herein includes one or more machines used for analysis of biological material (e.g., genetic material), as described herein. In some variations, this analysis of the biological material involves a chemical analysis and/or a nucleic acid amplification.
- an exemplary system disclosed herein which may be used to implement one or more steps of methods of the invention, includes a computing device in the form of a computer 110.
- Components shown in dashed outline are not technically part of the computer 110, but are used to illustrate the exemplary embodiment of Figure 11 .
- Components of computer 110 may include, but are not limited to, a processor 120, a system memory 130, a memory/graphics interface 121, also known as a Northbridge chip, and an I/O interface 122, also known as a Southbridge chip.
- the system memory 130 and a graphics processor 190 may be coupled to the memory/graphics interface 121.
- a monitor 191 or other graphic output device may be coupled to the graphics processor 190.
- a series of system busses may couple various system components including a high speed system bus 123 between the processor 120, the memory/graphics interface 121 and the I/O interface 122, a front-side bus 124 between the memory/graphics interface 121 and the system memory 130, and an advanced graphics processing (AGP) bus 125 between the memory/graphics interface 121 and the graphics processor 190.
- the system bus 123 may be any of several types of bus structures including, by way of example, and not limitation, such architectures include Industry Standard Architecture (ISA) bus, Micro Channel Architecture (MCA) bus and Enhanced ISA (EISA) bus.
- ISA Industry Standard Architecture
- MCA Micro Channel Architecture
- EISA Enhanced ISA
- the computer 110 typically includes a variety of computer-readable media.
- Computer-readable media can be any available media that can be accessed by computer 110 and includes both volatile and nonvolatile media, removable and non-removable media.
- Computer readable media may comprise computer storage media.
- Computer storage media includes both volatile and nonvolatile, removable and non-removable media implemented in any method or technology for storage of information such as computer readable instructions, data structures, program modules or other data.
- Computer storage media includes, but is not limited to, RAM, ROM, EEPROM, flash memory or other memory technology, CD-ROM, digital versatile disks (DVD) or other optical disk storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices, or any other physical medium which can be used to store the desired information and which can accessed by computer 110.
- the system memory 130 includes computer storage media in the form of volatile and/or nonvolatile memory such as read only memory (ROM) 131 and random access memory (RAM) 132.
- the system ROM 131 may contain permanent system data 143, such as identifying and manufacturing information.
- a basic input/output system (BIOS) may also be stored in system ROM 131.
- RAM 132 typically contains data and/or program modules that are immediately accessible to and/or presently being operated on by processor 120.
- Fig. 7 illustrates operating system 134, application programs 135, other program modules 136, and program data 137.
- the I/O interface 122 may couple the system bus 123 with a number of other busses 126, 127 and 128 that couple a variety of internal and external devices to the computer 110.
- a serial peripheral interface (SPI) bus 126 may connect to a basic input/output system (BIOS) memory 133 containing the basic routines that help to transfer information between elements within computer 110, such as during start-up.
- BIOS basic input/output system
- a super input/output chip 160 may be used to connect to a number of'legacy' peripherals, such as floppy disk 152, keyboard/mouse 162, and printer 196, as examples.
- the super I/O chip 160 may be connected to the I/O interface 122 with a bus 127, such as a low pin count (LPC) bus, in some embodiments.
- a bus 127 such as a low pin count (LPC) bus, in some embodiments.
- LPC low pin count
- Various embodiments of the super I/O chip 160 are widely available in the commercial marketplace.
- bus 128 may be a Peripheral Component Interconnect (PCI) bus, or a variation thereof, may be used to connect higher speed peripherals to the I/O interface 122.
- PCI Peripheral Component Interconnect
- a PCI bus may also be known as a Mezzanine bus.
- Variations of the PCI bus include the Peripheral Component Interconnect-Express (PCI-E) and the Peripheral Component Interconnect - Extended (PCI-X) busses, the former having a serial interface and the latter being a backward compatible parallel interface.
- bus 128 may be an advanced technology attachment (ATA) bus, in the form of a serial ATA bus (SATA) or parallel ATA (PATA).
- ATA advanced technology attachment
- the computer 110 may also include other removable/non-removable, volatile/nonvolatile computer storage media.
- Fig. 7 illustrates a hard disk drive 140 that reads from or writes to non-removable, nonvolatile magnetic media.
- the hard disk drive 140 may be a conventional hard disk drive..
- Removable media such as a universal serial bus (USB) memory 153, firewire (IEEE 1394), or CD/DVD drive 156 may be connected to the PCI bus 128 directly or through an interface 150.
- a storage media 154 may coupled through interface 150.
- Other removable/non-removable, volatile/nonvolatile computer storage media that can be used in the exemplary operating environment include, but are not limited to, magnetic tape cassettes, flash memory cards, digital versatile disks, digital video tape, solid state RAM, solid state ROM, and the like.
- the storage media is any non-transitory media, excluding, e.g., a signal.
- hard disk drive 140 is illustrated as storing operating system 144, application programs 145, other program modules 146, and program data 147. Note that these components can either be the same as or different from operating system 134, application programs 135, other program modules 136, and program data 137. Operating system 144, application programs 145, other program modules 146, and program data 147 are given different numbers here to illustrate that, at a minimum, they are different copies.
- a user may enter commands and information into the computer 20 through input devices such as a mouse/keyboard 162 or other input device combination.
- Other input devices may include a microphone, joystick, game pad, satellite dish, scanner, or the like. These and other input devices are often connected to the processor 120 through one of the I/O interface busses, such as the SPI 126, the LPC 127, or the PCI 128, but other busses may be used. In some embodiments, other devices may be coupled to parallel ports, infrared interfaces, game ports, and the like (not depicted), via the super I/O chip 160.
- the computer 110 may operate in a networked environment using logical connections to one or more remote computers, such as a remote computer 180 via a network interface controller (NIC) 170,.
- the remote computer 180 may be a personal computer, a server, a router, a network PC, a peer device or other common network node, and typically includes many or all of the elements described above relative to the computer 110.
- the logical connection between the NIC 170 and the remote computer 180 depicted in Figure 11 may include a local area network (LAN), a wide area network (WAN), or both, but may also include other networks.
- LAN local area network
- WAN wide area network
- Such networking environments are commonplace in offices, enterprise-wide computer networks, intranets, and the Internet.
- the remote computer 180 may also represent a web server supporting interactive sessions with the computer 110, or in the specific case of location-based applications may be a location server or an application server.
- the network interface may use a modem (not depicted) when a broadband connection is not available or is not used. It will be appreciated that the network connection shown is exemplary and other means of establishing a communications link between the computers may be used.
- a system for identifying susceptibility to a maculopathy, such as macular degeneration, or pathogenic ocular neovascularization, in a human subject includes tools for performing at least one step, preferably two or more steps, and in some aspects all steps of a method of the invention, where the tools are operably linked to each other.
- Operable linkage describes a linkage through which components can function with each other to perform their purpose.
- a system disclosed herein is a system for assessing risk of a human subject for developing a disease or condition selected from a maculopathy and pathogenic ocular neovascularization, the system comprising:
- Exemplary processors include all variety of microprocessors and other processing units used in computing devices.
- Exemplary computer-readable media are described above.
- the system generally can be created where a single processor and/or computer readable medium is dedicated to a single component of the system; or where two or more functions share a single processor and/or share a single computer readable medium, such that the system contains as few as one processor and/or one computer readable medium.
- some components of a system may be located at a testing laboratory dedicated to laboratory or data analysis, whereas other components, including components (optional) for supplying input information or obtaining an output communication, may be located at a medical treatment or counseling facility (e.g., doctor's office, health clinic, HMO, pharmacist, geneticist, hospital) and/or at the home or business of the human subject (patient) for whom the testing service is performed.
- a medical treatment or counseling facility e.g., doctor's office, health clinic, HMO, pharmacist, geneticist, hospital
- an exemplary system includes a database 208 that is operatively coupled to a computer-readable medium of the system and that contains population information correlating the measurement of VEGF-C and risk for developing the disease or condition in a population of humans.
- the database contains 208 data relating to the level of VEGF-C observed in a biological sample of a population of humans with the maculopathy and/or pathogenic ocular neovascularization and information about the level of VEGF-C observed in healthy subjects.
- data provides an indication as to the potential of developing maculopathy and/or pathogenic ocular neovascularization for a human subject that is identified as expressing an elevated level of VEGF-C.
- the database becomes more populated with patient data, it become a more powerful statistical tool for comparing an input with respect to a subject and making a prediction as to metastatic potential.
- Such information includes, but is not limited to, information about parameters such as age, sex, ethnicity, race, medical history, weight, diabetes status, blood pressure, family history, smoking history, and alcohol use in humans and impact of the at least one parameter on the disease or condition.
- parameters such as age, sex, ethnicity, race, medical history, weight, diabetes status, blood pressure, family history, smoking history, and alcohol use in humans and impact of the at least one parameter on the disease or condition.
- risk factors are combined using a multiplicative model.
- logistic regression or other statistical tools are used to combine risk factors.
- the system further includes a measurement tool 206 programmed to receive an input 204 from or about the human subject and generate an output that contains information about the VEGF-C measurement.
- the input 204 is not part of the system per se but is illustrated in the schematic Figure 12 .
- the input 204 will contain a specimen or contain data from which a level of VEGF-C in a biological sample can be directly read, or analytically determined.
- the input 204 from the human subject contains data that is unannotated or insufficiently annotated with respect to VEGF-C, requiring analysis by the measurement tool 206.
- the input can be raw data measurements from experiments designed to evaluate the level of VEGF-C in a biological sample.
- the measurement tool 206 comprises a tool, preferably stored on a computer-readable medium of the system and adapted to be executed on a processor of the system, to receive a data input about a subject and determine information about the level of VEGF-C in the biological sample from the data.
- the measurement tool 206 contains instructions, preferably executable on a processor of the system, for analyzing the unannotated input data and determining the level of VEGF-C of interest in the human subject.
- the input 204 from the human subject comprises a biological sample, such as a fluid (e.g., ocular fluid, blood, serum or plasma) or ocular tissue, blood vessel or lymphatic vessel tissue sample, that can be analyzed to determine the level of VEGF-C in the sample.
- a biological sample such as a fluid (e.g., ocular fluid, blood, serum or plasma) or ocular tissue, blood vessel or lymphatic vessel tissue sample, that can be analyzed to determine the level of VEGF-C in the sample.
- a biological sample such as a fluid (e.g., ocular fluid, blood, serum or plasma) or ocular tissue, blood vessel or lymphatic vessel tissue sample, that can be analyzed to determine the level of VEGF-C in the sample.
- an exemplary measurement tool 206 includes laboratory equipment for processing and analyzing the sample to determine the level of VEGF-C in the biological sample of the human subject.
- the measurement tool 206 includes: immunoassay reagents for measuring VEGF-C in the biological sample; and an analysis tool stored on a computer-readable medium of the system and adapted to be executed on a processor of the system, to determine the level of VEGF-C in the sample based on the immunoassay data.
- the measurement tool 206 further includes additional equipment and/or chemical reagents for processing the biological sample to purify VEGF-C from cells in a sample for further analysis using immunoassays, size separation tools, or other analytical equipment.
- the exemplary system further includes an analysis tool or routine 210 that: is operatively coupled to the database 208 and operatively coupled to the measurement tool 206, is stored on a computer-readable medium of the system, is adapted to be executed on a processor of the system to compare the information about the human subject with the population information in the database 208 and generate a conclusion with respect to potential for developing maculopathy and/or pathogenic ocular neovascularization in the human subject.
- the analysis tool 210 looks at the level of VEGF-C identified by the measurement tool 206 for the human subject, and compares this information to the database 208, to determine potential for developing maculopathy and/or pathogenic ocular neovascularization in the subject.
- the susceptibility can be based on the single parameter (the level of VEGF-C), or can involve a calculation based on other genetic and non-genetic data, as described above, that is collected and included as part of the input 204 from the human subject, and that also is stored in the database 208 with respect to a population of other humans.
- each parameter of interest is weighted to provide a conclusion with respect to the disease or condition.
- Such a conclusion is expressed in the conclusion in any statistically useful form, for example, as a relative risk, an odds ratio, a lifetime risk, or a probability that the subject will develop maculopathy and/or pathogenic ocular neovascularization.
- the system as just described further includes a communication tool 212.
- the communication tool is operatively connected to the analysis routine 210 and comprises a routine stored on a computer-readable medium of the system and adapted to be executed on a processor of the system, to: generate a communication containing the conclusion; and to transmit the communication to the human subject 200 or the medical practitioner 202, and/or enable the subject or medical practitioner to access the communication.
- the subject and medical practitioner are depicted in the schematic Figure 13 , but are not part of the system per se, though they may be considered users of the system.
- the communication tool 212 provides an interface for communicating to the subject, or to a medical practitioner for the subject (e.g., doctor, nurse, genetic counselor), the conclusion generated by the analysis tool 210 with respect to potential for developing maculopathy and/or pathogenic ocular neovascularization in the subject.
- a medical practitioner for the subject (e.g., doctor, nurse, genetic counselor)
- the communication is obtained by or delivered to the medical practitioner 202, the medical practitioner will share the communication with the human subject 200 and/or counsel the human subject about the medical significance of the communication.
- the communication is provided in a tangible form, such as a printed report or report stored on a computer readable medium such as a flash drive or optical disk.
- the communication is provided electronically with an output that is visible on a video display or audio output (e.g., speaker).
- the communication is transmitted to the subject or the medical practitioner, e.g., electronically or through the mail.
- the system is designed to permit the subject or medical practitioner to access the communication, e.g., by telephone or computer.
- the system may include software residing on a memory and executed by a processor of a computer used by the human subject or the medical practitioner, with which the subject or practitioner can access the communication, preferably securely, over the internet or other network connection.
- this computer will be located remotely from other components of the system, e.g., at a location of the human subject's or medical practitioner's choosing.
- the system as described further includes components that add a treatment or prophylaxis utility to the system.
- value is added to a determination of a subject developing maculopathy and/or pathogenic ocular neovascularization when a medical practitioner can prescribe or administer a standard of care that can prevent or delay onset of the disease or condition, and/or reduce the symptoms of the maculopathy and/or pathogenic ocular neovascularization.
- Exemplary medicinal protocols include administration of pharmaceutical agents for prophylaxis and/or treatment with a composition formulated for ophthalmic administration and comprising a VEGF-C inhibitor, a VEGFR-2 inhibitor, or a VEGFR-3 inhibitor, or combinations thereof.
- the system further includes a medical protocol database 214 operatively connected to a computer-readable medium of the system and containing information correlating the level of VEGF-C in the biological sample and medical protocols for human subjects with the maculopathy and/or pathogenic ocular neovascularization.
- medical protocols include any variety of medicines, lifestyle changes, diagnostic tests, increased frequencies of diagnostic tests, and the like that are designed to achieve effective therapy with minimum side effects.
- the information correlating the level of VEGF-C with protocols could include, for example, information about the success with which maculopathy and/or pathogenic ocular neovascularization is avoided or delayed, if a subject has a level of VEGF-C and follows a protocol.
- a system that analyzes inputs of VEGF-C or assessing the potential for developing maculopathy and/or pathogenic ocular neovascularization could generate a variety of treatment protocols, for a subject determined to have increased risk, including a therapeutic regimen that includes a composition formulated for ophthalmic administration and comprising a VEGF-C inhibitor, a VEGFR-2 inhibitor or a VEGFR-3 inhibitor;
- the system of this embodiment further includes a medical protocol tool or routine 216, operatively connected to the medical protocol database 214 and to the analysis tool or routine 210.
- the medical protocol tool or routine 216 preferably is stored on a computer-readable medium of the system, and adapted to be executed on a processor of the system, to: (i) compare (or correlate) the conclusion that is obtained from the analysis routine 210 (with respect to potential for the subject to develop maculopathy and/or pathogenic ocular neovascularization) and the medical protocol database 214, and (ii) generate a protocol report with respect to the probability that one or more medical protocols in the medical protocol database will achieve one or more of the goals of eliminating the disease or slowing onset of the disease.
- the communication tool 212 generates a communication that includes the protocol report in addition to, or instead of, the conclusion with respect to potential for developing the disease.
- Information about the level of VEGF-C not only can provide useful information about identifying or quantifying potential for developing maculopathy and/or pathogenic ocular neovascularization; it can also provide useful information about possible causative factors for a human subject identified with the disease, and useful information about therapies for the subject. In some variations, systems disclosed herein are useful for these purposes.
- An exemplary system for assessing or selecting a treatment protocol for a subject diagnosed with a maculopathy and/or pathogenic ocular neovascularization.
- An exemplary system schematically depicted in Figure 17, comprises:
- such a system further includes a communication tool 312 operatively connected to the medical protocol tool or routine 310 for communicating the conclusion to the subject 300, or to a medical practitioner for the subject 302 (both depicted in the schematic of Fig. 7 , but not part of the system per se).
- An exemplary communication tool comprises a routine stored on a computer-readable medium of the system and adapted to be executed on a processor of the system, to generate a communication containing the conclusion; and transmit the communication to the subject or the medical practitioner, or enable the subject or medical practitioner to access the communication.
- compositions and kits including a VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule and instructions (e.g., on a label or package insert such as instructions to the subject or to the clinician) for administering the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule to a subject to treat, prevent, and/or delay the development or progression of AMD.
- the anti-inflammatory agent can be in a pharmaceutical composition also including a pharmacologically acceptable carrier.
- pharmaceutically acceptable carrier includes saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
- a pharmaceutical composition is typically formulated to be compatible with its intended route of administration, e.g., ocular, oral, mucosal, topical, transdermal, or parenteral. Supplementary active compounds can also be incorporated into the compositions.
- a composition comprising a ligand binding molecule described herein is formulated for delivery to the eye of a subject (e.g., subconjunctivally, retrobulbarly, periocularly, subretinally, suprachoroidally, or intraocularly).
- a subject e.g., subconjunctivally, retrobulbarly, periocularly, subretinally, suprachoroidally, or intraocularly.
- Suitable ophthalmic carriers are known to those skilled in the art and all such conventional carriers may be employed as disclosed herein.
- Exemplary compounds incorporated to facilitate and expedite transdermal delivery of topical compositions into ocular or adnexal tissues include, but are not limited to, alcohol (ethanol, propanol, and nonanol), fatty alcohol (lauryl alcohol), fatty acid (valeric acid, caproic acid and capric acid), fatty acid ester (isopropyl myristate and isopropyl n-hexanoate), alkyl ester (ethyl acetate and butyl acetate), polyol (propylene glycol, propanedione and hexanetriol), sulfoxide (dimethylsulfoxide and decylmethylsulfoxide), amide (urea, dimethylacetamide and pyrrolidone derivatives), surfactant (sodium lauryl sulfate, cetyltrimethylannmonium bromide, polaxamers, spans, tweens, bile salts and lecit
- topically-administered compositions comprise surface adhesion molecule modulating agents including, but not limited to, a cadherin antagonist, a selectin antagonist, and an integrin antagonist.
- a particular carrier may take the form of a sterile, ophthalmic ointment, cream, gel, solution, or dispersion.
- suitable ophthalmic carriers are slow release polymers, e.g., "Ocusert" polymers, "Hydron” polymers, etc.
- Exemplary ophthalmic viscosity enhancers that can be used in the present formulation include: carboxymethyl cellulose sodium; methylcellulose; hydroxypropyl cellulose; hydroxypropylmethyl cellulose; hydroxyethyl cellulose; polyethylene glycol 300; polyethylene glycol 400; polyvinyl alcohol; and providone.
- Some natural products such as veegum, alginates, xanthan gum, gelatin, acacia and tragacanth, may also be used to increase the viscosity of ophthalmic solutions.
- a tonicity is important because hypotonic eye drops cause an edema of the cornea, and hypertonic eye drops cause deformation of the cornea.
- the ideal tonicity is approximately 300 mOsM.
- the tonicity can be achieved by methods described in Remington: The Science and Practice of Pharmacy, known to those versed in the art.
- Stabilizers may also be used such as, for example, chelating agents, e.g., EDTA.
- Antioxidants may also be used, e.g., sodium bisulfite, sodium thiosulfite, 8-hydroxy quinoline or ascorbic acid.
- Sterility typically will be maintained by conventional ophthalmic preservatives, e.g., chiorbutanol, benzalkonium chloride, cetylpyridium chloride, phenyl mercuric salts, thimerosal, etc., for aqueous formulations, and used in amounts which are nontoxic and which generally vary from about 0.001 to about 0.1% by weight of the aqueous solution.
- ointments include methyl and propyl parabens.
- Typical ointment bases include white petrolatum and mineral oil or liquid petrolatum.
- preserved aqueous carriers are preferred.
- Solutions may be manually delivered to the eye in suitable dosage form, e.g., eye drops, or delivered by suitable microdrop or spray apparatus typically affording a metered dose of medicament.
- suitable ophthalmic carriers include sterile, substantially isotonic, aqueous solutions containing minor amounts, i.e., less than about 5% by weight hydroxypropylmethylcellulose, polyvinyl alcohol, carboxymethylcellulose, hydroxyethylcellulose, glycerine and EDTA.
- the solutions are preferably maintained at substantially neutral pH and isotonic with appropriate amounts of conventional buffers, e.g., phosphate, borate, acetate, tris.
- penetration enhancers are added to the ophthalmologic carrier.
- Routes of administration suitable for the methods disclosed herein include both systemic and local administration.
- systemic administration means a mode of administration resulting in delivery of a pharmaceutical composition to essentially the whole body of the patient.
- Exemplary modes of systemic administration include, without limitation, intravenous injection and oral administration.
- local administration means a mode of administration resulting in significantly more pharmaceutical composition being delivered to and about the eyes than to regions distal from the eyes.
- a pharmaceutical composition comprising a VEGFR-2 inhibitor or VEGFR-3 inhibitor or a VEGF-C inhibitor described herein is administered topically, or by local injection (e.g., by intravitreal injection), or is released from an intraocular or periocular implant such as a bioerodible or reservoir-based implant.
- the composition is preferably administered in an amount effective to inhibit VEGF-C in the eye of the subject from binding to or stimulating VEGFR-2 and/or VEGFR-3 expressed in cells of the eye or vessels of the eye.
- an implant refers to any material that does not significantly migrate from the insertion site following implantation.
- An implant can be biodegradable, non-biodegradable, or composed of both biodegradable and non-biodegradable materials; a non-biodegradable implant can include, if desired, a refillable reservoir.
- Implants useful in the methods disclosed herein include, for example, patches, particles, sheets, plaques, microcapsules and the like, and can be of any shape and size compatible with the selected site of insertion, which can be, without limitation, the posterior chamber, anterior chamber, suprachoroid or subconjunctiva. It is understood that an implant disclosed herein generally releases the implanted pharmaceutical composition at an effective dosage to the eye of the patient over an extended period of time.
- a variety of ocular implants and extended release formulations suitable for ocular release are well known in the art, as described, for example, in U.S. Pat. Nos. 5,869,079 and 5,443,505 .
- a VEGFR-2 inhibitor or VEGFR-3 inhibitor or VEGF-C inhibitor described herein is applied to the eye via liposomes.
- the ligand binding molecule is contained within a continuous or selective-release device, for example, membranes such as, but not limited to, those employed in the OcusertTMSystem (Alza Corp., Palo Alto, Calif).
- the VEGFR-2 inhibitor or VEGFR-3 inhibitor or VEGF-C inhibitor is contained within, carried by, or attached to contact lenses which are placed on the eye.
- the a VEGFR-2 inhibitor or VEGFR-3 inhibitor or VEGF-C inhibitor described herein molecule is contained within a swab or sponge which can be applied to the ocular surface.
- Another embodiment disclosed herein involves a VEGFR-2 inhibitor or VEGFR-3 inhibitor or VEGF-C inhibitor described herein within a liquid spray which can be applied to the ocular surface.
- an effective amount can depend upon the degree to which a subject has abnormally elevated levels of markers, e.g. VEGF-C levels, of AMD.
- the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule is used to prevent the development or progression of AMD, that is, they are used prophylactically in subjects at risk of developing AMD, or in subjects that already have AMD but whose AMD is likely to progress, e.g., to a more severe form of the disease.
- an "effective amount" is that amount which can lower the risk of, slow, or prevent altogether the development or progression of AMD.
- the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule is administered in an effective amount, e.g., in an amount effective to reduce levels of one or more markers of angiogenesis and in particular VEGF-A or VEGF-C, preferably VEGF-C, to reduce the levels of the marker(s) to place the subject in a lower risk category, e.g., as described herein.
- the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule can be administered in one or more doses to achieve a desired therapeutic effect.
- doses of active compounds can be from about 0.01 mg/kg per day to 1000 mg/kg per day.
- doses ranging from 50-500 mg/kg will be suitable, typically administered orally, and in one to three (or more) administrations per day. Lower doses may result from other forms of administration, such as intravenous administration. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that subject tolerance permits. Multiple doses per day are contemplated to achieve appropriate systemic levels of compounds. The dosage and schedule will depend on the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule selected; a skilled practitioner would be able to select a regimen appropriate for the particular agent and subject.
- a number of anti-inflammatory agents are known in the art, and can be used in the methods described herein.
- a variety of administration routes are available. The particular mode selected will depend upon the particular drug selected, the severity of the condition being treated and the dosage required for therapeutic efficacy.
- the methods described herein, generally speaking, can be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects.
- modes of administration include oral, rectal, topical, nasal, transdermal, or parenteral routes.
- parenteral includes subcutaneous, intravenous, intramuscular, or infusion. Local administration to the macular area can also be used.
- implantable formulations e.g., VEGFR-2 inhibitor molecules and/or VEGFR-3 inhibitor molecules and/or VEGF-C inhibitor molecules that are contained in a slow-release formula that can be implanted at or near the site of inflammation.
- Oral administration will typically be used for prophylactic and long term treatment because of the convenience to the subject as well as the dosing schedule.
- a number of oral compositions are known in the art and can be used in the methods described herein.
- the delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule, increasing convenience to the subject and the physician.
- release delivery systems are available and known to those of ordinary skill in the art. They include polymer base systems such as poly(lactide-glycolide), copolyoxalates, polycaprolactones, polyesteramides, polyorthoesters, polyhydroxybutyric acid, and polyanhydrides. Microcapsules of the foregoing polymers containing drugs are described in, for example, U.S. Pat. No. 5,075,109 .
- Delivery systems can also include non-polymer systems that are: lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-, di- and tri-glycerides; hydrogel release systems; sylastic systems; peptide based systems; wax coatings; compressed tablets using conventional binders and excipients; partially fused implants; and the like.
- lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-, di- and tri-glycerides
- hydrogel release systems such as sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-, di- and tri-glycerides
- sylastic systems such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-, di- and tri-glycerides
- peptide based systems such as fatty acids
- wax coatings such as those described in U.S. Pat. Nos.
- Long-term release means that the implant is constructed and arranged to delivery therapeutic levels of the active ingredient for at least 30 days, e.g., 60 days.
- Long-term sustained release implants are known to those in the art and include some of the release systems described herein.
- disclosed herein is the use of a VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule to treat, delay or prevent the development or progression of AMD.
- VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule to modulate VEGF-C levels, thereby treating, delaying or preventing the development or progression of AMD.
- VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule in the preparation of a medicament for use in the treatment of AMD.
- Choroidal neovascularization is the major cause of severe visual loss in subjects with AMD. At least 40% of subjects with wet AMD exhibit some degree of resistance to anti-VEGF-A monotherapy.
- Plasma VEGF-A, VEGF-C and VEGF-D levels were measured in plasma samples from subjects with AMD and in control subjects without AMD and quantitated using a multiplex assay (Biorad).
- VEGF-C levels are significantly elevated in the plasma of AMD subjects compared to healthy volunteers (controls).
- VEGF-C, VEGFR-2 and VEGFR-3 were localized in retinal tissues of C57BL/6 mice 14 days following laser injury and clinical specimens from wet AMD subjects by immunofluorescence using commercially available antibodies (Abcam). Results indicated that VEGF-C and its cognate receptors (i.e., VEGFR-2 and VEGFR-3) are expressed and co-localized in CNV membranes in the samples tested.
- VEGF-C and VEGF-D participate in choroidal neovascularization
- a mouse model of laser-induced CNV was employed in which photocoagulation was induced at 8-9 positions on each mouse retina (50 ⁇ m, 700 mW, 100 ms).
- mice (5/group) were administered non-specific IgG (20 mg/kg IP every 2 days), EyleaTM (aflibercept, 20 mg/kg IP every 2 days), or VGX-300 (VEGFR-3 Trap for VEGF-C & VEGF-D; single-intravitreal injection of 40 ⁇ g on day 1).
- CNV areas and extent of leakage were determined by fluorescein angiography (FA) followed by intracardiac perfusion of FITC-dextran in gelatin (10%) on day 14 after photocoagulation ( Figure 2 ).
- IVTT intravitreal
- Figure 3 shows fundus images and fluorescein angiography of laser-induced CNV membranes 14 days after photocoagulation.
- Figure 4 shows CNV lesion sizes in choroidal flatmounts. Anatomical areas of CNV lesions 14 days after photocoagulation in IgG-treated animals ( Figure 4A ) was much larger than those of EyleaTM-treated ( Figure 4B ) and VGX-300-treated ( Figure 4C ) eyes.
- Figure 5 shows the incidence of CNV and intensity of leakage after 14 days in each of the treatment groups.
- Figure 6 shows the mean size of laser-induced CNV membranes (total area of leakage spots/total photocoagulated spots) and the percentage of relative increase in CNV area after 14 days in each treatment group. Both Eylea® and VGX-300 significantly reduced CNV area ( Figure 7 ) compared to the IgG control treated group. VGX-300 reduced lesion size to the approximate size of the laser-burn.
- mice were administered a single intravitreal (IVT) injection of a negative isotype antibody control IgG, Eylea® + IgG or VGX-300 + IgG.
- IVT intravitreal
- a total of 80 mg protein was administered in a 2 ml injection (for single-agent groups, 40 mg of IgG was added to each 40 mg dose of Eylea® or VGX-300).
- N 10 mince per treatment group.
- Extent of leakage and CNV areas were determined by fluorescein angiography followed by intracardiac perfusion of FITC-dextran in gelatin (10%) on days 7 and 14 post-laser burn.
- Figure 8 shows representative fundus images, angiography and choroidal flatmounts of laser-induced CNV membranes 7 and 14 days after laser-burn and administration.
- Figure 9(A) shows the incidence of laser-induced leaking spots on day 7 and on day 14 post-laser injury (leaking spots/photocoagulated spots ⁇ 100%.
- Figure 9(B) shows the mean size of laser-induced CNV membranes at day 14 post-laser injury.
- VGX-300-mediated blockade of VEGF-C/-D significantly inhibits choroidal neovascularization and vascular leakage comparably to EyleaTM in the laser-induced mouse model of wet AMD.
- Persistent angiogenesis and vascular leakage in these sub-responsive subjects may be mediated by VEGF-C.
- Established CNV lesions in the mouse regress following treatment with VGX-300 on day 7 post-laser injury.
- VEGF-C expression is higher in wet AMD and lower in control and dry AMD clinical specimens.
- VGX-300 reduces the expression of genes associated with angiogenesis and inflammation following laser-induced injury.
- Administration of single-agent VGX-300 may be an effective therapy for wet AMD.
- Administered in combination with anti-VEGF-A therapies, VGX-300 may have the potential to improve clinical responses in wet AMD by more effective inhibition of the pathways involved in disease progression.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Ophthalmology & Optometry (AREA)
- Mycology (AREA)
Description
- This invention relates to methods of using biomarkers as diagnostic and prognostic tools for age-related macular degeneration (AMD).
- Age-related macular degeneration (AMD) is a sudden worsening and distortion of central vision that progresses rapidly, typically with a course of only weeks or months. AMD is characterized by abnormalities in the macular area. The central area (or fovea) of the macula contains the highest density of cone photoreceptors in the retina and mediates high-acuity vision. The disease typically has a preclinical, asymptomatic phase, in which extracellular waste material accumulates in the space between the basement membrane (Bruch's membrane) and the epithelial layer, forming yellow-white spots known as drusen. Advanced forms of AMD includes both dry and wet (or "neovascular") AMD. The dry form of AMD is far more common, but the wet form occurs simultaneously with the dry form in about 15 % of cases. Dry AMD is characterized by progressive apoptosis of cells in the epithelial layer, in the overlying photoreceptor cells and in the underlying cells in the choroidal capillary layer. Wet AMD is characterized by choroidal neovascularization with vascular leakage into subretinal spaces.
- AMD impairs central vision that is required for reading, driving, face recognition and fine visual tasks. Neurosensory detachment, retinal hemorrhages and retinal scarring gradually result in decreased visual function of photoreceptors in the central vision, eventually resulting in legal blindness, with preservation of peripheral vision. AMD is the most common cause of blindness among the elderly. Subjects with a family history of AMD and those who smoke have a higher risk than non-smokers and those with no family history. Nevertheless, subjects who have favorable risk profiles also develop the disease. Current therapeutic efforts and clinical trials are primarily aimed at halting the growth of the neovascular membrane in wet AMD, e.g., using angiogenesis (VEGF-A) inhibitors, laser photocoagulation and/or photodynamic therapy. Antioxidants can retard the progression of the disease.
- Despite advances in treatment, AMD is still the most common cause of visual impairment in the developed world. Although genetic biomarkers are reasonably effective predictors of AMD risk and advanced AMD risk, there remains a significant need for new biomarkers that will improve the level of early diagnosis and enable treatments to be targeted to meet individual patient needs.
-
WO 2004/009773 describes methods and compositions for activating or inhibiting VEGF-D and/or VEGF-C.WO 2004/009773 mentions that diabetic retinopathy and ocular neovascularisation may be treated by inhibition of plasmin activation of VEGF-C.WO 2004/009733 does not mention VEGF-C as a biomarker for any disease. - Goydos et al. (2003, Clinical Cancer Research, Vol. 9, pages 5962-5967) describe the measurement of VEGF-C mRNA levels in melanomas presenting different stages of progression in an attempt to determine whether expression of VEGF-C correlates with stage of progression in patients with melanoma. Goydos et al. conclude that high levels of VEGF-C may be important in regional lymphatic disease in melanoma and that VEGF-C and LYVE-1 levels may identify tumors with a high risk of nodal metastases.
- Leclers et al. (2006, Anticancer Research, Vol. 26, pages 1885-1892) describe the quantification by real-time quantitative PCR (RT-PCR) of VEGFR-3, VEGF-C and VEGF-D in different human cell types and conclude that RT-PCR is a highly reliable and reproducible technique that could help in the elucidation of lymphangiogenic marker patterns of expression in cancer.
- Zhao et al. (2006, British J. Ophthalmology, 90(8), pages 1052-1059) report that VEGF-A regulates the expression of VEGF-C in human retinal pigment epithelial (RPE) cells and propose that a synergistic action of VEGF-C with VEGF-A may play a role in the aetiology of choroidal neovascularisation. The conclusions reached in Zhao et al. are based solely on in vitro experiments using RPE cells from individuals who have no evidence of any eye disease. Zhao el al. do not describe experiments using any model, in vitro or in vivo, of macular degeneration. Zhao et al. make no mention of the use of VEGF-C as a marker, biomarker, diagnostic or monitoring aide of any kind for any disease.
- Lavey et al. (2011, Optical Interactions with Tissue and Cells XXII, Proc. of SPIE, Vol. 7897, No. 1, pages 1-7) report that levels of VEGF-C and mRNA both increase in human retinal pigment epithelial cell cultures (hTERT-RPE1) following thermal stress produced by uniform heating in a water bath and that this supports previous research suggesting VEGF-C is a thermal stress protein. Lavey et al. conclude that VEGF-C expression within hTERT-RPE1 cells and within the extracellular matrix, and VEGF-C mRNA may serve as viable biomarkers of thermal stress in retinal cells, once a standard level of expression is established.
-
WO2000/064946 discloses antibodies that specifically inhibit VEGF binding to VEGF2 receptors. - Falavarjani (2010, J. Ophthalmic and Vision Research, Vol. 5, No. 1, page 71) reports that CCR3 may be a viable biomarker for early diagnosis of neovascular age-related macular degeneration.
-
WO 2001/006262 describes a method for determining a predisposition to developing macular degeneration, including age-related macular degeneration through detection of one or more markers for arterial wall disruptive disorder. -
WO 2005/084188 describes methods of using levels of markers of systemic inflammation, such as CRP, IL-6, TNF-alpha receptor II, ICAM and VCAM, to predict a subject's risk of development or progression of age-related macular degeneration. -
US 2010/0150920 describes a testing an ocular fluid for a biomarker for an ocular disease, including wet age-related macular degeneration , in which the biomarker is selected from CC9 D330, VEGFRY1175, VEGFRY996, PEDF, TNF-alpha, VEGF-A, VEGFRY951 and IL-1B. - The invention is as defined in the claims. The work described herein demonstrates that vascular endothelial growth factor C (VEGF-C) is a biomarker associated with AMD. The level of VEGF-C gene or protein expression can be used as a biomarker for assessing the risk of developing and/or progression of AMD and/or to determine the likelihood that specific subjects will benefit from certain treatments or therapies for AMD.
- In one aspect, described herein are new diagnostic or screening methods for a subject comprising measuring the level of VEGF-C expression in a biological sample from a subject to obtain a VEGF-C measurement, which VEGF-C measurement can be used to predict a subject's risk of developing AMD and/or progressing to more advanced AMD. In such methods, VEGF-C can be broadly considered to be a "predictive biomarker". These methods can be used, for example, to predict risk of development or progression of age-related maculopathy.
- In another aspect, described herein are new selection or screening methods for a subject comprising measuring the level of VEGF-C expression in a biological sample from a subject to obtain a VEGF-C measurement, which VEGF-C measurement can be used to select subjects for a clinical trial, and/or to select subjects likely to benefit from certain treatments, treatment regimes or therapies for AMD. In such methods, VEGF-C can be broadly considered to be a "selective biomarker", i.e. it is being used to identify subjects likely to benefit from certain treatments, treatment regimes or therapies (i.e. targeted therapy) or in a particular clinical trial for an AMD therapy. These methods can be used, for example, to determine the likelihood that certain subjects will benefit from the use of certain treatments, treatment regimes or therapies designed to prevent development or progression of AMD and/or designed to treat AMD. In one embodiment, subjects are identified who will benefit from treatment with an anti-angiogenic agent. In another embodiment, subjects are identified who will benefit from treatment with a VEGFR-2 inhibitor molecule and/or a VEGFR-3 inhibitor molecule (e.g. an inhibitor of VEGF-A, VEGF-C, VEGF-D, VEGFR-2 or VEGFR-3).
- In another aspect, described herein are new monitoring or selection methods for a subject comprising measuring the level of VEGF-C expression in a biological sample from a subject to obtain a VEGF-C measurement, which VEGF-C measurement can be used as a monitor of disease progression or as a monitor of the efficacy of response to certain treatments, treatment regimes or therapies in subjects being treated for AMD. In such methods, VEGF-C can be broadly considered to be a "responsive biomarker" or a "tracking biomarker" in which, for example, it is being used to monitor or track the response to a certain treatment, treatment regime or therapy.
- Also disclosed herein are methods for treating, preventing, and/or delaying the development or progression of AMD.
- In some embodiments, the biological sample comprises a tissue biopsy and the VEGF-C is measured in the tissue. In other embodiments, the biological sample includes blood or lymphatic tissue and the VEGF-C is measured in the vessel tissue.
- In other embodiments, the biological sample includes fluid from or around the area of the AMD (e.g. fluid from or around the eye) and the VEGF-C is measured in the fluid. In still further embodiments, the biological sample comprises blood, and the VEGF-C is measured in the blood, or in plasma or serum from the blood.
- In a preferred embodiment, VEGF-C acts as a systemic biomarker. In another preferred embodiment, the biological sample comprises blood, and the VEGF-C is measured in the blood, or in plasma or serum from the blood. In a particularly preferred embodiment, the biological sample comprises blood, and the VEGF-C is measured in plasma from the blood.
- The VEGF-C measurement may be used as a "predictive" biomarker for the prediction of development and/or progression of AMD, as a "selective" biomarker for the selection of subjects for clinical trials or the selection of subjects likely to benefit from certain treatments for AMD, or as a "responsive" or "tracking" biomarker for monitoring of AMD disease progression in a subject and/or monitoring the efficacy of a particular treatment, treatment regime or therapy in a subject being treated for AMD. VEGF-C measurements in otherwise healthy subjects, regardless of whether they have ever smoked, may also be predictive of development and progression of AMD.
- In addition, the likelihood that a specific subject will benefit to a greater or a lesser extent from the use of certain therapeutic agents for reducing the risk of development or progression of AMD can be determined by evaluating levels of VEGF-C in the subject, and comparing the levels to a reference or control for the marker.
- In another aspect, described herein are new methods for characterizing a mammalian subject's risk of development or progression of AMD comprising measuring the level of VEGF-C expression in a biological sample from a mammalian subject to obtain a VEGF-C measurement and comparing the subject's VEGF-C measurement with a reference or control level, the subject's risk of development or progression of AMD being characterized based upon the VEGF-C measurement in comparison to the reference or control.
- In some embodiments, the level of the subject's VEGF-C is higher than the reference or control (e.g. increased relative to a control or other reference (including a previous level obtained from the same subject)), and indicates that the subject:
- (i) has an increased risk of development or progression of AMD;
- (ii) has an increased likelihood of benefiting from certain treatments for AMD or benefiting from a clinical trial; or
- (iii) is not responding to a particular treatment or therapy for AMD and/or that the AMD is progressing.
- In some embodiments, the level of the subject's VEGF-C is lower than the reference or control (e.g. reduced relative to a control or other reference (including a previous level obtained from the same subject)), and indicates that the subject:
- (i) has an decreased risk of development or progression of AMD;
- (ii) has an decreased likelihood of benefiting from certain treatments for AMD or benefiting from a clinical trial; or
- (iii) is responding to a particular treatment or therapy for AMD and/or that the AMD is not progressing further (i.e. is stable) or is in remission.
- As used herein, progression of AMD refers to an increase in severity of the disease, e.g., an objective worsening in one or more parameters or symptoms associated with the disease, e.g., a progression from
Category Category 3 or 4, or a progression fromCategory - According to yet another aspect of the invention, methods are provided that use a subject's VEGF-C level together with one or more risk factors or other biomarkers for AMD, e.g., as described herein, to characterize a subject's risk profile of development and/or progression of AMD. The methods include obtaining a level of VEGF-C as biomarker in the subject which level is compared to a reference or control to establish a first risk value. At least one risk factor or other biomarker for AMD is also evaluated. The presence or level of the risk factor or other biomarker in the subject is compared to a second reference to establish a second risk value. The subject's risk profile for development or progression of AMD is characterized based upon the combination of the first risk value and the second risk value, wherein the combination of the first risk value and second risk value establishes a combined risk value, which is typically different from the first and second risk values. In some embodiments, the combined risk value is greater than either of the first and second risk values, e.g., the first and second risk values are additive. In some embodiments, the combined risk value is calculated with a multiplicative model. In some variations, logistic regression is used to calculate a combine risk value.
- In another aspect disclosed herein, methods are provided for evaluating the likelihood that a subject will benefit from treatment with a VEGFR-2 inhibitor molecule and/or a VEGFR-3 inhibitor molecule, and in particular the VEGFR-3 pathway, to reduce the risk of development or progression of AMD. The methods include obtaining a level of VEGF-C (e.g. active angiogenesis VEGF-C level) in a subject. This level then is compared to a reference or control, wherein the level of the VEGF-C in the subject in comparison to the reference or control is indicative of the likelihood that the subject will benefit from treatment with the agent. The subject then can be characterized in terms of the net benefit likely to be obtained by treatment with the agent.
- In a further aspect, disclosed herein are methods for determining whether a treatment or prevention for reducing risk of development of AMD or progression to advanced AMD is having an effect in a subject. The methods include obtaining a first level of VEGF-C in a subject; administering a selected treatment or prevention for AMD to the subject; obtaining a second level of VEGF-C in the subject; and comparing the first VEGF-C level to the second level of VEGF-C. A difference, or lack of difference, in the second level as compared to the first level indicates whether the treatment or prevention is effective or not effective. For example, if the second level is lower than the first level, then the treatment or prevention is likely to be effective. If there is no difference, or if the second level is higher than the first level, then the treatment or prevention is likely not to be effective, or has not yet become effective. The methods can include re-testing the subject a plurality of times, e.g., to determine whether the treatment is effective over time. In addition, once a treatment has been stopped, the subject can be tested one or more additional times to determine if their risk of developing AMD has changed or the subject has relapsed into AMD or AMD has started to progress after being in a stable condition.
- In some embodiments, the subject is apparently healthy, e.g., has no or few overt clinical signs of AMD (e.g., is in the first AERDS category); has minimal or early AMD (e.g., is in the second AERDS category); has intermediate AMD (e.g., is in the third AERDS category); or has advanced AMD (e.g., is in the fourth AERDS). In some embodiments, the subject is a non-smoker, e.g., has never smoked, or is a smoker, e.g., a current or past smoker. A non-smoker is a subject who, at the time of the evaluation, has never smoked, or has smoked less than a minimal number, e.g., 100 cigarettes in a lifetime, or less than a minimal duration, e.g., less than six months. Smokers include subjects who currently smoke, as well as subjects who have smoked at some time in the past but presently no longer smoke, or smoked more than a minimal number, e.g., 100 cigarettes in a lifetime, or more than a minimal duration, e.g., more than six months. In some embodiments, the subject has no risk factors as described herein. In some embodiments, the subject has one or more risk factors as described herein.
- In some embodiments, characterizing a subject's risk of development or progression of AMD includes characterizing the subject's risk of developing advanced AMD. In some embodiments, characterizing the subject's risk of future development or progression of AMD includes characterizing the subject's risk of developing neovascular AMD.
- The reference can be a single value, multiple values, a single range or multiple ranges. In some embodiments, the reference is a median value. In some embodiments, the reference is a plurality of marker level ranges, e.g., ranges associated with low, medium, and high risk categories, and the comparing step comprises determining in which marker level range the subject's level falls.
- In some embodiments, levels of multiple AMD biomarkers are obtained concurrently.
- One of skill in the art will appreciate that the reference value selected will typically depend on the particular marker selected and even upon the characteristics of the patient population in which the subject lies, described in greater detail below.
- As mentioned above, the methods described herein can be adapted to determine which subjects are most likely to benefit from treatment with an agent for reducing the risk in the development or progression of AMD. The methods can also be used to select candidate subjects and/or populations for clinical trials and for treatment with candidate drugs, by identifying, for example, subjects most likely to benefit from a new treatment or from a known treatment with a high risk profile of adverse side effects. Thus, the methods described herein can provide information for evaluating the likely net benefit of certain treatments for candidate subjects.
- Any available technique can be used for measuring VEGF-C expression, including direct and indirect techniques. For example, in one variation, the measuring comprises measuring VEGF-C protein in the biological sample. Exemplary techniques for measuring amounts or concentrations of VEGF-C protein in a sample are immunological techniques that involve use of a polyclonal or monoclonal antibody that specifically binds VEGF-C, or use of a VEGF-C-binding fragment of such an antibody. For example, the measuring comprises contacting the biological sample with a VEGF-C antibody (or with a polypeptide comprising an extracellular domain (ECD) fragment of VEGFR-3 that binds VEGF-C) or antigen-binding fragment thereof. Quantification of the amount of bound antibody (e.g., using a label or second, labeled antibody) provides a measurement of VEGF-C protein expressed in the sample. Immunoassays such as radioimmunoassay, immunoradiometric assay (labeled antibody), or an enzyme-linked immunosorbent assay (ELISA) are contemplated.
- In another variation, the measuring comprises measuring VEGF-C mRNA in the biological sample. Any available assay for measuring specific oligonucleotides is suitable. One technique for measuring VEGF-C mRNA comprises in situ hybridization to measure VEGF-C mRNA in the biological sample. Other techniques involve steps of isolating mRNA from the biological sample and measuring VEGF-C mRNA in the isolated mRNA, for example, by Northern hybridization procedures. In still another variation, quantitative reverse transcriptase polymerase chain reaction (PCR), real-time PCR, or other PCR techniques are employed to quantitatively amplify VEGF-C mRNA (relative to control samples) to provide a quantitative measurement of VEGF-C mRNA in the biological sample.
- The screening, diagnosing or selecting methods described herein may optionally comprise the step of prescribing for or administering to the subject identified as having elevated VEGF-C expression in the biological sample a composition comprising a VEGFR-2 inhibitor molecule and/or a VEGFR-3 inhibitor molecule (e.g. a VEGF-C antibody or a soluble VEGFR-3 protein trap).
- In another aspect, described herein is a method of treatment comprising obtaining a biological sample from a mammalian subject, determining that the biological sample has elevated expression of VEGF-C, and prescribing for or administering to the subject a composition comprising a VEGFR-2 inhibitor molecule and/or a VEGFR-3 inhibitor molecule (e.g. a VEGF-C antibody or a soluble VEGFR-3 protein trap). In some variations, the subject for whom the inhibitor composition is prescribed receives the composition following the prescribing.
- In some variations, the determining step comprises ordering a laboratory test that measures VEGF-C in the biological sample and learning the measurement from a report from the laboratory. In other variations, the determining step comprises measuring VEGF-C mRNA or VEGF-C protein in the biological sample.
- Aspects of the invention that are described herein as methods (especially methods that involve treatment) can alternatively be described as (medical) uses of reagents or therapeutics. For example, in one variation, disclosed herein is a use of a composition that comprises a VEGFR-2 inhibitor molecule and/or a VEGFR-3 inhibitor molecule for the treatment of AMD in a subject identified with AMD and identified with elevated VEGF-C expression (wherein the subject is identified as having elevated VEGF-C expression in the AMD by a method described herein).
- Agents contemplated which inhibit the VEGFR-2 pathway (VEGFR-2 inhibitor molecules) for use in the methods (or uses) described herein include, but are not limited to, (a) a VEGF-A antibody that inhibits ligand-mediated stimulation of VEGFR-2; (b) a VEGF-C antibody that inhibits ligand-mediated stimulation of VEGFR-2; (c) a VEGF-D antibody that inhibits ligand-mediated stimulation of VEGFR-2; (d) a soluble polypeptide that comprises an extracellular domain fragment of VEGFR-2 (i.e. a soluble VEGFR-2 trap) that binds VEGF-A and/or VEGF-C and/or VEGF-D and inhibits VEGF-A and/or VEGF-C and/or VEGF-D, as the case may be, from stimulating VEGFR-2; (e) an antisense or interfering nucleic acid (e.g., antisense oligonucleotide; micro-RNA, short interfering RNA) that inhibits VEGF-A, VEGF-C and/or VEGF-D expression; (e) an antisense or interfering nucleic acid (e.g., antisense oligonucleotide; micro-RNA, short interfering RNA) that inhibits VEGFR-2 expression; (f) an antibody that binds VEGFR-2 and inhibits VEGF-A and/or VEGF-C and/or VEGF-D from binding to and stimulating VEGFR-2; (g) a small molecule that inhibits VEGFR-2 expression or signaling; and (h) a molecule that inhibits proteolytic cleavage-activation of VEGF-C or VEGF-D.
- Agents contemplated which inhibit the VEGFR-3 pathway (VEGFR-3 inhibitor molecules) for use in the methods (or uses) described herein include, but are not limited to, (a) a VEGF-C antibody that inhibits ligand-mediated stimulation of VEGFR-3; (b) a VEGF-D antibody that inhibits ligand-mediated stimulation of VEGFR-3; (c) a soluble polypeptide that comprises an extracellular domain fragment of VEGFR-3 (i.e. a soluble VEGFR-3 trap) that binds VEGF-C and/or VEGF-D and inhibits VEGF-C and/or VEGF-D, as the case may be, from stimulating VEGFR-3; (d) an antisense or interfering nucleic acid (e.g., antisense oligonucleotide; micro-RNA, short interfering RNA) that inhibits VEGF-C and/or VEGF-D expression; (e) an antisense or interfering nucleic acid (e.g., antisense oligonucleotide; micro-RNA, short interfering RNA) that inhibits VEGFR-3 expression; (f) an antibody that binds VEGFR-3 and inhibits VEGF-C and/or VEGF-D from binding to and stimulating VEGFR-3; (g) a small molecule that inhibits VEGFR-3 expression or signaling; and (h) a molecule that inhibits proteolytic cleavage-activation of VEGF-C or VEGF-D.
- In the treatment methods (or uses) described herein, the methods optionally comprise administering to the subject in combination a VEGFR-2 inhibitor molecule and/or a VEGFR-3 inhibitor molecule and a standard or care therapeutic. With respect to any combination treatment or therapy regimes described herein, the VEGFR-2 inhibitor molecule and/or a VEGFR-3 inhibitor molecule can be administered simultaneously with the other active agents, which may be in admixture with the VEGFR-2 inhibitor molecule and/or a VEGFR-3 inhibitor molecule, or may be in a separate composition. Each composition preferably includes a pharmaceutically acceptable diluent, adjuvant, or carrier. When the agents are separately administered, they may be administered in any order.
- Also disclosed herein are kits including a package including one or more assays for an AMD biomarker as described herein and instructions for use in a method described herein, and optionally related materials such as marker level or range information for correlating the level of the marker as determined by the assay with a risk of development or progression of AMD. Such information can be in any useful form, e.g., charts, e.g., numeric or colour charts. In some embodiments, the instructions include information for determining the subject's risk of development or progression of AMD, by correlating the level of the marker determined by the assay and one or more risk factors with a risk of development or progression of AMD. In some embodiments, the kit includes assays for two, three, four or more AMD biomarkers. For example, the kit can include a microarray or a microfluidic device that can be used to determine the levels of two, three, four, or more AMD biomarkers, e.g., substantially simultaneously.
- Also disclosed herein are methods for treating subjects with agents that inhibit the VEGFR-2 and/or VEGFR-3 pathways, and in particular the VEGFR-3 pathway, to treat, prevent and/or delay the development or progression of AMD. In some embodiments, an agent which inhibits VEGF-C is administered to a subject who is known to have (i.e., has been determined to have, e.g., by a method described herein) an above-normal level of VEGF-C. The VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule is administered in an amount effective to treat, prevent, and/or delay the development or progression of AMD. In some embodiments, the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule is administered in an amount effective to reduce the subject's levels of VEGF-C to below a preselected value, e.g., a reference value that is associated with a lower risk category.
- Also disclosed herein are methods for treating eye disorders such as a maculopathy and pathogenic ocular neovascularization in a subject in need thereof, comprising administering to the subject a polypeptide comprising at least a first, a second and a third Ig-like domain of a wildtype VEGFR-3 amino acid sequence. In some embodiments, the eye disorder is age-related macular degeneration (AMD). In some embodiments, the polypeptide has an amino terminal residue selected from the group consisting of
positions 1 to 47 of SEQ ID NO: 4, and a carboxy-terminal residue selected from the group consisting of positions 226 to 775 of SEQ ID NO: 4, wherein VEGFR-3 fragment binds at least one of VEGF-C and VEGF-D. In some embodiments, the polypeptide comprises the first through third Ig-like domains of VEGFR-3, and the polypeptide lacks Ig-like domains IV-VII of the VEGFR-3 amino acid sequence. In some variations, the polypeptide consists of, or consists essentially of, the first three Ig-like domains, fused to a heterologous peptide. In some embodiments, the portion of the polypeptide corresponding to VEGFR-3 is selected from the group consisting of defined by positions 1-226, positions 1-229, and positions 1-329, positions 47-224, positions 47-225, positions 47-226, positions 47-227, positions 47-228, positions 47-229, positions 47-230, positions 47-231, positions 47-232, positions 47-236, positions 47-240, positions 47-245, positions 47-314, positions 47-210, and positions 47-247 of SEQ ID NO: 4. - In an additional aspect, disclosed herein are packages including a VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule, e.g., in a pharmaceutical composition, and instructions for administering the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule to a subject in order to treat, prevent, and/or delay the development or progression of AMD. In some embodiments, the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule is in a therapeutic composition also including a pharmacologically acceptable carrier. In some embodiments, the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule is in a form suitable for local delivery to the macular area.
- In some variations, disclosed herein is a system for identifying susceptibility to a maculopathy in a human subject. For example, in one variation, the system includes tools for performing at least one step, preferably two or more steps, and in some aspects all steps of a method of the invention, where the tools are operably linked to each other. Exemplary tools include laboratory equipment or reagents for performing assays and computer systems for processing data, comparing data, and/or transforming one type of data (e.g., VEGF-C measurements) into another (e.g., a risk score). Operable linkage describes a linkage through which components can function with each other to perform their purpose, and may include, for example, linkage through a computer network and/or the internet.
- The foregoing paragraphs are not intended to define every aspect of the invention, and additional aspects are described in other sections, such as the Detailed Description. The entire document is intended to be related as a unified disclosure, and it should be understood that all combinations of features described herein are contemplated, even if the combination of features are not found together in the same sentence, or paragraph, or section of this document. The invention includes, as an additional aspect, all embodiments of the invention narrower in scope in any way than the variations defined by specific paragraphs above. For example, where certain aspects of the invention that are described as a genus, it should be understood that every member of a genus is, individually, an aspect of the invention. Where protein therapy is described, embodiments involving polynucleotide therapy (using polynucleotides that encode the protein) are specifically contemplated, and the reverse also is true.
- Although the applicant(s) invented the full scope of the invention described herein, the applicants do not intend to claim subject matter described in the prior art work of others. Therefore, in the event that statutory prior art within the scope of a claim is brought to the attention of the applicants by a Patent Office or other entity or individual, the applicant(s) reserve the right to exercise amendment rights under applicable patent laws to redefine the subject matter of such a claim to specifically exclude such statutory prior art or obvious variations of statutory prior art from the scope of such a claim. Variations of the invention defined by such amended claims also are intended as aspects of the invention.
-
-
Figure 1 : Plasma concentrations of VEGF-A (n = 142), VEGF-C (n = 125) and VEGF-D (n = 70) in control and AMD subjects. -
Figure 2 : (a) OCT image of laser-induced bulb in choroidal layer. (a) shows the laser spot. (b) shows the fundus onday 14. (c) shows the angiography onday 14. -
Figure 3 : Effects of VEGF-A and VEGF-C Inhibition on Laser-induced CNV. Fundus images and angiography of laser-inducedCNV membranes 14 days after photocoagulation and administration of IgG (A&B), Eylea™ (C&D), VGX-300 (E&F) and VGX-300 + Eylea™ (G&H) are shown. -
Figure 4 : CNV lesion sizes in choroidal flatmounts. Anatomical areas ofCNV lesions 14 days after photocoagulation in IgG-treated (A), of Eylea™-treated (B) and VGX-300 treated (C) eyes. A grey circle shows the photocoagulation area; a grey arrow head identifies the optic nerve head; a white arrow highlights CNV leakage. -
Figure 5 : Incidence of CNV and intensity of leakage. (A) Incidence of laser-induced leaking spots (leakage spots/photocoagulated spots × 100%). (B) Comparison of leakage intensity after fluorescein angiography. -
Figure 6 : Effects of treatment on CNV area. (A) Mean size of laser-induced CNV membranes (total area of leakage spots/total photocoagulated spots). (B) Percentage of relative increase in CNV area (refer toFig. 1 for calculation method). The CNV area as shown inFigure 5(A) was determined from fluorescein angiography as shown inFigure 4(b) and (c) . Percentage of relative increase of CNV area, as shown inFigure 5(B) was determined by calculating [(Area 2 - Area 1)/Area 1] x 100%. -
Figure 7 : Effects of treatment on CNV size. Mean size of laser-induced CNV membranes atday 14 post-laser injury -
Figure 8 : Representative fundus images, angiography and choroidal flatmounts of laser-inducedCNV membranes -
Figure 9 : Regression of CNV lesions following VGX-300 treatment: (A) Incidence of laser-induced leaking spots onday 7 and onday 14 post-laser injury (leaking spots/photocoagulated spots × 100%); (B) Mean size of laser-induced CNV membranes atday 14 post-laser injury. -
Figure 10 : The normalized accumulated mRNA expression levels of a panel of angiogenic and inflammatory genes onday -
Figure 11 is an exemplary system comprising exemplary computer components. -
Figure 12 is a flow chart depicting system components and operation. -
Figure 13 is another flow chart depicting system components and operation. - As used herein, "age-related macular degeneration" or "AMD" includes both early, intermediate, and advanced AMD. Patients with early AMD are usually asymptomatic, and present clinically with yellowish drusen seen underneath the retinal pigment epithelium, with areas of mottled retinal pigment epithelium hyperpigmentation and hypopigmentation.
- Patients usually develop rapid visual loss when neovascular AMD occurs. Typically, patients describe sudden worsening of central vision with distortion of straight lines (metamorphopsia) or a dark patch in their central vision (scotoma), or both. In geographic atrophy, there is slower progressive loss of vision over many years. Clinically, there is a sharply demarcated area of depigmentation showing retinal pigment epithelium atrophy. Neovascular AMD is characterised by subretinal or intraretinal fluid and haemorrhage; occasionally, the choroidal neovascularisation complex can be seen clinically. "Advanced AMD" includes both dry AMD and wet AMD (wet AMD is also referred to as neovascular AMD). Subjects with advanced AMD are those who can be categorized in Category 4 according to the AREDS classification.
- Various AMD classification schemes have been developed. The Age-Related Eye Disease Study (AREDS) classified age-related macular degeneration into four categories as follows (AREDS Report No 8, Arch Ophthalmol, 2001, 119, 1417-36):
- Category 1: None or a few small drusen (<63 µm in diameter).
- Category 2: Any or all of the following: multiple small drusen, few intermediate drusen (63-124 µm in diameter), or retinal pigment epithelium abnormalities.
- Category 3: Any or all of the following: extensive intermediate drusen, and at least one large drusen (≥125 µm in diameter, roughly equivalent to the size of the retinal vein at the rim of the optic disc), and geographic atrophy not involving the fovea.
- Category 4: Geographic atrophy involving the fovea or any of the features of neovascular age-related macular degeneration, and visual loss presumed to be due to age-related macular degeneration. Although not part of this classification, advanced AMD might also include the involutional, atrophic stage of neovascular AMD that is not amenable to further treatment.
- In the AREDS, the 5-year risk of developing advanced AMD in at least one eye in control participants was 1.3% in eyes in
Category 2, 18.3% in those inCategory 3, and 43.9% in those in Category 4. - Polypoidal choroidal vasculopathy is difficult to distinguish clinically from choroidal neovascularisation. Occasionally, orange, bulging dilatations might be visible under the retina. However, polypoidal choroidal vasculopathy more commonly presents with recurrent serous and haemorrhagic retinal pigment epithelium detachments. Retinal angiomatous proliferation is characterised clinically by signs of haemorrhage, oedema, and exudates within the retinal layers in addition to other typical signs of choroidal neovascularisation. In some cases, the anastomosis between the retinal and subretinal new vessels might be visible.
- As used herein, a "subject" is a mammal, e.g., human, canine, feline, ovine, primate, equine, porcine, caprine, camelid, avian, bovine, and murine organisms. Typically, the subject is a human.
- As used herein, "apparently healthy" means that a subject does not have clinical signs of AMD, e.g., is in
AERDS Category 1, and is essentially free of current need for treatment. In other words, such subjects, if examined by a medical professional, would be characterized as healthy and generally free of symptoms of acute disease. - As used herein, a "risk factor" means a risk factor that is known to be associated with an increased risk of development or progression of AMD.
- Within any given population, there is an absolute risk of developing a disease or trait, defined as the chance of a person developing the specific disease or trait over a specified time-period. For example, a woman's lifetime absolute risk of breast cancer is one in nine. That is to say, one woman in every nine will develop breast cancer at some point in their lives. Risk is typically measured by looking at very large numbers of people, rather than at a particular individual. Risk is often presented in terms of Absolute Risk (AR) and Relative Risk (RR). Relative Risk is used to compare risks associating with two variants or the risks of two different groups of people. For example, it can be used to compare a group of people with a an elevated level of a biomarker with another group having a "normal" level of the same biomarker. For a disease, a relative risk of 2 means that one group has twice the chance of developing a disease as the other group. The risk presented is usually the relative risk for a person, or a specific genotype of a person, compared to a matched population, such as a population with matched gender and ethnicity, with the understanding that ethnicity is usually as self-reported by a subject.
- Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
- The results provided herein regarding the elevated levels of VEGF-C in subjects with AMD suggest that VEGF-C is a major driver of AMD. The results provided herein suggest that elevated VEGF-C levels can, independently of or dependently on other risk factors and/or biomarkers, be predictive of developing AMD, of AMD progression and of suitability of certain subjects for targeted therapy or clinical trials. The results provided herein suggest that monitoring VEGF-C levels can also be predictive of efficacy of a treatment, treatment regime or therapy. The information about VEGF-C levels as a biomarker does not duplicate, and is likely to be independent of the information provided by other known or presumed risk factors. Even when numerous other known risk factors are controlled for, VEGF-C measurement as a biomarker improves prediction. Furthermore, using an AMD biomarker as an assay for AMD risk can provide a simpler method of evaluating a subject's risk that does not require information about a subject's personal medical history.
- The results presented herein suggest that elevated VEGF-C levels are associated with development and/or progression of AMD. Anti-VEGF-C agents or agents which inhibit the biological pathway of VEGF-C, i.e. inhibitors of the VEGFR-2 and/or VEGFR-3 pathways, may have a role in slowing the progression to advanced AMD, with VEGF-C levels providing a biomarker to provide a method of identifying people for whom these agents would be more or less effective.
- The results presented herein suggest that anti-VEGF-C agents or agents which inhibit the biological pathway of VEGF-C, i.e. inhibitors of the VEGFR-2 and/or VEGFR-3 pathways, may have a role in preventing and/or treating AMD, with VEGF-C levels providing a biomarker to provide a method of identifying people for whom these agents would be more or less effective.
- The findings described herein demonstrate that angiogenesis is associated with the pathogenesis of AMD. It is believed that VEGF-A, a key molecule in driving angiogenesis, is associated with the pathogenesis of AMD. As a result, there are several anti-VEGF-A products approved for treatment of AMD. These include Lucentis™ (an antibody fragment targeting VEGF-A) and Eylea™ (a soluble VEGFR-1/VEGFR-2 trap). Both Lucentis™ and Eylea™ target and bind to VEGF-A (but not to VEGF-C). Avastin™, the full length antibody version of Lucentis™ is also used in off-label treatment of AMD. The findings described herein demonstrate that angiogenesis associated with AMD pathogenesis may not just involve VEGF-A. Elevated levels of VEGF-C, a molecule also associated with driving angiogenesis, also appears to be associated with AMD development and progression.
- The measuring of VEGF-C can occur at any one or more of the following time points: prior to an AMD diagnosis being made (e.g. in apparently healthy subjects), after a diagnosis of AMD has been made (e.g. in a screening or selection for potential targeted therapy), prior to initiation of a standard of care treatment, treatment regime or therapy for AMD, during treatment for AMD with a standard of care therapy or a targeted treatment, treatment regime or therapy, or after a course of treatment, treatment regime of therapy has been completed (e.g. to monitor for relapse). In some embodiments, the measuring of VEGF-C occurs after a subject with AMD does not respond to anti-angiogenic therapies, including standard of care anti-angiogenic therapies. For example, the measuring of VEGF-C occurs after a subject with AMD does not respond to, stops responding to or becomes less responsive to treatment with a standard of care anti-angiogenic agent such as, for example, Lucentis™, Avastin™ or Eylea™. These embodiments are not mutually exclusive. A subject undergoing AMD therapy can be monitored for VEGF-C expression to identify a time point at which VEGF-C becomes elevated. If the subject is already being treated with an anti-angiogenic standard of care therapy targeting VEGF-A and/or the VEGFR-1 and/or VEGFR-2 pathways (e.g. Lucentis™, Avastin™ or Eylea™), the subject may benefit from treatment with a VEGFR-3 inhibitor molecule that inhibits the action of VEGF-C such as, for example, a VEGF-C antibody, a VEGFR-3 antibody or a soluble VEGFR-3 trap. Alternatively, if the subject is not being treated with an anti-angiogenic standard of care therapy targeting VEGF-A and/or the VEGFR-1 and/or VEGFR-2 pathways, the subject may benefit from treatment with a standard of care anti-angiogenic agents or an agent that more specifically inhibits the action of VEGF-C such as, for example, a VEGF-C antibody, a VEGFR-3 antibody or a soluble VEGFR-3 trap. In the methods of prevention and treatment of AMD described herein, a combination of a standard of care anti-angiogenics for AMD (e.g. Lucentis™, Avastin™ or Eylea™) and a VEGFR-3 inhibitor molecule (e.g. a VEGF-C antibody, a VEGFR-3 antibody or a soluble VEGFR-3 trap) is envisaged. Such a combination anti-angiogenic therapy may provide significant benefits to the patient.
- VEGF-C (SEQ ID NOs: 1 and 2) is originally expressed as a larger precursor protein, prepro-VEGF-C, having extensive amino- and carboxy-terminal peptide sequences flanking a VHD, with the C-terminal peptide containing tandemly repeated cysteine residues in a motif typical of
Balbiani ring 3 protein. The prepro-VEGF-C polypeptide is processed in multiple stages to produce a mature and most active VEGF-C polypeptide (ΔNΔC VEGF-C) of about 21-23 kD (as assessed by SDS-PAGE under reducing conditions). Such processing includes cleavage of a signal peptide (approximately residues 1-31 of SEQ ID NO: 2); cleavage of a carboxyl-terminal peptide (approximately residues 228-419 of SEQ ID NO: 2) to produce a partially-processed form of about 29 kD; and cleavage (apparently extracellularly) of an amino-terminal peptide (approximately residues 32-102 of SEQ ID NO: 2) to produce a fully-processed mature form of about 21-23 kD (approximately residues 103-227 of SEQ ID NO: 2). Experimental evidence demonstrates that partially-processed forms of VEGF-C (e.g., the 29 kD form) are able to bind the Flt4 (VEGFR-3) receptor, whereas high affinity binding to VEGFR-2 occurs only with the fully processed forms of VEGF-C. Moreover, it has been demonstrated that amino acids 103-227 of SEQ ID NO: 2 are not all critical for maintaining VEGF-C functions. For example, a polypeptide consisting of amino acids 112-215 (and lacking residues 103-111 and 216-227) of SEQ ID NO: 2 retains the ability to bind and stimulate VEGF-C receptors. The cysteine residue atposition 156 has been shown to be important for VEGFR-2 binding ability. It appears that VEGF-C polypeptides naturally associate as non-disulfide linked dimers. - A level of VEGF-C as a biomarker in a subject can be obtained by any art recognized methods. Typically, the level is obtained by measuring the level of VEGF-C in a sample including a body fluid, for example, blood, lymph, saliva, urine and the like. In a preferred embodiment, a level of VEGF-C is measured in a blood sample. In a preferred embodiment, a level of VEGF-C is measured in plasma.
- In some embodiments, the methods described herein are practiced through the detection of a VEGF-C protein. In general, methods for detecting a VEGF-C protein can comprise contacting a biological sample with a compound that binds to and forms a complex with the polypeptide for a period sufficient to form the complex, and detecting the complex, so that if a complex is detected, a polypeptide disclosed herein is detected. The level of VEGF-C can be determined by immunoassays, e.g., enzyme-linked immunoassays (EIA) or enzyme-linked immunosorbent assays (ELISA); particle agglutination or flocculation tests (e.g., rapid latex agglutination); laser and rate nephelometry; turbidometry; or other known techniques for determining the presence and/or quantity of the marker. VEGF-C protein detection can be accomplished using antibodies specific for the protein in any of a number of formats commonly used by those of skill in the art for such detection. In some embodiments, the compound is a polypeptide comprising an ECD fragment of VEGFR-3 that binds VEGF-C.
- For example, the production and characterization of monoclonal antibodies specific for VEGF-C is described in
U.S. Patent Nos. 7,109,308 ;7,208,582 ;7,402,312 ;7,423,125 ;7,576,189 and7,850,963 . Such antibodies may be employed in ELISA-based techniques and Western blotting techniques to detect the presence of VEGF-C in a biological sample from a subject being tested. Methods for setting up ELISA assays and preparing Western blots of a sample are well known to those of skill in the art. The biological sample can be any tissue or fluid as described herein. In some variations, the tissue of fluid is from the eye, including the back of the eye; in some variations, the tissue or fluid is systemic, such as blood or serum/plasma. - In one embodiment, the antibodies or fragments can be utilized in enzyme immunoassays, wherein the subject antibody or fragment, or second antibodies, are conjugated to an enzyme. When a biological sample comprising a VEGF-C protein is combined with the subject antibodies, binding occurs between the antibodies and the VEGF-C protein. In one embodiment, a biological sample containing cells expressing a mammalian VEGF-C protein, or biological fluid containing secreted VEGF-C is combined with the subject antibodies, and binding occurs between the antibodies and the VEGF-C protein present in the biological sample comprising an epitope recognized by the antibody. This bound protein can be separated from unbound reagents and the presence of the antibody-enzyme conjugate specifically bound to the VEGF-C protein can be determined, for example, by contacting the sample with a substrate of the enzyme which produces a color or other detectable change when acted on by the enzyme. In another embodiment, the subject antibodies can be unlabeled, and a second, labeled antibody can be added which recognizes the subject antibody.
- Examples of suitable protein assay kits include those based on Luminex technology (i.e. which use the Luminex analysers) and microbead capture such as the BioPlex™ kits available from BioRad.
- The methods can include obtaining a level of VEGF-C in a subject by sending one or more samples of the subject biological sample (e.g. body fluid) to a laboratory, e.g., a commercial laboratory, for measurement of levels. In some embodiments, the methods include measuring the level of the biomarker in a body fluid from a subject, and providing information regarding the level of the biomarker, e.g., to the subject or a caregiver, e.g., a clinical entity such as a physician, nurse, hospital, clinical practice, or third-party payor, e.g., an insurance company.
- Assaying VEGF-C by immunohistochemistry (IHC) requires at least one anti-VEGF-C antibody. Using standard approaches the anti-VEGF-C antibody can be used to detect the presence of VEGF-C protein in tissue samples obtained from the subject, including paraffin-embedded and frozen tumor sections. Typically, the tissue sections are initially treated in such a way as to retrieve the antigenic structure of proteins that were fixed in the initial process of collecting and preserving the tumor material. Slides are then blocked to prevent non-specific binding by the anti-VEGF-C detection antibody. The presence of VEGF-C protein is then detected by binding of the VEGF-C antibody to the VEGF-C protein. The detection antibody is linked to an enzyme, either directly or indirectly, e.g., through a secondary antibody that specifically recognizes the detection antibody. Typically, the tissue sections are washed and blocked with non-specific protein such as bovine serum albumin (BSA) between steps. The slide is developed using an appropriate enzyme substrate to produce a visible signal, and the samples are then counterstained with hematoxylin.
- Similarly, also disclosed herein is a method of detecting and/or quantitating expression of a mammalian VEGF-C protein or a portion of the VEGF-C protein by a cell, in which a composition comprising a cell or fraction thereof (e.g., a soluble fraction) is contacted with an antibody or functional fragment thereof which binds to a mammalian VEGF-C protein or a portion of the VEGF-C protein under conditions appropriate for binding of the antibody or fragment thereto, and binding is monitored. Detection of the antibody, indicative of the formation of a complex between antibody and or a portion of the protein, indicates the presence of the protein.
- The method can be used to detect expression of VEGF-C in a biological sample of a mammalian subject (e.g., in a sample, such as a body fluid, such as blood, saliva or other suitable sample). The level of expression of VEGF-C in a biological sample of that subject can also be determined, for instance, by flow cytometry, and the level of expression (e.g., staining intensity) can be correlated with disease susceptibility, progression or risk.
- In certain other embodiments, VEGF-C polynucleotides such as mRNA encoding a mammalian VEGF-C protein may be measured. In general, methods for detecting VEGF-C mRNA can comprise contacting a biological sample with a compound that binds to and forms a complex with VEGF-C mRNA for a period sufficient to form the complex, and detecting the complex in a quantitative or semi-quantitative way. Such methods can also comprise amplification techniques involving contacting a biological sample with nucleic acid primers that anneal to VEGF-C mRNA or its complement, and amplifying annealed polynucleotides, so that if a polynucleotide is amplified, a VEGF-C polynucleotide is detected.
- In the amplification procedures, polynucleotide sequences encoding a VEGF-C protein may be used in hybridization or PCR assays of fluids or tissues from biopsies to detect VEGF-C protein expression. Such methods may be qualitative or quantitative in nature and may include Southern or northern analysis, dot blot or other membrane-based technologies; PCR technologies; dip stick, pin, chip and ELISA technologies. All of these techniques are well known in the art and are the basis of many commercially available diagnostic kits.
- One such procedure known in the art is quantitative real-time PCR. Real-time quantitative PCR can be conveniently accomplished using the commercially available ABI PRISM® 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions. PCR reagents can be obtained from PE-Applied Biosystems, Foster City, CA. Gene target quantities obtained by real time RT-PCR may be normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreenT™ (Molecular Probes, Inc. Eugene, OR). GAPDH expression is quantified by real time RT-PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA is quantified using RiboGreenTM RNA quantification reagent from Molecular Probes. Methods of RNA quantification by RiboGreen™ are taught in Jones et al. (1998). Controls are analyzed in parallel to verify the absence of DNA in the RNA preparation (-RT control) as well as the absence of primer dimers in control samples lacking template RNA. In addition, RT-PCR products may be analyzed by gel electrophoresis.
- A reverse transcriptase PCR (RT-PCR) amplification procedure may be performed in order to quantify the amount of mRNA amplified. Methods of reverse transcribing RNA into cDNA are well known and described in Sambrook et al. (1989). Alternative methods for reverse transcription utilize thermostable DNA polymerases. These methods are described in
WO 90/07641, filed December 21, 1990 - Conditions for incubating a nucleic acid probe or antibody with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the nucleic acid probe or antibody used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or immunological assay formats can readily be adapted to employ the nucleic acid probes or antibodies disclosed herein. Examples of such assays can be found in Chard (1986); Bullock et al., (1982, 1983 and 1985); and Tijssen (1985). The tests disclosed herein include cells, protein extracts of cells, or biological fluids such as, blood, serum, and plasma. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing protein extracts or membrane extracts of cells are well known in the art and can be readily be adapted in order to obtain a sample which is compatible with the system utilized.
- In addition, such assays may be useful in evaluating the efficacy of a particular therapeutic treatment regime in animal studies, in clinical trials, or in monitoring the treatment of an individual patient.
- The screening methods described herein may optionally comprise the step of prescribing for or administering to the subject identified as having elevated VEGF-C expression in the biological sample a composition comprising a molecule that inhibits the VEGFR-2 and/or VEGFR-3 pathway, preferably the VEGFR-3 pathway. By "prescribing" is meant providing an order or authorization for the therapy, which may be dispensed to the subject for self-administration and/or administered by a medical professional that is difference from the prescribing professional. In some variations, the subject receives (is administered or self-administered) the therapy following the prescribing.
- To assess the relative level of VEGF-C (mRNA or protein) expression, the level of VEGF-C expression in a biological sample can be subjected to one or more of various comparisons. In general, it can be compared to: (a) VEGF-C mRNA or protein expression levels in a collection of comparable biological samples from subjects with AMD; (b) VEGF-C mRNA or protein expression levels in a collection of biological samples from healthy subjects; or (c) VEGF-C mRNA or protein expression levels in an arbitrary standard.
- In some variations, to provide a basis for the identification of patients at risk of developing AMD or at risk of their AMD progressing or to identify patients likely to benefit from a targeted therapy for AMD, VEGF-C measurements from multiple individuals are obtained, both healthy individuals and individuals with AMD, to establish a data set of VEGF-C mRNA or protein expression. With an established data set a variety of standard statistical analyses can be performed to identify when a measurement of VEGF-C is elevated, e.g., in a statistically significant manner relative to a healthy control. To assess the relative level of VEGF-C expression, the level of VEGF-C expression in a biological sample from a subject with AMD can be subjected to one or more of various comparisons. In general, it can be compared to: (a) VEGF-C mRNA or protein expression level(s) in comparable biological samples from healthy subjects; or (b) VEGF-C mRNA or protein expression level in an arbitrary standard. In some embodiments, a VEGF-C measurement of at least 1.0, 1.5, 2.0, 2.5 or at least 3.0 standard deviation(s) greater than a median VEGF-C measurement in corresponding healthy tissue is scored as elevated VEGF-C expression. In other embodiments, a VEGF-C measurement that is statistically significantly greater than VEGF-C measurements in corresponding healthy tissue, with a p-value less than 0.1, or less than 0.05, or less than 0.01, or less than 0.005, or less than 0.001 is scored as elevated VEGF-C expression. As a data set enlarges, the comparison can be refined by stratifying the data for additional variables, such as the age, sex, ethnicity, body mass, smoking habits or other factors that differentiate subjects.
- In some embodiments, the screening methods described herein comprise comparing VEGF-C expression in the biological sample of an individual subject with a previous VEGF-C expression in the same subject, wherein elevated VEGF-C expression in the subsequent measurement identifies the subject as a subject for whom targeted AMD therapy will have efficacy.
- In some embodiments, the methods described herein also include comparing the level of VEGF-C for the subject with a reference. The reference can take a variety of forms. It can be a single predetermined "cut-off" (threshold) value or concentration of VEGF-C, such as a median or mean, that has been determined from observations to represent an elevated measure of VEGF-C that (when equalled or exceeded) is predictive of the risk of development or progression of AMD in a subject or is predictive of the suitability of a subject for a clinical trial or is predictive of the suitability of a subject to be treated for AMD by use of particular treatments or therapies. It can be established based upon comparative groups, such as where the risk in one defined group is higher than, e.g., double, the risk in another defined group. It can be a range, for example, where the tested population is divided equally (or unequally) into groups, such as a low-risk group, a medium-risk group, and a high-risk group, or into quintiles (fifths), quartiles (quarters), or tertiles (thirds), the lowest group being subjects with the lowest risk and the highest being subjects with the highest risk.
- The reference can depend upon the particular population selected. For example, an apparently healthy, non-smoker population (no detectable disease and no prior history of AMD) can have a different "normal" range of markers of VEGF-C than a smoking population, or a population the members of which have some stage of AMD. Accordingly, the reference selected may take into account the category in which a subject falls. Appropriate ranges and categories can be selected with no more than routine experimentation by those of ordinary skill in the art. In some embodiments, the reference is a predetermined value.
- Determination of a suitable cut-off is made using, e.g., statistical analysis of VEGF-C protein or mRNA concentration data collected from multiple healthy and/or AMD patients (including subjects in whom VEGF-C has been measured and for whom targeted therapy based on the VEGF-C biomarker measurement has been employed and monitored for efficacy). If a "cut-off" value is employed, the cut-off concentration preferably is statistically determined to have optimal discriminating value for subjects who benefit from the targeted therapy (e.g., to have maximum sensitivity and specificity). It will be appreciated that statistical analysis of a dataset will permit clinicians to make informed decisions based on concentrations other than the optimal discriminating concentration (e.g., above or below the optimal discriminating concentration). For example, using receiver-operating-characteristic curves, or using other statistical summaries of VEGF-C concentration and treatment outcome data collected as disclosed herein, the practitioner is capable of selecting a cut-off VEGF-C concentration having a desired level of sensitivity or specificity for predicting efficacy of targeted therapy. Considerations regarding the probability of success of targeted therapy based on VEGF-C measurement, versus the probability of success of alternative therapies based on any available clinical data, can guide the selection of an appropriate cut-off concentration of VEGF-C for making a treatment decision.
- The identifying, monitoring or selecting step of the screening or diagnostic methods described herein optionally comprises comparing the measurement of VEGF-C to a reference or control measurement of VEGF-C, and scoring the VEGF-C measurement from the sample as elevated, lowered (e.g. during targeted therapy) or normal based on statistical analysis or a ratio relative to the reference or control measurement. In some embodiments, the reference or control measurement comprises at least one of the following; (a) a database containing multiple VEGF-C measurements from healthy subjects and/or AMD subjects in biological samples of the same type (e.g. blood, tissue etc.); or (b) a reference value calculated from multiple VEGF-C measurements from healthy subjects and/or subjects with AMD, optionally further including statistical distribution information for the multiple measurements, such as standard deviation.
- In some embodiments, a VEGF-C measurement of at least 1.0 standard deviation greater than a median VEGF-C measurement in corresponding healthy subjects is scored as elevated VEGF-C expression. In other embodiments, a VEGF-C measurement that is statistically significantly greater than VEGF-C measurements in corresponding healthy subjects, with a p-value less than 0.1, or less than 0.05, or less than 0.01, or less than 0.005, or less than 0.001 is scored as elevated VEGF-C expression.
- Preferred methods for measuring VEGF-C employ an agent that binds VEGF-C with great specificity and binding affinity, to permit measurements of VEGF-C that are typically in the picogram per mL range. Although exemplified with antibodies, other suitable binding reagents exist and can be used to practice the invention.
- For example, in some embodiments, VEGFR-2 and/or VEGFR-3 is used to measure the amount of VEGF-C in a sample. In such embodiments, the methods described herein comprises contacting the biological sample with VEGFR-2 and/or VEGFR-3 (or fragments thereof that bind to VEGF-C) and measuring the amount of bound VEGFR-2 and/or VEGFR-3. VEGFR-2 and VEGFR-3 are receptor tyrosine kinases that bind VEGF-C and the ligand-binding portions of the extracellular domain have been well characterized (
U.S. Patent No. 7,422,741 and International Patent Publication No.WO 2005/087808 ). Although both receptors bind VEGF-C with high affinity, they also bind VEGF-D, a factor to consider in assay design. Thus, if VEGFR-2/VEGFR-3 is used as a capture moiety, then the sample can be pre-treated to remove VEGF-D or probed with a detection antibody that is specific for the VEGF-C. - Elevated levels of VEGF-C in a sample indicate an increased risk of developing AMD or of AMD progression or an increased likelihood that the subject will benefit from a targeted therapy for AMD comprising use of a VEGFR-2 inhibitor molecule and/or a VEGFR-3 inhibitor molecule, for example, a VEGF-A antibody (e.g. Avastin™; Lucentis™), a VEGF-C antibody, a soluble VEGFR-2 trap (e.g. Eylea™), a soluble VEGFR-3 trap (e.g. VGX-300) or a VEGFR-3 antibody.
- Also provided are novel kits or assays that are specific for, and have appropriate sensitivity with respect to, biomarker references selected on the basis of the present invention. In some embodiments, therefore, the kits or assays would differ from those presently commercially available, by including, for example, different cut-offs, and/or different sensitivities at particular cut-offs as well as instructions or other printed material for characterizing risk of developing AMD or progressing to advanced AMD, based upon the outcome of the assay.
- In one embodiment, the use of VEGF-C measurement as a predictive, selective or responsive/tracking biomarker is independent of other predictors or biomarkers for AMD. Prediction, selection, response or tracking based on VEGF-C measurement may be additive with one or more other biomarkers (genetic or biological) or risk factors known to be associated with AMD, and does not simply duplicate the information derivable from evaluating those other biomarkers or risk factors.
- Rick factors and other biomarkers for AMD will be known to the skilled person in the art and include for example those described in Kuo et al. (2013, Expert Rev. Ophthalmol., 8(2), 127), Sharma et al. (2012, DNA & Cell Biology, 31(11), 1618), Lim et al. (2012, The Lancet, 379, 1728), Ross et al. (2007, Expert Rev. Ophthalmol., 2(3), 443) and
WO 2005/083430 (Massachusetts Eye & Ear Infirmary). - Risk factors for AMD include, for example, smoking, obesity, poor body mass index, fat intake, antioxidant vitamin and mineral intake, low dietary intake of vitamins A, C and E, and zinc, low dietary intake of lutein and omega-3 fatty acids, age, sex, family history of AMD, and physical exercise levels.
- Other biomarkers for AMD include genetic biomarkers, inflammatory biomarkers, nutrient biomarkers and other biomarkers. Examples of reported genetic biomarkers for AMD include CFH (complement factor H; chr 1), ABCA4 (ATP-binding cassette transporter; chr 1), COL8A1 (collagen type 8
alpha 1 subunit; chr 3), CF1 (complement factor 1; chr 4), VEGF-A (vascular endothelial growth factor A; chr 6), FRK/COL10A1 (fyn-related kinase/alpha chain of type X collagen; chr 6), CFB (complement factor B [properdin]; chr 6), C2 (complement component 2; chr 6), ARMS2/HTRA1 (HtrA-serinepeptidasel; chr 10), LIPC (hepatic lipase; chr 15), CETP (cholesterylester transfer protein; chr 16), APOE (apolipoprotein E; chr 19), EECC6 (excision repair cross-complementing rodent repair deficiency, complementation group 6), C3 (complement component 3; chr 19), TIMP3 (tissue inhibitor ofmetalloproteinase 3; chr 22), and TNFRSF10A (tumour necrosis factor receptor superfamily 10a; chr 8). - Various immunological molecules and inflammatory mediators have been identified at the site of AMD lesions. Examples of reported inflammatory biomarkers for AMD include markers of systemic inflammation such as, for example, CRP (C-reactive protein), cytokines, TNF-R2 (tissue necrosis factor alpha receptor-II and cellular adhesion molecules (CAMs). Cytokines include the human interleukins. In particular, IL-6 has been reported as a biomarker for AMD. Other reported inflammatory biomarkers of AMD include fibrinogen and VEGF-A.
- Various nutrients have been reported in the literature as having demonstrated risk reduction for AMD after supplementation. Several nutrients have shown promise and been reported as potential biomarkers. These include, for example, omega-3 fatty acids, various vitamins including vitamins A, D and E (α-tocopherol) and xanthophylls (e.g. lutein and zeaxanthin).
- Other reported biomarkers for AMD include homocysteine levels, von Willebrand factors, and plasma leptin levels.
- In another embodiment, the use of VEGF-C measurement as a predictive, selective or responsive/tracking biomarker is dependent on combining the VEGF-C measurement (or a "risk" or "benefit" value associated with the VEGF-C measurement) as a factor in combination with one or more other risk factors for AMD and/or measured values of another biomarker for AMD. Prediction, selection or responsiveness/tracking based may be based on a multifactorial evaluation in which the VEGF-C measurement (or value associated with the measured level) is combined with at least one other biomarker or risk factor level or value. For example, VEGF-C levels may be used in combination with other factors such as, for example, smoking, obesity, body mass index, fat intake, antioxidant vitamin and mineral intake, age, sex, family history of AMD, and physical exercise levels, inter alia. In another example, VEGF-C levels may be used in combination with another biomarker such as, for example, VEGF-A levels. Standard multivariate statistical analysis tools are used to optimize the predictive value of VEGF-C in combination with one or more of these additional biomarkers and/or risk factors.
- The study described herein evaluated systemic biomarkers, in a large and well-characterized population of subjects with and without maculopathy from two geographical areas in the United States. Standardized collection of risk factor information including direct measurements of blood pressure and body mass index, as well as classification of maculopathy by means of standardized ophthalmological examinations and fundus photography, was employed.
- Also provided herein are methods for evaluating the likelihood that a subject will benefit from treatment with a VEGFR-2 inhibitor molecule and/or a VEGFR-3 inhibitor molecule for reducing risk of development or progression of AMD. The method includes determining the level of VEGF-C in the subject; if the level of VEGF-C is high, then the subject is likely to benefit from the administration of a VEGFR-2 inhibitor molecule and/or a VEGFR-3 inhibitor molecule.
- The methods described herein can also be used to evaluate the efficacy of a treatment for reducing the risk of development or progression of AMD. For example, the method can include determining the level of VEGF-C before, concurrently with, and/or after the administration of the treatment. In some embodiments, the subject receives multiple treatments, e.g., a treatment is administered in multiple doses, e.g., one or more doses per day for one or more days, weeks, months, or years, and the level of VEGF-C is determined, e.g., before any treatment, and after one or more treatments. In some embodiments, the treatment is the administration of a VEGF-A antibody, a VEGF-C antibody, a VEGFR-3 antibody, a soluble VEGFR-2 trap or a soluble VEGFR-3 trap or a combination of two or more, preferably no more than two, of these. In some embodiments, the methods described herein are performed as part of a clinical trial of a treatment to reduce the risk of the development or progression of AMD. These methods have important implications for subject treatment and also for clinical development of new therapeutics. Physicians typically select therapeutic regimens for subject treatment based upon the expected net benefit to the subject. The net benefit is derived from the risk to benefit ratio. The present methods permit selection of subjects who are more likely to benefit by intervention, thereby aiding the physician in selecting a therapeutic regimen. This might include using drugs with a higher risk profile where the likelihood of expected benefit has increased. Likewise, clinical investigators may desire to select for clinical trials a population with a high or low likelihood of obtaining a net benefit with a particular protocol. The methods described herein can be used by clinical investigators to select such a population. Thus, in some embodiments, the methods provide entry criteria and methods for selecting subjects for clinical trials, e.g., trials of AMD therapeutics, by selecting subjects having a given level of VEGF-C biomarker, having a level that is above or below a reference.
- Anti-angiogenic agents which can be used in methods of treatment or treatment steps described herein include, e.g., anecortave acetate (Alcon), which reduces production of matrix metalloproteinase, a key agent in the growth of neovascular membranes; or an agent that inhibits vascular endothelial growth factor A (VEGF-A). A number of inhibitors of VEGF-A signalling are known in the art and can include, e.g., ZD6474 (Tuccillo et al., Clin Cancer Res. 2005 ); COX-2, Tie2 receptor, angiopoietin, and neuropilin inhibitors; pigment epithelium-derived factor (PEDF), endostatin, and angiostatin (21-25); VEGF-A inhibitory aptamers, e.g., Macugen™ (pegaptanib, Pfizer); antibodies or fragments thereof, e.g., VEGF-A antibodies, e.g., bevacizumab (Avastin™, Genentech), or fragments thereof, e.g., ranibizumab (Lucentis™, Genetech); soluble fms-like tyrosine kinase 1 (sFltl) polypeptides or polynucleotides (Harris et al., Clin Cancer Res. 2001 Jul;7(7):1992-7;
U.S. Pat. No. 5,861,484 ); PTK787/ZK222 584 (Maier et al., Graefes Arch Clin Exp Ophthalmol. 2005 ; KRN633 (Maier et al., Mol Cancer Ther. 2004 Dec;3(12):1639-49); VEGF-Trap™ (Eylea™, Regeneron); intravitreal steroids, e.g., triamcinolone; and Alpha2-antiplasmin (Matsuno et al, Blood 2003;120:3621-3628). For reviews of VEGF-A and its inhibitors, see, e.g., Campochiaro, Ocular neovascularisation and excessive vascular permeability, Expert Opin Biol Ther. 2004 Sep;4(9): 1395-402; Ferrara, Vascular Endothelial Growth Factor: Basic Science and Clinical Progress, Endocr. Rev., August 1, 2004; 25(4):581-611; and Verheul and Pinedo, Vascular endothelial growth factor and its inhibitors, Drugs Today (Bare). 2003;39 Suppl C:81-93. - The term "VEGFR-2 inhibitor molecule" as used herein refers to any molecule that acts with specificity to reduce VEGF-C/VEGFR-2, VEGF-D/VEGFR-2 or VEGF-A/VEGFR-2 interactions, e.g., by blocking VEGF-C or VEGF-D binding to VEGFR-2, by blocking VEGF-A binding to VEGFR-2 or by reducing expression of VEGFR-2. In one embodiment, the VEGFR-2 inhibitor inhibits VEGF-C and VEGF-D binding to VEGFR-2. In another embodiment, the VEGFR-2 inhibitor inhibits binding of VEGF-A to VEGFR-2. The VEGFR-2 inhibitor can be a polypeptide comprising a soluble VEGFR-2 ECD fragment (amino acids 20-764 of human VEGFR-2, whose sequence is set forth in UniProtKB/Swiss-Prot accession no. P35968) that binds VEGF-A or VEGF-C or VEGF-D; VEGFR-2 antisense polynucleotides or short-interfering RNA (siRNA); anti-VEGFR-2 antibodies; a VEGFR-2 inhibitor polypeptide comprising an antigen-binding fragment of an anti-VEGFR-2 antibody that inhibits binding between VEGFR-2 and VEGF or VEGF-C or VEGF-D; an aptamer that inhibits binding between VEGFR-2 and VEGF-A; an aptamer that inhibits binding between VEGFR-2 and VEGF-C; an aptamer that inhibits binding between VEGFR-2 and VEGF-D; or a fusion protein comprising the soluble VEGFR-2 polypeptide fragment fused to an immunoglobulin constant region fragment (Fc). In some embodiments, a VEGFR-2 polypeptide fragment is fused to alkaline phosphatase (AP).
- In other embodiments, the molecule that inhibits the VEGFR-2 pathways is, bevacizumab (Avastin™, Genentech), or fragments thereof, e.g., ranibizumab (Lucentis™, Genentech) or Soluble VEGFR1/2 trap (VEGF-Trap™ (Eylea™, Regeneron)).
- The term "VEGFR-3 inhibitor molecule" as used herein refers to any molecule that reduces the interaction of VEGF-C and/or VEGF-D with VEGFR-3 and includes, but is not limited to, an antibody that binds VEGF-C and inhibits VEGF-C stimulation of VEGFR-3; or a fragment of said antibody that retains the inhibitory activity; an antibody that binds VEGFR-3 and inhibits VEGF-C stimulation of VEGFR-3; or a fragment of said antibody that retains the inhibitory activity; a polypeptide that comprises a VEGFR-3 ECD fragment that binds VEGF-C and inhibits VEGF-C stimulation of VEGFR-3 (
WO 2005/098909 ); an antisense or interfering nucleic acid (e.g., antisense oligonucleotide; micro-RNA, short interfering RNA) that inhibits VEGF-C expression; an antisense or interfering nucleic acid that inhibits VEGFR-3 expression; and a polypeptide that comprises a VEGFR-2 ECD fragment that binds VEGF-C and inhibits VEGF-C stimulation of VEGFR-3. - The term "VEGF-C inhibitor molecule" as used herein refers to any molecule that reduces the interaction of VEGF-C with VEGFR-2 and/or VEGFR-3 and includes, but is not limited to, an antibody that binds VEGF-C and inhibits VEGF-C stimulation of VEGFR-3; or a fragment of said antibody that retains the inhibitory activity; an antibody that binds VEGFR-3 and inhibits VEGF-C stimulation of VEGFR-3; or a fragment of said antibody that retains the inhibitory activity; an antibody that binds VEGFR-2 and inhibits VEGF-C stimulation of VEGFR-2; or a fragment of said antibody that retains the inhibitory activity; a polypeptide that comprises a VEGFR-2 or VEGFR-3 ECD fragment that binds VEGF-C and inhibits VEGF-C stimulation of VEGFR-2 or VEGFR-3 (
WO 2005/098909 ); an antisense or interfering nucleic acid (e.g., antisense oligonucleotide; micro-RNA, short interfering RNA) that inhibits VEGF-C expression; an antisense or interfering nucleic acid that inhibits VEGFR-3 expression; and a polypeptide that comprises a VEGFR-2 ECD fragment that binds VEGF-C and inhibits VEGF-C stimulation of VEGFR-3. - In a similar fashion, the term "VEGF-A inhibitor molecule" as used herein refers to any molecule that reduces the interaction of VEGF-A with VEGFR-1 or VEGFR-2 (especially VEGFR-2), and includes, but is not limited to, an antibody that binds VEGF-A and inhibits VEGF-A stimulation of its receptors; an antibody that binds the receptor(s) and inhibits ligand-mediated stimulation of the receptor(s); antibody fragments; soluble extracellular domain fragments of the receptor(s) that bind VEGF-A, including domain swap fusions of receptors; and the like.
- In some embodiments, a VEGFR-3 ECD receptor fragment comprises at least the first three Ig-like domains of the receptor. Soluble receptors capable of binding VEGF-C and VEGF-D, thereby inhibiting VEGF-C or VEGF-D activity or signaling via VEGFR-3, are also disclosed in
WO2000/023565 ,WO2000/021560 ,WO2002/060950 andWO2005/087808 . Those soluble receptors, optionally modified with the ΔN2 sequon change described below and optionally other modifications described herein, are contemplated as aspects disclosed herein. - Table 1 defines approximate boundaries of the Ig-like domains for human VEGFR-3. These boundaries are significant as the boundaries chosen can be used to form ligand binding molecules, and so can influence the binding properties of the resulting constructs. It will be appreciated that a construct containing two (or more adjacent Ig-like domains preferably will include most or all of the amino acids that naturally occur between the include domains.
Table 1: Immunoglobulin-like domains for human VEGFR-3 VEGFR-3 SEQ ID NO: 3 positions VEGFR-3 SEQ ID NO: 4 positions D1 158-364 47-115 D2 479-649 154-210 D3 761-961 248-314 D4 1070-1228 351-403 D5 1340-1633 441-538 D6 1739-1990 574-657 D7 2102-2275 695-752 - Soluble receptor constructs for use as a VEGFR-3 ECD fragment comprise at least one Ig-like domain of VEGFR-3 as described in Table 1, to as many as seven. The ligand binding molecule optionally will include sequence before the most N-terminally positioned Ig-like domain, optionally will include sequence beyond the most C-terminally Ig-like domain, and optionally will include sequence between the Ig-like domains as well. Variants, e.g., with one or more amino acid substitutions, additions, or deletions of an amino acid residue, are also contemplated. In some embodiments, the ligand binding molecule comprises a fragment of human VEGFR-3 comprising at least the first three Ig-like domains of human VEGFR-3.
- In some embodiments, the VEGFR-3 ECD fragment comprises Ig-like domains I-III of VEGFR-3 (referred to herein as "VGX-300") as described in Makinen et al., Nat. Med., 7:199-205 and International Publication Nos.
WO2000/023565 ,WO2000/021560 ,WO2002/060950 andWO2005/087808 . In exemplary embodiments, the VEGFR-3 ECD fragment comprises a portion of a human VEGFR-3 ECD, wherein the portion binds to one or both of human VEGF-C and human VEGF-D, and comprises at least the first, second and third Ig-like domains of the VEGFR-3 ECD and preferably polypeptide lacks VEGFR-3 Ig-like domains 4-7 and preferably any transmembrane domain and preferably any intracellular domain. - In some embodiments, VEGFR-3 ECD fragments are contemplated in which the soluble receptor polypeptide comprises an amino acid sequence at least 90, 91, 92, 93, 94, or 95% identical to a VEGFR-3 fragment, wherein the VEGFR-3 fragment comprises an amino acid sequence consisting of a portion of SEQ ID NO: 4, wherein the carboxy-terminal residue of the fragment is selected from the group consisting of positions 211 to 247 of SEQ ID NO: 4, and wherein the fragment and the polypeptide bind VEGF-C or VEGF-D. In some variations, the fragment has an amino terminal amino acid selected from the group consisting of positions of 1 to 47 of SEQ ID NO: 4. In some variations, the VEGFR-3 fragment used to make the soluble receptor has an amino terminal residue selected from the group consisting of
positions 1 to 47 of SEQ ID NO: 4, and a carboxy-terminal residue selected from the group consisting of positions 226 to 775 of SEQ ID NO: 4, wherein VEGFR-3 fragment binds at least one of VEGF-C and VEGF-D. Specific peptides include a fragment of VEGFR-3 defined by positions 1-226, positions 1-229, and positions 1-329, positions 47-224, positions 47-225, positions 47-226, positions 47-227, positions 47-228, positions 47-229, positions 47-230, positions 47-231, positions 47-232, positions 47-236, positions 47-240, positions 47-245, positions 47-314, positions 47-210, and positions 47-247 of SEQ ID NO: 4. - In some embodiments, the amino acid sequence of the ECD fragment of VEGFR-3 is modified from wildtype VEGFR-3 to eliminate the second putative N-linked glycosylation sequon of wildtype VEGFR-3, and wherein the polypeptide lacks VEGFR-3 Ig-like domains 4-7 and preferably any transmembrane domain and preferably any intracellular domain.
- In some embodiments, the VEGFR-3 ECD fragment comprises a modified VEGFR-3 ECD fragment (referred to as VGX-301ΔN2) as described in International Patent Application Nos.:
PCT/AU2014/000161 PCT/AU2014/000114 - In some embodiments, the VEGFR-3 ECD fragment comprises a polypeptide similar or identical in amino acid sequence to a human VEGFR-3 polypeptide (SEQ ID NO: 4) or fragment thereof, with the proviso that positions of the VEGFR-3 ECD fragment corresponding to positions 104-106 of the human VEGFR-3 polypeptide set forth in SEQ ID NO: 4 are not identical to N-X-S or N-X-T, wherein the VEGFR-3 ECD fragment binds human VEGF-C. The fragment minimally comprises enough of the VEGFR-3 sequence to bind the ligand, and may comprise the complete receptor. Extracellular domain fragments are preferred. Preferred polypeptides have an amino acid sequence at least 80% identical to a ligand binding fragment thereof. Fragments that are more similar, e.g., 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100% are highly preferred. Fragments that are 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, and 75% are also contemplated. A genus of similar polypeptides can alternatively be defined by the ability of encoding polynucleotides to hybridize to the complement of a nucleotide sequence that corresponds to the cDNA sequence encoding the VEGFR-3 receptor.
- In some embodiments, the VEGFR-3 ECD fragment comprises a polypeptide comprising a fragment of human VEGFR-3 (SEQ ID NO: 4) selected from the group consisting of positions 1-226 or 25-226 of SEQ ID NO: 4, positions 1-229 or 25-229 of SEQ ID NO: 4 and positions 1-329 or 25-229 of SEQ ID NO: 4, with the proviso that positions 104-106 of SEQ ID NO: 4 are not identical to N-X-S or N-X-T. In some embodiments, the VEGFR-3 ECD fragment is a polypeptide comprising a fragment of human VEGFR-3 (SEQ ID NO: 4) selected from the group consisting of positions 47-224 of SEQ ID NO: 4, positions 47-225 of SEQ ID NO: 4, positions 47-226 of SEQ ID NO: 4, positions 47-227 of SEQ ID NO: 4, positions 47-228 of SEQ ID NO: 4, positions 47-229 of SEQ ID NO: 4, positions 47-230 of SEQ ID NO: 4, positions 47-231 of SEQ ID NO: 4, positions 47-232 of SEQ ID NO: 4, positions 47-236 of SEQ ID NO: 4, positions 47-240 of SEQ ID NO: 4, and positions 47-245 of SEQ ID NO: 4, with the proviso that positions 104-106 of the encoded ligand binding fragment of VEGFR-3 are not identical to N-X-S or N-X-T. In some embodiments, the VEGFR-3 ECD fragment is a polypeptide comprising a fragment of human VEGFR-3 (SEQ ID NO: 4), selected from the group consisting of positions 47-314 of SEQ ID NO: 4, positions 47-210 of SEQ ID NO: 4, and positions 47-247 of SEQ ID NO: 4, with the proviso that positions 104-106 of SEQ ID NO: 4 are not identical to N-X-S or N-X-T.
- In some embodiments, the VEGFR-3 ECD fragment is operably linked to an immunoglobulin or a portion of an immunoglobulin as the fusion partner. In this embodiment, the VEGFR-3 ECD fragment is operably linked to all or a portion of an immunoglobulin, particularly a human immunoglobulin, even more particularly the Fc portion of a human immunoglobulin. Such fusion proteins can be prepared by transfecting cells with DNA encoding VEGFR-3 subunit:Fc fusion protein and expressing the dimers in the same cells. In a particular embodiment, the ligand binding polypeptides are the same on each monomer subunit (i.e the dimer is a homodimer). Methods for making immunoglobulin fusion proteins are well known in the art, such as the ones described in Hollenbaugh and Aruffo ("Construction of Immunoglobulin Fusion Proteins", in Current Protocols in Immunology, Suppl. 4, pages 10.19.1-10.19.11, 1992) or
WO 01/03737 - In some embodiments, the VEGFR-3 ECD fragment comprises an amino acid sequence that is similar or identical to the amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the VEGFR-3 ECD fragment comprises an amino acid sequence comprising amino acids 22-290 or 23-290 of SEQ ID NO: 5. In some embodiments, the ligand binding molecule comprises amino acids 22-537or 23-537 of SEQ ID NO: 5 or amino acids 1-537 of SEQ ID NO: 5.
- In some embodiments, the molecule comprises short interfering RNA (siRNA) that inhibits VEGF-C expression. RNA interference of the VEGF family of proteins and receptors is described in
U.S. Patent application Publication Nos.: 2006/0217332 ,2006/0025370 ,2005/0233998 ,2005/0222066 and2005/0171039 . Interfering RNA directed to VEGF or VEGFR family members is described inU.S. Patent Publication No. 2006/0217332 . - In some embodiments, the molecule comprises a zinc finger protein that inhibits VEGF-C expression.
- Exemplary VEGFR-3 antibodies and their production are described in
U.S. Patent Nos. 6,107,046 and6,824,777 ;U.S. Patent Publication Nos. 2006/0269548 and2006/0177901 ; and International Patent Application No.PCT/FI95/00337 WO 95/33772 - Exemplary VEGF-C antibodies are described, for example, in International Patent Application Nos.
PCT/FI1996/000427 WO/1997/005250 ) andPCT/US1998/001973 (WO/1998/033917 ); andU.S. Patent Publication Nos. 2004/0147726 ,2005/0232921 ,2005/0192429 ,2005/0059117 ,2005/0282228 ,2003/0176674 , and2006/0121025 ,2006/0030000 , andU.S. Patent No. 6,403,088 . -
- Any chemical substance that can be safely administered as a therapeutic and that can be used to modulate biochemical pathway targets identified herein, such as VEGF-A mediated stimulation of VEGF receptors, may be used as disclosed herein. Small molecules that inhibit the interaction between VEGF-C and/or VEGFR-3 with VEGFR-3 are specifically contemplated. VEGF-C/VEGF-D inhibitors are disclosed in
U.S. Patent No. 7,045,133 . - That patent describes, for example, monomeric monocyclic peptide inhibitors based on
loop loop - The VEGF receptors are receptor tyrosine kinases and intracellular signaling is initiated through receptor phosphorylation. Accordingly, one preferred class of molecules for practice as disclosed herein is tyrosine kinase inhibitors, including those described in and Morin, Oncogene, 19(56):6574-83, 2000. VEGFR-3 inhibitors are disclosed in
U.S. Patent Publication No. 2002-0164667 . - In another embodiment, the methods described herein optionally further comprise administering a tyrosine kinase inhibitor that inhibits VEGFR-2 and/or VEGFR-3 activity.
- Exemplary tyrosine kinase inhibitors for use in the methods described herein include, but are not limited to, AEE788 (TKI, VEGFR-2, EGFR: Novartis); ZD6474 (TKI, VEGFR-1, -2,-3, EGFR: Zactima: AstraZeneca); AZD2171 (TKI, VEGFR-1, -2: AstraZeneca); SU 11248 (TKI, VEGFR-1, -2, PDGFR: Sunitinib: Pfizer); AG13925 (TKI, VEGFR-1, -2: Pfizer); AG013736 (TKI, VEGFR-1, -2: Pfizer); CEP-7055 (TKI, VEGFR-1, -2,-3: Cephalon); CP-547,632 (TKI, VEGFR-1, -2: Pfizer); GW7S6024 (TKL VEGFR-1, -2, -3: GlaxoSmithKline); GW786034 (TKI, VEGFR-1, -2, -3: GlaxoSmithKline); sorafenib (TKI, Bay 43-9006, VEGFR-1, -2, PDGFR: Bayer/Onyx); SU4312 (TKI, VEGFR-2, PDGFR: Pfizer); AMG706 (TKI, VEGFR-1, -2, -3: Amgen); XL647 (TKI, EGFR, HER2, VEGFR, ErbB4: Exelixis); XL999 (TKI, FGFR, VEGFR, PDGFR, Fll-3: Exelixis); PKC412 (TKI, KIT, PDGFR, PKC, FLT3, VEGFR-2: Novartis); AEE788 (TKI, EGFR, VEGFR2, VEGFR-1: Novartis): OSI-030 (TKI, c-kil, VEGFR: OSI Pharmaceuticals); OS1-817 (TKI c-kit, VEGFR: OSI Pharmaceuticals); DMPQ (TKI, ERGF, PDGFR, ErbB2. p56. pkA, pkC); MLN518 (TKI, Flt3, PDGFR, c-KIT (T53518: Millennium Pharmaceuticals); lestaurinib (TKI, FLT3, CEP-701, Cephalon); ZD 1839 (TKI, EGFR: gefitinib, Iressa: AstraZcneca); OSI-774 (TKI, EGFR: Erlotininb: Tarceva: OSI Pharmaceuticals); lapatinib (TKI, ErbB-2, EGFR, and GD-2016: Tykerb: GlaxoSmithKline).
-
- In some embodiments, the methods described herein further comprise administering an inhibitor of the PI3/AKT/mTOR pathway. In some embodiments, the inhibitor is a PI3 kinase inhibitor selected from the group consisting of wortmannin (Calbiochem), 3-methyladenine (3-MA, Sigma), LY294002 (Calbiochem) and chloroquine.
- In some embodiments, the inhibitor is a mTOR (mammalian target of rapamycin) inhibitor. Exemplary mTOR inhibitors include, but are not limited to, the following:
Brand Name or Product # Generic Name Patent (U.S. Unless Specified) or Reference Rapamune® rapamycin (sirolimus) 3,929,992; 5,288,711; 5,516,781 RAD001 (Certican®) everolimus; 40-O-(2-hydroxyethyl)-rapamycin EP663916 U.S. Pat. Appl. 20030170287 CCI-779 Rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid 6,617,333; 5,362,718; 6,277,983 Tumstatin and related polypeptides U.S. Pat. Appl. 20030144481 ABT578 U.S. Pat. Appl. 20030073737 "rapalogs," e.g., AP23573 AP22594 U.S. Pat. Appl. 20030073737 ;WO01/02441 WO01/14387 AP23841 ARIAD Pharmaceuticals TAFA93 Isotechnika - In addition to rapamycin and those derivatives of rapamycin listed in the above table those discussed in
U.S. Pat. Appl. No. 20030170287 may also be used. See alsoWO 94/09010 WO 96/41807 WO 98/02441 WO01/14387 U.S. Pat. 6,503,921 . Derivatives of other mTOR inhibitors are also contemplated. -
- Other compounds that may be administered in combination with the VEGFR-2 inhibitors or VEGFR-3 inhibitors described herein include PDGF inhibitors. A PDGF Inhibitor Product inhibitor product may be administered in combination with one or more of the agents described herein for inhibiting binding between the VEGF family of proteins and VEGF receptors. In some embodiments, the inhibitor products are co-administered in a single composition. In other embodiments, the inhibitor products administered as separate compositions.
- Exemplary PDGF inhibitors are also described in Table 1 above. Exemplary PDGF inhibitors include antibodies that bind to a PDGF protein (e.g., PDGF-A, -B, -C, and/or -D and/or homodimers or heterodimers thereof); antibodies that bind to a PDGF receptor (e.g., PDGF-α and/or PDGF-β and/or heterodimers or homodimers thereof); and PDGF ligand traps comprised of a soluble, ligand-binding extracellular domain fragment of either or both receptors, optionally fused to a heterologous protein such as an immunoglobulin constant domain.
- The term "PDGF" refers to a platelet-derived growth factor that regulates cell growth or division. As used herein, the term "PDGF" includes the various subtypes of PDGF including PDGF-B, PDGF-A, PDGF-C, PDGF-D, variant forms thereof and dimerized forms thereof, including PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD. Platelet derived growth factors includes homo- or heterodimers of A-chain (PDGF-A) and B-chain (PDGF-B) that exert their action via binding to and dimerization of two related receptor tyrosine kinase platelet-derived growth factor cell surface receptors (i.e., PDGFRs), PDGFR-α and PDGFR-β. In addition, PDGF-C and PDGF-D, two additional protease-activated ligands for the PDGFR complexes, have been identified (Li et al., (2000) Nat. Cell. Biol. 2: 302-9; Bergsten et al., (2001) Nat. Cell. Biol. 3: 512-6; and Uutele et al., (2001) Circulation 103: 2242-47). Due to the different ligand binding specificities of the PDGFRs, it is known that PDGFR-α/α binds PDGF-AA, PDGF-BB, PDGF-AB, and PDGF-CC; PDGFR-β/β binds PDGF-BB and PDGF-DD; whereas PDGFR-α/β binds PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD (Betsholtz et al., (2001) BioEssays 23: 494-507). As used herein, the term "PDGF" also refers to those members of the class of growth factors that induce DNA synthesis and mitogenesis through the binding and activation of a PDGFR on a responsive cell type. PDGFs can effect, for example: directed cell migration (chemotaxis) and cell activation; phospholipase activation; increased phosphatidylinositol turnover and prostaglandin metabolism; stimulation of both collagen and collagenase synthesis by responsive cells; alteration of cellular metabolic activities, including matrix synthesis, cytokine production, and lipoprotein uptake; induction, indirectly, of a proliferative response in cells lacking PDGF receptors; and potent vasoconstrictor activity. The term "PDGF" can be used to refer to a "PDGF" polypeptide, a "PDGF" encoding gene or nucleic acid, or a dimerized form thereof.
- The term "PDGF inhibitor product" refers to an agent that reduces, or inhibits, either partially or fully, the activity or production of a PDGF. A PDGF inhibitor product can directly or indirectly reduce or inhibit the activity or production of a specific PDGF such as PDGF-B. Furthermore, "PDGF inhibitor products" include agents that act on a PDGF ligand or its cognate receptor so as to reduce or inhibit a PDGF-associated receptor signal. Examples of "PDGF inhibitor products" include antisense molecules, ribozymes or RNAi that target a PDGF nucleic acid; PDGF aptamers, PDGF antibodies to PDGF itself or its receptor, or soluble PDGF receptor decoys that prevent binding of a PDGF to its cognate receptor; antisense molecules, ribozymes or RNAi that target a cognate PDGF receptor (PDGFR) nucleic acid; PDGFR aptamers or PDGFR antibodies that bind to a cognate PDGFR receptor; and PDGFR tyrosine kinase inhibitors.
- In one embodiment, the PDGF inhibitor product is selected from: a compound of Formula A, B, C, D or E as described and defined is
US 2012/0100136 , p1B3 antibody, CDP860, IMC-3G3, 162.62 antibody, 163.31 antibody, 169.14 antibody, 169.31 antibody, αR1 antibody, 2A1E2 antibody, M4TS.11 antibody, M4TS.22 antibody, Hyb 120.1.2.1.2 antibody, Hyb 121.6.1.1.1 antibody, Hyb 127.5.7.3.1 antibody, Hyb 127.8.2.2.2 antibody, Hyb 1.6.1 antibody, Hyb 1.11.1 antibody, Hyb 1.17.1 antibody, Hyb 1.18.1 antibody, Hyb 1.19.1 antibody, Hyb 1.23.1 antibody, Hyb 1.24 antibody, Hyb 1.25 antibody, Hyb 1.29 antibody, Hyb 1.33 antibody, Hyb 1.38 antibody, Hyb 1.39 antibody, Hyb 1.40 antibody, Hyb 1.45 antibody, Hyb 1.46 antibody, Hyb 1.48 antibody, Hyb 1.49 antibody, Hyb 1.51 antibody, Hyb 6.4.1 antibody, F3 antibody, Humanized F3 antibody, C1 antibody, Humanized C1 antibody, 6.4 antibody, anti-mPDGF-C goat IgG antibody, C3.1 antibody, PDGFR-B1 monoclonal antibody, PDGFR-B2 monoclonal antibody, 6D11 monoclonal antibody, Sis 1 monoclonal antibody, PR7212 monoclonal antibody, PR292 monoclonal antibody, HYB 9610 monoclonal antibody, HYB 9611 monoclonal antibody, HYB 9612 monoclonal antibody, or HYB 9613 monoclonal antibody, or a pharmaceutically acceptable salt thereof of any of any of the aforementioned. - In a preferred embodiment, one or more inhibitors of VEGF-A/VEGF-C//VEGF-D/VEGFR-2/VEGFR-3 described herein are administered in combination with a PDGFR-beta antibody (such as that being developed by Regeneron Inc. for ocular indications) or an anti-PDGF aptamer (such as E10030 being developed by Ophthotech Inc. for ocular indications).
- In some embodiments, the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule is administered in conjunction with another modality for treating, preventing or delaying the development of AMD. A number of such treatments are known in the art, e.g., photodynamic therapy or laser photocoagulation to treat wet AMD, diet and exercise regiments, and or vitamin supplements, e.g., as described in AREDS Research Group, Arch Ophthalmol 2001 :119, 1417-1436; Seddon et al, JAMA, 1994; 272: 1413-1420, and
U.S. Pat. No. 6,660,297 . In some embodiments, the methods include administering to the subject an anti-angiogenesis agent as described above. - Another aspect disclosed herein is a system that is capable of carrying out a part or all of a method of the invention, or carrying out a variation of a method of the invention as described herein in greater detail. Exemplary systems include, as one or more components, computing systems, environments, and/or configurations that may be suitable for use with the methods and include, but are not limited to, personal computers, server computers, hand-held or laptop devices, multiprocessor systems, microprocessor-based systems, set top boxes, programmable consumer electronics, network PCs, minicomputers, mainframe computers, distributed computing environments that include any of the above systems or devices, and the like. In some variations, a system disclosed herein includes one or more machines used for analysis of biological material (e.g., genetic material), as described herein. In some variations, this analysis of the biological material involves a chemical analysis and/or a nucleic acid amplification.
- With reference to
Figure 11 , an exemplary system disclosed herein, which may be used to implement one or more steps of methods of the invention, includes a computing device in the form of acomputer 110. Components shown in dashed outline are not technically part of thecomputer 110, but are used to illustrate the exemplary embodiment ofFigure 11 . Components ofcomputer 110 may include, but are not limited to, aprocessor 120, asystem memory 130, a memory/graphics interface 121, also known as a Northbridge chip, and an I/O interface 122, also known as a Southbridge chip. Thesystem memory 130 and a graphics processor 190 may be coupled to the memory/graphics interface 121. Amonitor 191 or other graphic output device may be coupled to the graphics processor 190. - A series of system busses may couple various system components including a high
speed system bus 123 between theprocessor 120, the memory/graphics interface 121 and the I/O interface 122, a front-side bus 124 between the memory/graphics interface 121 and thesystem memory 130, and an advanced graphics processing (AGP)bus 125 between the memory/graphics interface 121 and the graphics processor 190. Thesystem bus 123 may be any of several types of bus structures including, by way of example, and not limitation, such architectures include Industry Standard Architecture (ISA) bus, Micro Channel Architecture (MCA) bus and Enhanced ISA (EISA) bus. As system architectures evolve, other bus architectures and chip sets may be used but often generally follow this pattern. For example, companies such as Intel and AMD support the Intel Hub Architecture (IHA) and the Hypertransport™ architecture, respectively. - The
computer 110 typically includes a variety of computer-readable media. Computer-readable media can be any available media that can be accessed bycomputer 110 and includes both volatile and nonvolatile media, removable and non-removable media. By way of example, and not limitation, computer readable media may comprise computer storage media. Computer storage media includes both volatile and nonvolatile, removable and non-removable media implemented in any method or technology for storage of information such as computer readable instructions, data structures, program modules or other data. Computer storage media includes, but is not limited to, RAM, ROM, EEPROM, flash memory or other memory technology, CD-ROM, digital versatile disks (DVD) or other optical disk storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices, or any other physical medium which can be used to store the desired information and which can accessed bycomputer 110. - The
system memory 130 includes computer storage media in the form of volatile and/or nonvolatile memory such as read only memory (ROM) 131 and random access memory (RAM) 132. Thesystem ROM 131 may containpermanent system data 143, such as identifying and manufacturing information. In some embodiments, a basic input/output system (BIOS) may also be stored insystem ROM 131.RAM 132 typically contains data and/or program modules that are immediately accessible to and/or presently being operated on byprocessor 120. By way of example, and not limitation,Fig. 7 illustratesoperating system 134,application programs 135, other program modules 136, and program data 137. - The I/
O interface 122 may couple thesystem bus 123 with a number ofother busses computer 110. A serial peripheral interface (SPI)bus 126 may connect to a basic input/output system (BIOS)memory 133 containing the basic routines that help to transfer information between elements withincomputer 110, such as during start-up. - A super input/
output chip 160 may be used to connect to a number of'legacy' peripherals, such asfloppy disk 152, keyboard/mouse 162, andprinter 196, as examples. The super I/O chip 160 may be connected to the I/O interface 122 with abus 127, such as a low pin count (LPC) bus, in some embodiments. Various embodiments of the super I/O chip 160 are widely available in the commercial marketplace. - In one embodiment,
bus 128 may be a Peripheral Component Interconnect (PCI) bus, or a variation thereof, may be used to connect higher speed peripherals to the I/O interface 122. A PCI bus may also be known as a Mezzanine bus. Variations of the PCI bus include the Peripheral Component Interconnect-Express (PCI-E) and the Peripheral Component Interconnect - Extended (PCI-X) busses, the former having a serial interface and the latter being a backward compatible parallel interface. In other embodiments,bus 128 may be an advanced technology attachment (ATA) bus, in the form of a serial ATA bus (SATA) or parallel ATA (PATA). - The
computer 110 may also include other removable/non-removable, volatile/nonvolatile computer storage media. By way of example only,Fig. 7 illustrates a hard disk drive 140 that reads from or writes to non-removable, nonvolatile magnetic media. The hard disk drive 140 may be a conventional hard disk drive.. - Removable media, such as a universal serial bus (USB) memory 153, firewire (IEEE 1394), or CD/
DVD drive 156 may be connected to thePCI bus 128 directly or through aninterface 150. Astorage media 154 may coupled throughinterface 150. Other removable/non-removable, volatile/nonvolatile computer storage media that can be used in the exemplary operating environment include, but are not limited to, magnetic tape cassettes, flash memory cards, digital versatile disks, digital video tape, solid state RAM, solid state ROM, and the like. In some variations, the storage media is any non-transitory media, excluding, e.g., a signal. - The drives and their associated computer storage media discussed above and illustrated in
Figure 11 , provide storage of computer readable instructions, data structures, program modules and other data for thecomputer 110. InFig. 7 , for example, hard disk drive 140 is illustrated as storingoperating system 144,application programs 145, other program modules 146, andprogram data 147. Note that these components can either be the same as or different fromoperating system 134,application programs 135, other program modules 136, and program data 137.Operating system 144,application programs 145, other program modules 146, andprogram data 147 are given different numbers here to illustrate that, at a minimum, they are different copies. A user may enter commands and information into the computer 20 through input devices such as a mouse/keyboard 162 or other input device combination. Other input devices (not shown) may include a microphone, joystick, game pad, satellite dish, scanner, or the like. These and other input devices are often connected to theprocessor 120 through one of the I/O interface busses, such as theSPI 126, theLPC 127, or thePCI 128, but other busses may be used. In some embodiments, other devices may be coupled to parallel ports, infrared interfaces, game ports, and the like (not depicted), via the super I/O chip 160. - The
computer 110 may operate in a networked environment using logical connections to one or more remote computers, such as aremote computer 180 via a network interface controller (NIC) 170,. Theremote computer 180 may be a personal computer, a server, a router, a network PC, a peer device or other common network node, and typically includes many or all of the elements described above relative to thecomputer 110. The logical connection between theNIC 170 and theremote computer 180 depicted inFigure 11 may include a local area network (LAN), a wide area network (WAN), or both, but may also include other networks. Such networking environments are commonplace in offices, enterprise-wide computer networks, intranets, and the Internet. Theremote computer 180 may also represent a web server supporting interactive sessions with thecomputer 110, or in the specific case of location-based applications may be a location server or an application server. - In some embodiments, the network interface may use a modem (not depicted) when a broadband connection is not available or is not used. It will be appreciated that the network connection shown is exemplary and other means of establishing a communications link between the computers may be used.
- In some variations, disclosed herein is a system for identifying susceptibility to a maculopathy, such as macular degeneration, or pathogenic ocular neovascularization, in a human subject. For example, in one variation, the system includes tools for performing at least one step, preferably two or more steps, and in some aspects all steps of a method of the invention, where the tools are operably linked to each other. Operable linkage describes a linkage through which components can function with each other to perform their purpose.
- In some variations, a system disclosed herein is a system for assessing risk of a human subject for developing a disease or condition selected from a maculopathy and pathogenic ocular neovascularization, the system comprising:
- (a) at least one processor;
- (b) at least one computer-readable medium;
- (c) a database operatively coupled to a computer-readable medium of the system and containing population information correlating measurements of the disease or condition and VEGF-C measurements in a population of humans;
- (d) a measurement tool that receives an input about the human subject and generates information from the input about the measurement of VEGF-C in a biological sample from the human subject; and
- (e) an analysis tool or routine that:
- (i) is operatively coupled to the database and the measurement tool,
- (ii) is stored on a computer-readable medium of the system,
- (iii) is adapted to be executed on a processor of the system, to compare the information about the human subject with the population information in the database and generate a conclusion with respect to risk of the subject for developing the disease or condition.
- Exemplary processors (processing units) include all variety of microprocessors and other processing units used in computing devices. Exemplary computer-readable media are described above. When two or more components of the system involve a processor or a computer-readable medium, the system generally can be created where a single processor and/or computer readable medium is dedicated to a single component of the system; or where two or more functions share a single processor and/or share a single computer readable medium, such that the system contains as few as one processor and/or one computer readable medium. In some variations, it is advantageous to use multiple processors or media, for example, where it is convenient to have components of the system at different locations. For instance, some components of a system may be located at a testing laboratory dedicated to laboratory or data analysis, whereas other components, including components (optional) for supplying input information or obtaining an output communication, may be located at a medical treatment or counseling facility (e.g., doctor's office, health clinic, HMO, pharmacist, geneticist, hospital) and/or at the home or business of the human subject (patient) for whom the testing service is performed.
- Referring to
Figure 12 an exemplary system includes adatabase 208 that is operatively coupled to a computer-readable medium of the system and that contains population information correlating the measurement of VEGF-C and risk for developing the disease or condition in a population of humans. - In a simple variation, the database contains 208 data relating to the level of VEGF-C observed in a biological sample of a population of humans with the maculopathy and/or pathogenic ocular neovascularization and information about the level of VEGF-C observed in healthy subjects. Such data provides an indication as to the potential of developing maculopathy and/or pathogenic ocular neovascularization for a human subject that is identified as expressing an elevated level of VEGF-C. As the database becomes more populated with patient data, it become a more powerful statistical tool for comparing an input with respect to a subject and making a prediction as to metastatic potential. Such information includes, but is not limited to, information about parameters such as age, sex, ethnicity, race, medical history, weight, diabetes status, blood pressure, family history, smoking history, and alcohol use in humans and impact of the at least one parameter on the disease or condition. These more robust databases can be used by an
analysis routine 210 to calculate a combined score with respect to potential for developing maculopathy and/or pathogenic ocular neovascularization for a human subject. In some variations, risk factors are combined using a multiplicative model. In some variations, logistic regression or other statistical tools are used to combine risk factors. - In addition to the
database 208, the system further includes a measurement tool 206 programmed to receive aninput 204 from or about the human subject and generate an output that contains information about the VEGF-C measurement. (Theinput 204 is not part of the system per se but is illustrated in the schematicFigure 12 .) Thus, theinput 204 will contain a specimen or contain data from which a level of VEGF-C in a biological sample can be directly read, or analytically determined. - In another variation, the
input 204 from the human subject contains data that is unannotated or insufficiently annotated with respect to VEGF-C, requiring analysis by the measurement tool 206. For example, the input can be raw data measurements from experiments designed to evaluate the level of VEGF-C in a biological sample. In such variations, the measurement tool 206 comprises a tool, preferably stored on a computer-readable medium of the system and adapted to be executed on a processor of the system, to receive a data input about a subject and determine information about the level of VEGF-C in the biological sample from the data. For example, the measurement tool 206 contains instructions, preferably executable on a processor of the system, for analyzing the unannotated input data and determining the level of VEGF-C of interest in the human subject. - In yet another variation, the
input 204 from the human subject comprises a biological sample, such as a fluid (e.g., ocular fluid, blood, serum or plasma) or ocular tissue, blood vessel or lymphatic vessel tissue sample, that can be analyzed to determine the level of VEGF-C in the sample. In this variation, an exemplary measurement tool 206 includes laboratory equipment for processing and analyzing the sample to determine the level of VEGF-C in the biological sample of the human subject. - In some variations the measurement tool 206 includes: immunoassay reagents for measuring VEGF-C in the biological sample; and an analysis tool stored on a computer-readable medium of the system and adapted to be executed on a processor of the system, to determine the level of VEGF-C in the sample based on the immunoassay data.
- In some variations, the measurement tool 206 further includes additional equipment and/or chemical reagents for processing the biological sample to purify VEGF-C from cells in a sample for further analysis using immunoassays, size separation tools, or other analytical equipment.
- The exemplary system further includes an analysis tool or routine 210 that: is operatively coupled to the
database 208 and operatively coupled to the measurement tool 206, is stored on a computer-readable medium of the system, is adapted to be executed on a processor of the system to compare the information about the human subject with the population information in thedatabase 208 and generate a conclusion with respect to potential for developing maculopathy and/or pathogenic ocular neovascularization in the human subject. In simple terms, theanalysis tool 210 looks at the level of VEGF-C identified by the measurement tool 206 for the human subject, and compares this information to thedatabase 208, to determine potential for developing maculopathy and/or pathogenic ocular neovascularization in the subject. The susceptibility can be based on the single parameter (the level of VEGF-C), or can involve a calculation based on other genetic and non-genetic data, as described above, that is collected and included as part of theinput 204 from the human subject, and that also is stored in thedatabase 208 with respect to a population of other humans. Generally speaking, each parameter of interest is weighted to provide a conclusion with respect to the disease or condition. Such a conclusion is expressed in the conclusion in any statistically useful form, for example, as a relative risk, an odds ratio, a lifetime risk, or a probability that the subject will develop maculopathy and/or pathogenic ocular neovascularization. - In some variations, the system as just described further includes a
communication tool 212. For example, the communication tool is operatively connected to theanalysis routine 210 and comprises a routine stored on a computer-readable medium of the system and adapted to be executed on a processor of the system, to: generate a communication containing the conclusion; and to transmit the communication to thehuman subject 200 or themedical practitioner 202, and/or enable the subject or medical practitioner to access the communication. (The subject and medical practitioner are depicted in the schematicFigure 13 , but are not part of the system per se, though they may be considered users of the system. Thecommunication tool 212 provides an interface for communicating to the subject, or to a medical practitioner for the subject (e.g., doctor, nurse, genetic counselor), the conclusion generated by theanalysis tool 210 with respect to potential for developing maculopathy and/or pathogenic ocular neovascularization in the subject. Usually, if the communication is obtained by or delivered to themedical practitioner 202, the medical practitioner will share the communication with thehuman subject 200 and/or counsel the human subject about the medical significance of the communication. In some variations, the communication is provided in a tangible form, such as a printed report or report stored on a computer readable medium such as a flash drive or optical disk. In some variations, the communication is provided electronically with an output that is visible on a video display or audio output (e.g., speaker). In some variations, the communication is transmitted to the subject or the medical practitioner, e.g., electronically or through the mail. In some variations, the system is designed to permit the subject or medical practitioner to access the communication, e.g., by telephone or computer. For instance, the system may include software residing on a memory and executed by a processor of a computer used by the human subject or the medical practitioner, with which the subject or practitioner can access the communication, preferably securely, over the internet or other network connection. In some variations of the system, this computer will be located remotely from other components of the system, e.g., at a location of the human subject's or medical practitioner's choosing. - In some variations, the system as described (including embodiments with or without the communication tool) further includes components that add a treatment or prophylaxis utility to the system. For instance, value is added to a determination of a subject developing maculopathy and/or pathogenic ocular neovascularization when a medical practitioner can prescribe or administer a standard of care that can prevent or delay onset of the disease or condition, and/or reduce the symptoms of the maculopathy and/or pathogenic ocular neovascularization. Exemplary medicinal protocols include administration of pharmaceutical agents for prophylaxis and/or treatment with a composition formulated for ophthalmic administration and comprising a VEGF-C inhibitor, a VEGFR-2 inhibitor, or a VEGFR-3 inhibitor, or combinations thereof.
- For example, in some variations, the system further includes a medical protocol database 214 operatively connected to a computer-readable medium of the system and containing information correlating the level of VEGF-C in the biological sample and medical protocols for human subjects with the maculopathy and/or pathogenic ocular neovascularization. Such medical protocols include any variety of medicines, lifestyle changes, diagnostic tests, increased frequencies of diagnostic tests, and the like that are designed to achieve effective therapy with minimum side effects. The information correlating the level of VEGF-C with protocols could include, for example, information about the success with which maculopathy and/or pathogenic ocular neovascularization is avoided or delayed, if a subject has a level of VEGF-C and follows a protocol.
- By way of example, in some variations, a system that analyzes inputs of VEGF-C or assessing the potential for developing maculopathy and/or pathogenic ocular neovascularization could generate a variety of treatment protocols, for a subject determined to have increased risk, including a therapeutic regimen that includes a composition formulated for ophthalmic administration and comprising a VEGF-C inhibitor, a VEGFR-2 inhibitor or a VEGFR-3 inhibitor;
- The system of this embodiment further includes a medical protocol tool or routine 216, operatively connected to the medical protocol database 214 and to the analysis tool or routine 210. The medical protocol tool or routine 216 preferably is stored on a computer-readable medium of the system, and adapted to be executed on a processor of the system, to: (i) compare (or correlate) the conclusion that is obtained from the analysis routine 210 (with respect to potential for the subject to develop maculopathy and/or pathogenic ocular neovascularization) and the medical protocol database 214, and (ii) generate a protocol report with respect to the probability that one or more medical protocols in the medical protocol database will achieve one or more of the goals of eliminating the disease or slowing onset of the disease.
- Some variations of the system just described include the
communication tool 212. In some examples, the communication tool generates a communication that includes the protocol report in addition to, or instead of, the conclusion with respect to potential for developing the disease. - Information about the level of VEGF-C not only can provide useful information about identifying or quantifying potential for developing maculopathy and/or pathogenic ocular neovascularization; it can also provide useful information about possible causative factors for a human subject identified with the disease, and useful information about therapies for the subject. In some variations, systems disclosed herein are useful for these purposes.
- For instance, in some variations disclosed herein is a system for assessing or selecting a treatment protocol for a subject diagnosed with a maculopathy and/or pathogenic ocular neovascularization. An exemplary system, schematically depicted in Figure 17, comprises:
- (a) at least one processor;
- (b) at least one computer-readable medium;
- (c) a
medical treatment database 308 operatively connected to a computer-readable medium of the system and containing information correlating the level of VEGF-C and potential for the subject to develop maculopathy and/or pathogenic ocular neovascularization; - (d) a
measurement tool 306 to receive an input (304, depicted inFigure 13 but not part of the system per se) about the human subject and generate information from theinput 304 about the level of VEGF-C indicative of maculopathy and/or pathogenic ocular neovascularization in a human subject diagnosed with the disease; and - (e) a medical protocol routine or tool 310 operatively coupled to the
medical treatment database 308 and themeasurement tool 306, stored on a computer-readable medium of the system, and adapted to be executed on a processor of the system, to compare the information with respect to the level of VEGF-C in a biological sample of the subject and the medical treatment database, and generate a conclusion with respect to at least one of:- (i) the probability that one or more medical treatments will be efficacious for treatment of the disease for the subject; and
- (ii) which of two or more medical treatments will be more efficacious for the patient. In some variation, the subject is a subject diagnosed with the disease or condition, and the medical intervention is to treat the disease or condition. In some variations, the subject has no symptoms or evidence of the disease or condition and the medical treatments are prophylactic.
- Preferably, such a system further includes a
communication tool 312 operatively connected to the medical protocol tool or routine 310 for communicating the conclusion to the subject 300, or to a medical practitioner for the subject 302 (both depicted in the schematic ofFig. 7 , but not part of the system per se). An exemplary communication tool comprises a routine stored on a computer-readable medium of the system and adapted to be executed on a processor of the system, to generate a communication containing the conclusion; and transmit the communication to the subject or the medical practitioner, or enable the subject or medical practitioner to access the communication. - Disclosed herein are compositions and kits including a VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule and instructions (e.g., on a label or package insert such as instructions to the subject or to the clinician) for administering the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule to a subject to treat, prevent, and/or delay the development or progression of AMD. The anti-inflammatory agent can be in a pharmaceutical composition also including a pharmacologically acceptable carrier.
- As used herein, "pharmaceutically acceptable carrier" includes saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. A pharmaceutical composition is typically formulated to be compatible with its intended route of administration, e.g., ocular, oral, mucosal, topical, transdermal, or parenteral. Supplementary active compounds can also be incorporated into the compositions.
- In some embodiments, a composition comprising a ligand binding molecule described herein is formulated for delivery to the eye of a subject (e.g., subconjunctivally, retrobulbarly, periocularly, subretinally, suprachoroidally, or intraocularly). Suitable ophthalmic carriers are known to those skilled in the art and all such conventional carriers may be employed as disclosed herein. Exemplary compounds incorporated to facilitate and expedite transdermal delivery of topical compositions into ocular or adnexal tissues include, but are not limited to, alcohol (ethanol, propanol, and nonanol), fatty alcohol (lauryl alcohol), fatty acid (valeric acid, caproic acid and capric acid), fatty acid ester (isopropyl myristate and isopropyl n-hexanoate), alkyl ester (ethyl acetate and butyl acetate), polyol (propylene glycol, propanedione and hexanetriol), sulfoxide (dimethylsulfoxide and decylmethylsulfoxide), amide (urea, dimethylacetamide and pyrrolidone derivatives), surfactant (sodium lauryl sulfate, cetyltrimethylannmonium bromide, polaxamers, spans, tweens, bile salts and lecithin), terpene (d-limonene, alphaterpeneol, 1,8-cineole and menthone), and alkanone (N-heptane and N-nonane). Moreover, topically-administered compositions comprise surface adhesion molecule modulating agents including, but not limited to, a cadherin antagonist, a selectin antagonist, and an integrin antagonist. Thus, a particular carrier may take the form of a sterile, ophthalmic ointment, cream, gel, solution, or dispersion. Also including as suitable ophthalmic carriers are slow release polymers, e.g., "Ocusert" polymers, "Hydron" polymers, etc.
- Exemplary ophthalmic viscosity enhancers that can be used in the present formulation include: carboxymethyl cellulose sodium; methylcellulose; hydroxypropyl cellulose; hydroxypropylmethyl cellulose; hydroxyethyl cellulose;
polyethylene glycol 300; polyethylene glycol 400; polyvinyl alcohol; and providone. - Some natural products, such as veegum, alginates, xanthan gum, gelatin, acacia and tragacanth, may also be used to increase the viscosity of ophthalmic solutions.
- A tonicity is important because hypotonic eye drops cause an edema of the cornea, and hypertonic eye drops cause deformation of the cornea. The ideal tonicity is approximately 300 mOsM. The tonicity can be achieved by methods described in Remington: The Science and Practice of Pharmacy, known to those versed in the art.
- Stabilizers may also be used such as, for example, chelating agents, e.g., EDTA. Antioxidants may also be used, e.g., sodium bisulfite, sodium thiosulfite, 8-hydroxy quinoline or ascorbic acid. Sterility typically will be maintained by conventional ophthalmic preservatives, e.g., chiorbutanol, benzalkonium chloride, cetylpyridium chloride, phenyl mercuric salts, thimerosal, etc., for aqueous formulations, and used in amounts which are nontoxic and which generally vary from about 0.001 to about 0.1% by weight of the aqueous solution. Conventional preservatives for ointments include methyl and propyl parabens. Typical ointment bases include white petrolatum and mineral oil or liquid petrolatum. However, preserved aqueous carriers are preferred. Solutions may be manually delivered to the eye in suitable dosage form, e.g., eye drops, or delivered by suitable microdrop or spray apparatus typically affording a metered dose of medicament. Examples of suitable ophthalmic carriers include sterile, substantially isotonic, aqueous solutions containing minor amounts, i.e., less than about 5% by weight hydroxypropylmethylcellulose, polyvinyl alcohol, carboxymethylcellulose, hydroxyethylcelullose, glycerine and EDTA. The solutions are preferably maintained at substantially neutral pH and isotonic with appropriate amounts of conventional buffers, e.g., phosphate, borate, acetate, tris.
- In some embodiments, penetration enhancers are added to the ophthalmologic carrier.
- Routes of administration suitable for the methods disclosed herein include both systemic and local administration. As used herein, the term "systemic administration" means a mode of administration resulting in delivery of a pharmaceutical composition to essentially the whole body of the patient. Exemplary modes of systemic administration include, without limitation, intravenous injection and oral administration. The term "local administration," as used herein, means a mode of administration resulting in significantly more pharmaceutical composition being delivered to and about the eyes than to regions distal from the eyes.
- In some embodiments, a pharmaceutical composition comprising a VEGFR-2 inhibitor or VEGFR-3 inhibitor or a VEGF-C inhibitor described herein is administered topically, or by local injection (e.g., by intravitreal injection), or is released from an intraocular or periocular implant such as a bioerodible or reservoir-based implant. The composition is preferably administered in an amount effective to inhibit VEGF-C in the eye of the subject from binding to or stimulating VEGFR-2 and/or VEGFR-3 expressed in cells of the eye or vessels of the eye.
- As used herein, the term "implant" refers to any material that does not significantly migrate from the insertion site following implantation. An implant can be biodegradable, non-biodegradable, or composed of both biodegradable and non-biodegradable materials; a non-biodegradable implant can include, if desired, a refillable reservoir. Implants useful in the methods disclosed herein include, for example, patches, particles, sheets, plaques, microcapsules and the like, and can be of any shape and size compatible with the selected site of insertion, which can be, without limitation, the posterior chamber, anterior chamber, suprachoroid or subconjunctiva. It is understood that an implant disclosed herein generally releases the implanted pharmaceutical composition at an effective dosage to the eye of the patient over an extended period of time. A variety of ocular implants and extended release formulations suitable for ocular release are well known in the art, as described, for example, in
U.S. Pat. Nos. 5,869,079 and5,443,505 . - In other embodiments, a VEGFR-2 inhibitor or VEGFR-3 inhibitor or VEGF-C inhibitor described herein is applied to the eye via liposomes. In still another embodiment, the ligand binding molecule is contained within a continuous or selective-release device, for example, membranes such as, but not limited to, those employed in the Ocusert™System (Alza Corp., Palo Alto, Calif). As an additional embodiment, the VEGFR-2 inhibitor or VEGFR-3 inhibitor or VEGF-C inhibitor is contained within, carried by, or attached to contact lenses which are placed on the eye. In yet another embodiment, the a VEGFR-2 inhibitor or VEGFR-3 inhibitor or VEGF-C inhibitor described herein molecule is contained within a swab or sponge which can be applied to the ocular surface. Another embodiment disclosed herein involves a VEGFR-2 inhibitor or VEGFR-3 inhibitor or VEGF-C inhibitor described herein within a liquid spray which can be applied to the ocular surface.
- In some embodiments, the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule is in a form suitable for local delivery to the macular area, e.g., an implantable form. An effective amount is a dosage of the VEGFR-2 inhibitor molecule and/or VEGFR-3 and/or VEGF-C inhibitor molecule sufficient to provide a medically desirable result. The effective amount will vary with the particular condition being treated, the age and physical condition of the subject being treated, the severity of the condition, the duration of the treatment, the nature of the concurrent therapy (if any), the specific route of administration and the like factors within the knowledge and expertise of the health practitioner. For example, an effective amount can depend upon the degree to which a subject has abnormally elevated levels of markers, e.g. VEGF-C levels, of AMD. In some embodiments, the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule is used to prevent the development or progression of AMD, that is, they are used prophylactically in subjects at risk of developing AMD, or in subjects that already have AMD but whose AMD is likely to progress, e.g., to a more severe form of the disease. Thus, an "effective amount" is that amount which can lower the risk of, slow, or prevent altogether the development or progression of AMD.
- In some embodiments, the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule is administered in an effective amount, e.g., in an amount effective to reduce levels of one or more markers of angiogenesis and in particular VEGF-A or VEGF-C, preferably VEGF-C, to reduce the levels of the marker(s) to place the subject in a lower risk category, e.g., as described herein. The VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule can be administered in one or more doses to achieve a desired therapeutic effect. Generally, doses of active compounds can be from about 0.01 mg/kg per day to 1000 mg/kg per day. It is expected that doses ranging from 50-500 mg/kg will be suitable, typically administered orally, and in one to three (or more) administrations per day. Lower doses may result from other forms of administration, such as intravenous administration. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that subject tolerance permits. Multiple doses per day are contemplated to achieve appropriate systemic levels of compounds. The dosage and schedule will depend on the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule selected; a skilled practitioner would be able to select a regimen appropriate for the particular agent and subject. A number of anti-inflammatory agents are known in the art, and can be used in the methods described herein. A variety of administration routes are available. The particular mode selected will depend upon the particular drug selected, the severity of the condition being treated and the dosage required for therapeutic efficacy. The methods described herein, generally speaking, can be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects. Such modes of administration include oral, rectal, topical, nasal, transdermal, or parenteral routes. The term "parenteral" includes subcutaneous, intravenous, intramuscular, or infusion. Local administration to the macular area can also be used. In some embodiments, disclosed herein is the use of implantable formulations, e.g., VEGFR-2 inhibitor molecules and/or VEGFR-3 inhibitor molecules and/or VEGF-C inhibitor molecules that are contained in a slow-release formula that can be implanted at or near the site of inflammation. Oral administration will typically be used for prophylactic and long term treatment because of the convenience to the subject as well as the dosing schedule. A number of oral compositions are known in the art and can be used in the methods described herein. The delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule, increasing convenience to the subject and the physician.
- Many types of release delivery systems are available and known to those of ordinary skill in the art. They include polymer base systems such as poly(lactide-glycolide), copolyoxalates, polycaprolactones, polyesteramides, polyorthoesters, polyhydroxybutyric acid, and polyanhydrides. Microcapsules of the foregoing polymers containing drugs are described in, for example,
U.S. Pat. No. 5,075,109 . Delivery systems can also include non-polymer systems that are: lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-, di- and tri-glycerides; hydrogel release systems; sylastic systems; peptide based systems; wax coatings; compressed tablets using conventional binders and excipients; partially fused implants; and the like. Specific examples include, but are not limited to, erosional systems in which the anti-inflammatory agent is contained in a form within a matrix such as those described inU.S. Pat. Nos. 4,452,775 ,4,667,014 ,4,748,034 and5,239,660 , and diffusional systems in which an active component permeates at a controlled rate from a polymer such as described inU.S. Pat. Nos. 3,832,253 , and3,854,480 . Pump-based hardware delivery systems can be used, some of which are adapted for implantation. In addition,U.S. Pat. No. 6,331,313 describes a biocompatible ocular drug delivery implant device that can be used to deliver VEGFR-2 inhibitor molecules and/or VEGFR-3 inhibitor molecules directly to the macular region. Use of a long-term sustained release implant may be particularly suitable for treatment of chronic conditions. Long-term release means that the implant is constructed and arranged to delivery therapeutic levels of the active ingredient for at least 30 days, e.g., 60 days. Long-term sustained release implants are known to those in the art and include some of the release systems described herein. Thus, disclosed herein is the use of a VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule to treat, delay or prevent the development or progression of AMD. - Further disclosed herein is the use of a VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule to modulate VEGF-C levels, thereby treating, delaying or preventing the development or progression of AMD.
- Finally, disclosed herein is the use of a VEGFR-2 inhibitor molecule and/or VEGFR-3 inhibitor molecule and/or VEGF-C inhibitor molecule in the preparation of a medicament for use in the treatment of AMD.
- The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.
- Choroidal neovascularization (CNV) is the major cause of severe visual loss in subjects with AMD. At least 40% of subjects with wet AMD exhibit some degree of resistance to anti-VEGF-A monotherapy. We sought to investigate if circulating and tissue levels of VEGF-C are elevated in AMD subjects and determine if VEGF-C/-D blockade can inhibit choroidal neovascularization and leakage in a mouse model of wet AMD
- Plasma VEGF-A, VEGF-C and VEGF-D levels were measured in plasma samples from subjects with AMD and in control subjects without AMD and quantitated using a multiplex assay (Biorad).
- The results are summarized in
Figure 1 . VEGF-C levels are significantly elevated in the plasma of AMD subjects compared to healthy volunteers (controls). - VEGF-C, VEGFR-2 and VEGFR-3 were localized in retinal tissues of C57BL/6
mice 14 days following laser injury and clinical specimens from wet AMD subjects by immunofluorescence using commercially available antibodies (Abcam). Results indicated that VEGF-C and its cognate receptors (i.e., VEGFR-2 and VEGFR-3) are expressed and co-localized in CNV membranes in the samples tested. - To determine whether VEGF-C and VEGF-D participate in choroidal neovascularization, a mouse model of laser-induced CNV was employed in which photocoagulation was induced at 8-9 positions on each mouse retina (50 µm, 700 mW, 100 ms).
- Mice (5/group) were administered non-specific IgG (20 mg/kg IP every 2 days), Eylea™ (aflibercept, 20 mg/kg IP every 2 days), or VGX-300 (VEGFR-3 Trap for VEGF-C & VEGF-D; single-intravitreal injection of 40 µg on day 1). CNV areas and extent of leakage were determined by fluorescein angiography (FA) followed by intracardiac perfusion of FITC-dextran in gelatin (10%) on
day 14 after photocoagulation (Figure 2 ). - Laser-induced CNV was created in C57BL/6 mice using a 532 nm laser under direct visualization using a Micron III® fundus camera (4-9 spots/eye; 50 µm size, 50 ms, 550 Mw). On
day 0 post-laser injury, mice were administered a single intravitreal (IVT) injection of a negative isotype antibody control IgG, Eylea®, VGX-300 or the combination of VGX-300 and Eylea®. N=15 mice per treatment group. For each injection, a total of 80 mg protein was administered in a 2 ml injection (for single-agent groups, 40 mg of IgG was added to each 40 mg dose of Eylea® or VGX-300).Figure 3 shows fundus images and fluorescein angiography of laser-inducedCNV membranes 14 days after photocoagulation.Figure 4 shows CNV lesion sizes in choroidal flatmounts. Anatomical areas ofCNV lesions 14 days after photocoagulation in IgG-treated animals (Figure 4A ) was much larger than those of Eylea™-treated (Figure 4B ) and VGX-300-treated (Figure 4C ) eyes.Figure 5 shows the incidence of CNV and intensity of leakage after 14 days in each of the treatment groups.Figure 6 shows the mean size of laser-induced CNV membranes (total area of leakage spots/total photocoagulated spots) and the percentage of relative increase in CNV area after 14 days in each treatment group. Both Eylea® and VGX-300 significantly reduced CNV area (Figure 7 ) compared to the IgG control treated group. VGX-300 reduced lesion size to the approximate size of the laser-burn. - Laser-induced CNV was created in C57BL/6 mice using a 532 nm laser under direct visualization using a Micron III® fundus camera (4-9 spots/eye; 50 µm size, 50 ms, 550 Mw). On
day 7 post-laser injury, mice were administered a single intravitreal (IVT) injection of a negative isotype antibody control IgG, Eylea® + IgG or VGX-300 + IgG. For each injection, a total of 80 mg protein was administered in a 2 ml injection (for single-agent groups, 40 mg of IgG was added to each 40 mg dose of Eylea® or VGX-300). N=10 mince per treatment group. Extent of leakage and CNV areas were determined by fluorescein angiography followed by intracardiac perfusion of FITC-dextran in gelatin (10%) ondays Figure 8 shows representative fundus images, angiography and choroidal flatmounts of laser-inducedCNV membranes Figure 9(A) shows the incidence of laser-induced leaking spots onday 7 and onday 14 post-laser injury (leaking spots/photocoagulated spots × 100%.Figure 9(B) shows the mean size of laser-induced CNV membranes atday 14 post-laser injury. - The modulation of expression of a panel of angiogenesis and inflammatory genes in mouse CNV following VGX-300 administration was evaluated by quantitative RT-PCR (qRT-PCR).
Figure 10 shows the normalized accumulated mRNA expression levels of a panel of angiogenic and inflammatory genes onday - The results demonstrate that VGX-300-mediated blockade of VEGF-C/-D significantly inhibits choroidal neovascularization and vascular leakage comparably to Eylea™ in the laser-induced mouse model of wet AMD. Persistent angiogenesis and vascular leakage in these sub-responsive subjects may be mediated by VEGF-C. Established CNV lesions in the mouse regress following treatment with VGX-300 on
day 7 post-laser injury. VEGF-C expression is higher in wet AMD and lower in control and dry AMD clinical specimens. VGX-300 reduces the expression of genes associated with angiogenesis and inflammation following laser-induced injury. Administration of single-agent VGX-300 may be an effective therapy for wet AMD. Administered in combination with anti-VEGF-A therapies, VGX-300 may have the potential to improve clinical responses in wet AMD by more effective inhibition of the pathways involved in disease progression. -
- <110> Baldwin, ET AL.
- <120> BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION (AMD)
- <130>
28967/47631A - <160> 5
- <170> PatentIn version 3.5
- <210> 1
<211> 1997
<212> DNA
<213> Homo sapiens - <400> 1
- <210> 2
<211> 419
<212> PRT
<213> Homo sapiens - <400> 2
- <210> 3
<211> 4195
<212> DNA
<213> Homo sapiens - <220>
<221> CDS
<222> (20)..(3913) - <400> 3
- <210> 4
<211> 1298
<212> PRT
<213> Homo sapiens - <400> 4
- <210> 5
<211> 537
<212> PRT
<213> Homo sapiens - <400> 5
Claims (12)
- The use of a VEGF-C measurement from a biological sample from a human subject as a predictive marker, a selective marker, a responsive marker, or a tracking marker for AMD, wherein the biological sample comprises blood, serum or plasma.
- The use according to claim 1, wherein the VEGF-C measurement occurs prior to an AMD diagnosis being made, after a diagnosis of AMD has been made, prior to initiation of a standard of care treatment, treatment regime or therapy for AMD, during treatment for AMD with a standard of care therapy or a targeted treatment, treatment regime or therapy, or after a course of treatment, treatment regime or therapy has been completed.
- The use according to claim 2, wherein the VEGF-C measurement occurs after a subject with AMD does not respond to, stops responding to or becomes less responsive to treatment with a standard of care anti-angiogenic.
- The use according to claim 3, wherein the standard of care anti-angiogenic includes a therapy targeting VEGF-A, VEGFR-1 and/or VEGFR-2 pathways.
- A method of assessing the risk of a human subject developing AMD comprising:(a) measuring VEGF-C in a biological sample from the subject to obtain a VEGF-C measurement, wherein the biological sample comprises blood, serum or plasma, and(b) determining an increased risk of the subject developing AMD from an elevated measurement of VEGF-C in the biological sample, or determining a normal or decreased risk of the subject developing the AMD from the absence of the elevated measurement.
- The method according to claim 5, wherein determining the risk comprises calculating a risk score for the subject developing the AMD based on the measurement of the VEGF-C in the sample.
- A method for assessing the risk of AMD in a human subject progressing to a more advanced or severe form of AMD comprising:(a) measuring VEGF-C in a biological sample from the subject at a first time point to obtain a first VEGF-C measurement, wherein the subject is identified as having at least one symptom of AMD;(b) measuring VEGF-C in a biological sample from the subject at a second time point, after the first time point, to obtain a second VEGF-C measurement; and(c) comparing the first and second VEGF-C measurements to determine if the amount of VEGF-C is changing in the subject between the time pointswherein the biological sample in each of (a) and (b) comprises blood, serum or plasma.
- The use according to any one of claims 1-4, or method according to claim 5 or claim 6, wherein a determination of elevated VEGF-C is made compared to one or more of the following reference measurements of VEGFC:(a) a VEGF-C measurement from the subject from a biological sample obtained at an earlier point in time; or(b) a VEGF-C measurement from one or more apparently healthy control human subjects.
- The method according to any one of claims 5-7 and 8, or use according to any one of claims 1-4 and 8, wherein the AMD is wet AMD.
- The method according to any one of claims 5-9, or use according to any one of claims 1-4, 8 and 9, wherein the VEGF-C measurement is selected from measurements, in the biological sample, of VEGF-C protein, VEGF-C mRNA and VEGF-C protein biological activity.
- The method according to any one of claims 5-10, further comprising measuring at least one additional maculopathy biomarker.
- The method according to any one of claims 5-11, further comprising measuring at least one environmental or lifestyle factor selected from the group consisting of age, smoking history, weight, body mass index, diet, and exercise habits.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361821056P | 2013-05-08 | 2013-05-08 | |
PCT/US2014/036865 WO2014182635A1 (en) | 2013-05-08 | 2014-05-05 | Biomarkers for age-related macular degeneration (amd) |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2994758A1 EP2994758A1 (en) | 2016-03-16 |
EP2994758B1 true EP2994758B1 (en) | 2017-12-20 |
Family
ID=50972781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14731098.1A Active EP2994758B1 (en) | 2013-05-08 | 2014-05-05 | Biomarkers for age-related macular degeneration (amd) |
Country Status (3)
Country | Link |
---|---|
US (3) | US10274503B2 (en) |
EP (1) | EP2994758B1 (en) |
WO (1) | WO2014182635A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3693381A1 (en) * | 2013-02-18 | 2020-08-12 | Vegenics Pty Limited | Ligand binding molecules and uses thereof |
CA3046668A1 (en) * | 2017-01-03 | 2018-07-12 | Vitrean, Inc. | Methods and devices for treating a retinal detachment |
WO2021030198A1 (en) * | 2019-08-09 | 2021-02-18 | Vedanta Biosciences, Inc. | Compositions and methods for suppressing pathogenic organisms |
US11641151B2 (en) * | 2021-05-11 | 2023-05-02 | Aac Microtech (Changzhou) Co., Ltd. | Linear vibration motor with elastic members with brackets, foams and damping glue |
US20220368206A1 (en) * | 2021-05-11 | 2022-11-17 | Aac Microtech (Changzhou) Co., Ltd. | Linear vibration motor |
WO2023200766A1 (en) * | 2022-04-14 | 2023-10-19 | Belite Bio, Inc | Methods, compositions and systems for evaluation of visual function |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000064946A2 (en) * | 1999-04-28 | 2000-11-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
WO2001006262A1 (en) * | 1999-02-19 | 2001-01-25 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration |
WO2005084188A2 (en) * | 2004-02-25 | 2005-09-15 | Massachusetts Eye & Ear Infirmary | Systemic inflammatory markers and age-related macular degeneration (amd) |
US20100150920A1 (en) * | 2008-12-04 | 2010-06-17 | Bert Glaser | System and Method for Identifying Biomarkers in Ocular Fluid That Are Indicative of Ocular Disease |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3929922A (en) | 1965-09-29 | 1975-12-30 | Studiengesellschaft Kohle Mbh | Novel large ring compounds |
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
US4667014A (en) | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US4932207A (en) | 1988-12-28 | 1990-06-12 | Sundstrand Corporation | Segmented seal plate for a turbine engine |
JPH04167172A (en) | 1990-10-31 | 1992-06-15 | Nec Corp | Vector processor |
US5516781A (en) | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
CA2086391C (en) | 1992-04-14 | 1996-09-24 | Patrick J. Coyne | Adjustable seat and back cushion |
US5288711A (en) | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
US6824777B1 (en) | 1992-10-09 | 2004-11-30 | Licentia Ltd. | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US6107046A (en) | 1992-10-09 | 2000-08-22 | Orion Corporation | Antibodies to Flt4, a receptor tyrosine kinase and uses thereof |
CA2158745C (en) | 1993-03-25 | 2007-06-19 | Richard L. Kendall | Inhibitor of vascular endothelial cell growth factor |
US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5840301A (en) | 1994-02-10 | 1998-11-24 | Imclone Systems Incorporated | Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors |
US6448077B1 (en) | 1994-02-10 | 2002-09-10 | Imclone Systems, Inc. | Chimeric and humanized monoclonal antibodies specific to VEGF receptors |
US7109308B1 (en) | 1994-03-08 | 2006-09-19 | Human Genome Sciences, Inc. | Antibodies to human vascular endothelial growth factor 2 |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
ATE326484T1 (en) | 1994-06-09 | 2006-06-15 | Licensing Oy | MONOCLONAL ANTIBODY AGAINST FLT4 RECEPTOR TYROSINE KINASE AND ITS USE FOR DIAGNOSIS AND THERAPY |
EP1353952B1 (en) | 1994-11-14 | 2007-04-11 | Ludwig Institute For Cancer Research | Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy |
US6645933B1 (en) | 1995-08-01 | 2003-11-11 | Helsinki University Licensing Ltd. Oy | Receptor ligand VEGF-C |
US6403088B1 (en) | 1995-08-01 | 2002-06-11 | Helsinki University Licensing, Ltd. | Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3) |
WO1998033917A1 (en) | 1994-11-14 | 1998-08-06 | The Ludwig Institute For Cancer Research | Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof |
US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
AU712193B2 (en) | 1995-06-09 | 1999-10-28 | Novartis Ag | Rapamycin derivatives |
US7423125B2 (en) | 1995-08-01 | 2008-09-09 | Vegenics Limited | Antibodies to VEGF-C |
DE69628652T3 (en) | 1995-09-08 | 2012-05-03 | Genentech, Inc. | VEGF-RELATED PROTEIN |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
AU735648B2 (en) | 1996-07-12 | 2001-07-12 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
DE19638745C2 (en) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoclonal antibodies against the extracellular domain of the human VEGF receptor protein (KDR) |
US6986890B1 (en) | 1996-11-21 | 2006-01-17 | Kyowa Hakko Kogyo Co., Ltd. | Anti-human VEGF receptor Flt-1 monoclonal antibody |
US5847959A (en) | 1997-01-28 | 1998-12-08 | Etec Systems, Inc. | Method and apparatus for run-time correction of proximity effects in pattern generation |
US6342507B1 (en) | 1997-09-05 | 2002-01-29 | Isotechnika, Inc. | Deuterated rapamycin compounds, method and uses thereof |
AU774266B2 (en) | 1998-10-09 | 2004-06-24 | Vegenics Limited | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
WO2000023565A2 (en) | 1998-10-19 | 2000-04-27 | Ludwig Institute For Cancer Research | Novel neuropilin/growth factor binding and uses thereof |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
CA2377732A1 (en) | 1999-07-02 | 2001-01-11 | Edward Mendell Company | Treatment of pulp to produce microcrystalline cellulose |
CA2379388C (en) | 1999-07-13 | 2012-05-29 | George N. Cox, Iii | Immunoglobulin fusion proteins |
IL147803A0 (en) | 1999-08-24 | 2002-08-14 | Ariad Gene Therapeutics Inc | 28-epirapalogs |
US6277983B1 (en) | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
EP1248642A4 (en) | 2000-01-18 | 2005-05-18 | Ludwig Inst Cancer Res | Vegf-d/vegf-c/vegf peptidomimetic inhibitor |
US7611711B2 (en) | 2001-01-17 | 2009-11-03 | Vegenics Limited | VEGFR-3 inhibitor materials and methods |
US6660297B2 (en) | 2001-03-23 | 2003-12-09 | Bausch & Lomb Incorporated | Nutritional supplement to treat macular degeneration |
US20050232921A1 (en) | 2001-04-13 | 2005-10-20 | Rosen Craig A | Vascular endothelial growth factor 2 |
EP1385862A4 (en) | 2001-04-13 | 2005-03-02 | Human Genome Sciences Inc | Vascular endothelial growth factor 2 |
US7402312B2 (en) | 2001-04-13 | 2008-07-22 | Human Genome Sciences, Inc. | Antibodies to vascular endothelial growth factor 2 (VEGF-2) |
EP2228389B1 (en) | 2001-04-13 | 2015-07-08 | Human Genome Sciences, Inc. | Antibodies against vascular endothelial growth factor 2 |
US20050222066A1 (en) | 2001-05-18 | 2005-10-06 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
AU2004266311B2 (en) | 2001-05-18 | 2009-07-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US7517864B2 (en) | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20060269548A1 (en) | 2001-07-12 | 2006-11-30 | Kari Alitalo | Lymphatic endothelial cells materials and methods |
UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
GB0124545D0 (en) | 2001-10-11 | 2001-12-05 | Novartis Ag | Organic compounds |
TW200306826A (en) | 2002-01-10 | 2003-12-01 | Novartis Ag | Drug delivery systems for the prevention and treatment of vascular diseases |
AU2003252039A1 (en) | 2002-07-23 | 2004-02-09 | Vegenics Limited | Methods and compositions for activating or inhibiting vegf-d and vegf-c |
WO2005083430A1 (en) | 2004-02-25 | 2005-09-09 | Massachusetts Eye & Ear Infirmary | Biomarkers for age-related macular degeneration (amd) |
US7422741B2 (en) | 2004-03-05 | 2008-09-09 | Vegenics Limited | VEGFR-3 fusion proteins |
EP2230681B1 (en) | 2004-04-05 | 2011-12-07 | Axcelis Technologies, Inc. | Drive system for scanning a workpiece with an ion beam |
US7150970B2 (en) | 2004-08-02 | 2006-12-19 | University Of Iowa Research Foundation | Methods of inhibiting VEGF-C |
WO2010127029A1 (en) | 2009-05-01 | 2010-11-04 | Ophthotech Corporation | Methods for treating or preventing ophthalmological diseases |
EP2538965B1 (en) * | 2010-02-25 | 2017-04-12 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
EP3693381A1 (en) | 2013-02-18 | 2020-08-12 | Vegenics Pty Limited | Ligand binding molecules and uses thereof |
WO2015123715A1 (en) | 2014-02-21 | 2015-08-27 | Vegenics Pty Limited | Ligand binding molecules and uses thereof |
-
2014
- 2014-05-05 EP EP14731098.1A patent/EP2994758B1/en active Active
- 2014-05-05 WO PCT/US2014/036865 patent/WO2014182635A1/en active Application Filing
- 2014-05-05 US US14/888,062 patent/US10274503B2/en active Active
-
2019
- 2019-03-25 US US16/363,886 patent/US11209444B2/en active Active
-
2021
- 2021-11-19 US US17/531,448 patent/US20220404377A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001006262A1 (en) * | 1999-02-19 | 2001-01-25 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration |
WO2000064946A2 (en) * | 1999-04-28 | 2000-11-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
WO2005084188A2 (en) * | 2004-02-25 | 2005-09-15 | Massachusetts Eye & Ear Infirmary | Systemic inflammatory markers and age-related macular degeneration (amd) |
US20100150920A1 (en) * | 2008-12-04 | 2010-06-17 | Bert Glaser | System and Method for Identifying Biomarkers in Ocular Fluid That Are Indicative of Ocular Disease |
Non-Patent Citations (1)
Title |
---|
KHALIL GHASEMI FALAVARJANI: "A highly specific biomarker for early diagnosis and treatment of neovascular age-related macular degeneration.", 1 January 2010 (2010-01-01), pages 71, XP055346307, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380675/pdf/jovr-5-1-179-618-1-pb.pdf> [retrieved on 20170215] * |
Also Published As
Publication number | Publication date |
---|---|
US20190285653A1 (en) | 2019-09-19 |
US20160084853A1 (en) | 2016-03-24 |
US20220404377A1 (en) | 2022-12-22 |
WO2014182635A1 (en) | 2014-11-13 |
US10274503B2 (en) | 2019-04-30 |
EP2994758A1 (en) | 2016-03-16 |
US11209444B2 (en) | 2021-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11209444B2 (en) | Treatment for age-related macular degeneration (AMD) and pathogenic ocular neovascularization | |
Al-Zamil et al. | Recent developments in age-related macular degeneration: a review | |
Funatsu et al. | Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients | |
Funatsu et al. | Prediction of macular edema exacerbation after phacoemulsification in patients with nonproliferative diabetic retinopathy | |
Miao et al. | Inflammatory cytokines in aqueous humor of patients with choroidal neovascularization | |
Hubens et al. | Increased ratios of complement factors C3a to C3 in aqueous humor and serum mark glaucoma progression | |
Kuo et al. | Systemic soluble tumor necrosis factor receptors 1 and 2 are associated with severity of diabetic retinopathy in Hispanics | |
Muether et al. | Intraocular growth factors and cytokines in patients with dry and neovascular age-related macular degeneration | |
JP2009511524A (en) | EGFR-dependent regulation of chemokine expression and the effect of chemokine expression regulation on the treatment and diagnosis of tumors and their side effects | |
Kamal Sharma et al. | Single nucleotide polymorphism and serum levels of VEGFR2 are associated with age related macular degeneration | |
Shimizu et al. | Plasma level of interleukin-6 is an indicator for predicting diabetic macular edema | |
Pongsachareonnont et al. | Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment | |
US20050250745A1 (en) | Biomarkers for age-related macular degeneration (AMD) | |
US20200054745A1 (en) | Methods for treatment of age-related macular degeneration | |
Chan et al. | Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis) | |
Hartnett et al. | Aqueous vascular endothelial growth factor as a predictor of macular thickening following cataract surgery in patients with diabetes mellitus | |
Kuo et al. | Correlation between the progression of diabetic retinopathy and inflammasome biomarkers in vitreous and serum–a systematic review | |
Zhang et al. | Effect of intravitreal conbercept injection on VEGF‑A and‑B levels in the aqueous and vitreous humor of patients with proliferative diabetic retinopathy | |
TW201823471A (en) | Methods of treating patients with a retinoic acid receptor-[alpha] agonist and an anti-CD38 antibody | |
US20100150920A1 (en) | System and Method for Identifying Biomarkers in Ocular Fluid That Are Indicative of Ocular Disease | |
US8916586B2 (en) | Anti-angiogenic compound | |
Saini et al. | Association between Heat Shock Protein-Specific T-Cell Counts and Retinal Nerve Fiber Layer Thickness in Patients with Primary Open-Angle Glaucoma | |
Bloch | Implementation studies of ranibizumab for neovascular age-related macular degeneration. | |
Funatsu et al. | Vitreous fluid biomarkers | |
Chung et al. | Serum myostatin levels are positively associated with diabetic retinopathy in individuals with type 2 diabetes mellitus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20151208 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20170221 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20170816 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: LASHKARI, KAMERAN Owner name: MA, JIE Owner name: OPTHEA LIMITED |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: LASHKARI, KAMERAN Inventor name: OPTHEA LIMITED Inventor name: MA, JIE |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BALDWIN, MEGAN, E. Inventor name: LASHKARI, KAMERAN Inventor name: MA, JIE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 956837 Country of ref document: AT Kind code of ref document: T Effective date: 20180115 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602014018761 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20171220 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180320 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 956837 Country of ref document: AT Kind code of ref document: T Effective date: 20171220 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180320 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180321 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180420 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602014018761 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20180921 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20180531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180505 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180505 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180531 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602014018761 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180505 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20140505 Ref country code: MK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171220 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171220 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230519 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230526 Year of fee payment: 10 |
|
P02 | Opt-out of the competence of the unified patent court (upc) changed |
Effective date: 20230921 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240521 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240521 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20240620 AND 20240627 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20240602 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20240628 AND 20240703 |